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ABSTRACT 
 
Heterocyclic Small Molecule Peptidomimetics. 
(December 2008) 
Jing Liu, B.S., Nankai University 
Chair of Advisory Committee: Dr. Kevin Burgess 
 
 Polymer-supported synthesis of a close analog (i.e. A) of an early lead, a 14-
membered ring peptidomimetic D3, was described.  The monovalent molecule was 
attached to different length linkers, and they were then paired sequentially on a triazine 
scaffold via our previously published methodology to give a small library of bivalent 
compounds 1 representing all combinations of linkers of the different lengths in a fast and 
efficient combinatorial manner.  Cellular assays identified 1-ss as a TrkA receptor 
antagonist towards NGF and it was shown to bind TrkA with ~200 nM affinity and 
retains high selectivity towards TrkA in binding assays.   
A set of monovalent diketopiperazine (DKP) mimics 4-7 was synthesized 
efficiently from corresponding dipeptides via intramolecular SN2 cyclization reactions in 
solution.  These DKP compounds contain two amino acid side-chain functionalities to 
mimic the sequences that occur at “hot-spots” in loop regions.  The monovalent mimics 
were assembled into a library of biotin-labeled bivalent molecules 9 via the combinatorial 
strategy described above with some modification.  In primary screening, compound 9gg 
showed preferential binding to TrkC receptors in FACScan assay and blocked the trophic 
activity of NT-3 in TrkC cells at 10 uM in cell survival assay.   
The preparation of monovalent 1,3,4-oxadizole-based mimics 12 was achieved 
from corresponding amino acid building blocks on gram scale in a highly efficient 
solution phase parallel synthesis manner in good yields.  These heterocyclic compounds 
feature various natural amino acid side-chain functionalities including those occuring 
most frequently at hot-spots such as those of Tyr, Lys, Glu and Ser.  Attempts to 
assemble them into bivalent molecules were done by coupling the monovalent mimics to 
 iv 
the triazine scaffold sequentially in solution and simply manipulating the solvent systems.  
For some reasons, some reactions did not proceed cleanly.  Studies have been carried out 
and the problems were partially solved.  The biological activities of these oxadiazoles are 
under investigation.  So far, six compounds have shown activities in four different 
bioassays.   
Two different peptidomimetic types that resemble protein A and protein G 
binding regions were generated and tested as binding factors in affinity columns for 
purification of IgG.  They are cyclic hexapeptides 19, which were prepared via Fmoc-
SPPS and solution phase intramoleculer macrocyclization, and heterocycle-based small 
molecules 22 and 23 featuring a variety of aromatic functionalities generated via solution 
phase parallel synthesis.  Four compounds showed some affinity towards a Fab fragment 
of IgG in SAR screening, and they were attached to a dendrimer core on a solid support 
to give four multivalent mimetics 25.   
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CHAPTER I 
INTRODUCTION 
1.1 Heterocyclic Amide Surrogates of Dipeptide Mimetics 
Many protein-protein interaction events are mediated through secondary structure 
units like helices, β-sheets and turns.  To improve understanding of these molecular 
interactions, studies have been performed via mimicry of the crucial interacting sites.  
Small peptides and peptidomimetics are typically used to mimic or disrupt the structural 
environment at hot-spots.   
Hetercycles are frequently found in natural and synthetic bioactive compounds.  
Heterocyclic building blocks can be useful as scaffolds for peptide backbone 
modifications.  They import rigidity and enable the functionalized side-chain substituents 
to adopt relatively constrained conformations.  Conceptually rigid analogs also surrender 
less entropy upon binding to their receptors.  Many reports describe using heterocycles as 
successful peptide bond surrogates or protein recognition motif mimics to achieve ideal 
potency in biological assays.   
Dipeptide mimetics can be accessed from conventional procedures and show 
various functionalities.  They can also be used as protein secondary structure mimics and 
incorporated in active sequences for structural modification.  Here, we mainly address the 
heterocyclic dipeptide mimetics.   
 
 
 
 
 
 
 
____________ 
This dissertation follows the style of the Journal of Organic Chemistry. 
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 In general, we think the incorporation of amino acid side-chains, especially the 
ones that occur most frequently at hot-spots, is important for the mimic; it is also a direct 
means to introduce diverse functionalities to the heterocyclic system.  In addition, the two 
“branches” should have some degrees of freedom for bond rotation; this allows the 
mimics to be somewhat flexible to be able to access close conformations to those of the 
parental peptides in binding protein targets.  On the other hand, too much flexibility may 
cause the entropic cost of binding at a protein interface to be prohibitively high.  A 
schematic view of the heterocyclic dipeptide mimetics is shown in Figure 1.1.   
 
 
R2
heterocyclic
scaffold
R1
some freedom 
for rotation
side-chain with
functionality
side-chain with
functionality
 
Figure 1.1.  Schematic view of dipeptide mimetics based on a heterocyclic amide bond 
surrogate featuring two amino acid side-chains. 
 
 
 There are many types of dipeptide mimetics reported in the literature; they usually 
are rationally designed molecules and exhibit interesting characteristics, e.g. 
carbohydrate-based dieptide isosteres.1 (Figure 1.2a)  Sugar amino acids (SAAs) with 
naturally occurring rigid ring systems resemble conformationally restricted dipeptides, 
thus they are used as turn mimics and scaffolds to replace amide bonds in linear peptides. 
2,3  Usually, specific functionalities are introduced at the sugar hydroxyls, or via 
backbone modifications.   
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Figure 1.2.  Various sugar amino acids as a. dipeptide isosteres;1 and b. Gly-Gly 
replacement in Leu-enkephalin analogs.4  
 
 
 Bicyclic dipeptide mimetics are common peptidomimetic species. (Figure 1.3) 
They normally feature rigid backbones, which is crucial to maintain restricted 
conformations, and several substitution sites to access more molecular diversity.  Not to 
mention many of them are also interesting targets for organic synthesis and biologically 
active compounds in medicinal chemistry.   
 
 
N
O N
O
R1
R4
O
R2
R3
N
O
O CO2H
H
HBocHN
H
Bartlett (2001)
NN
O
O
MeO2C
R1
R2
Patek (1998)Baldwin (1993)  
Figure 1.3.  Various conformationally constrained bicyclic dipeptide mimetics.5-12 
 
 4 
N
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H
*
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N
XR
1
H2N
H
CO2HO
R2
X =S, CH2
Hruby (2004, 2006)
PG
 
Figure 1.3. continued. 
 
 
 Many dipeptide mimetics have been reported in the literature, however, only 
heterocyclic dipeptide mimetics that are pertinent to our research are described in detail 
in this chapter.   
 
1.2 Five-membered Heterocyclic Dipeptide Mimetics 
1.2.1 Azole-based Dipeptide Mimetics 
Several types of five-membered heterocycles are used as amide bond surrogates 
of dipeptide mimetics, and many of them are based on azoles.  Luthman and coworkers 
reported the synthesis of enantiopure heterocyclic Phe-Gly dipeptidomimetics containing 
1,3,4-oxadiazole, 1,2,4-oxadiazole, and 1,2,4-triazole ring systems as building blocks.13 
(Figure 1.4)  These pseudopeptides were used as Phe-Gly replacements in the 
biologically active peptides dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) and 
substance P (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-MetNH2, SP).  In the 
biological test of the µ- and δ-opioid receptor affinities of the dermorphin 
pseudopeptides, all mimetics except one type (1,3,4-oxadiazole, n = 0) displayed 
excellent affinities for the µ-receptor (IC50 = 12-31 nM) in the same range as dermorphin 
itself (IC50 = 6.2 nM); the tested pseudopeptides also retained their agonist activity at 
human µ-receptors.  However, the SP pseudopeptides showed considerably lower 
affinities (IC50 > 1 µM) for the NK1 receptor than SP itself (IC50 = 1.5 nM), which 
indicated that the heterocyclic replacements prevent the pseudopeptides from adopting 
bioactive conformations.   
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Figure 1.4.  Three types of pseudopeptides as Phe-Gly replacements.   
 
 
 “Click” chemistry has made triazoles more accessible in recent years.  They can 
be prepared from robust methods and have become versatile building blocks in organic 
synthesis.  Triazoles have various applications, e.g. peptide amide bond surrogates.14,15  
Last year, Raines’s group prepared several 1,4- and 1,5-disubstituted 1,2,3-triazoles as 
cis-peptide bond surrogates.16 (Figure 1.5)  The 1,4-disubstituted triazoles were prepared 
via Huisgen’s 1,3-dipolar cycloaddition reaction, and the 1,5-disubstituted triazoles were 
prepared via Ru(II)-mediated 1,3-dipolar cycloaddition of various amino alkynes and 
azido acids.  In the subsequent tests, they found that Xaa-1,5-triazole-Ala modules can 
serve as viable mimics of Xaa-cis-Pro segments in a protein, and the 1,5-regioisomers are 
superior to the 1,4-regioisomers in mimicking the cis-prolyl bond.   
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Figure 1.5.  Xaa-1,5-triazole-Ala and Xaa-1,4-triazole-Ala modules as mimics of Xaa-
cis-Pro segments.   
 
 
 To improve the properties of a pseudotetrapeptide FR-139317, which is a potent 
and highly selective antagonist of the endothelin-A (ETA) receptor, von Geldern and his 
coworkers replaced Leu-Trp and Trp-X of the amide bond framework of FR-139317 with 
two different heterocyclic surrogates, respectively.17,18 (Figure 1.6)  The replacements 
generated two novel series of azole-based ETA selective antagonists, but show a 
substantially different structure-activity profile from the peptidic series, particularly with 
regard to the side chain group incorporated into the heterocycle.  The introduction of a 
heterocycle itself also has profound effects on the activity of the compounds.   
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Figure 1.6.  Azole-based Leu-Trp and Trp-X surrogates in potential endothelin 
antagonists. 
 
 
 Kessler’s group reported the synthesis of a new family of oxazole-based 
peptidomimetics as useful building blocks for the synthesis of orthogonally protected 
macrocyclic scaffolds.19 (Scheme 1.1)  These highly functionalized oxazoles were 
prepared from α-amino β-keto esters by acylation of the anion derived from N-
(diphenylmethylene)-glycine methyl ester, using Fmoc-protected amino acid chlorides as 
acylating agents.  Subsequent coupling with another amino acid with mixed anhydride 
activation afforded the corresponding intermediate, and the following cyclization yielded 
the desired oxadizole rings.  These building blocks were used for preparing macrocycles 
containing Lys and Glu residues, which are presented as orthogonally protected scaffolds 
for supramolecular chemistry.   
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Scheme 1.1.  Synthesis of oxazole-based dipeptide mimetics as useful building blocks. 
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 The same group also reported an efficient two-step solid-phase synthesis of 1,3-
azole-based peptides and peptidomimetics.20 (Scheme 1.2)  A series of 1,3-oxazole-, 
thiazole-, and imidazole-containing peptides were prepared from dipeptides that were 
composed of C-terminal threonine, serine, cysteine, or diaminopropionic acid via 
different cyclodehydration procedures followed or preceded by oxidation.  The methods 
are compatible with Fmoc solid-phase peptide synthesis (Fmoc-SPPS) conditions.  The 
reported methodology provides an efficient and flexible means to synthesize azole-based 
derivatives and allows the solid-phase synthesis of natural product libraries, small 
molecule combinatorial libraries, and 1,3-azole-based peptidomimetics.  There was no 
report of the biological activities of these synthetic molecules.   
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Scheme 1.2.  Solid-phase synthesis of 1,3-azole-based peptidomimetics.   
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 Du et al reported a convenient ‘one-pot’ synthesis of a series of oxadiazole-based 
peptidomimetics.21 (Scheme 1.3)  The α-1,2,4-oxadiazolo esters were synthesized from 
malonic diesters and amidoximes under solvent-free conditions.  It is likely that the 
reaction goes through a ketene intermediate generated from the malonic diester by 
elimination of a molecule of alcohol.  This strategy is both time and cost efficient 
compared to previously described methods.  No biological activities of these molecules 
was reported.   
 
 
Scheme 1.3.  A ‘one-pot’ synthesis of 1,2,4-oxadiazole-based peptidomimetics.   
 
O
R1
O
R2
O
O
R3 +
N
R4H2N
HO heating
O
O
N
NO
R4
R2
R1
R4 = CH3, CO2CH2CH3,
N
O
N
O
N
N
N
R1 = CH3, CH2CH3, PhCH2
R2 = H2, CH2CH(CH3)2, PhCH2, 
        Ph, C5H9, (CH3)2
R3 = CH3, CH2CH2, C(CH3)3
 
 
 10 
 
 Heller and coworker prepared a series of highly substituted pyrazoles from 1,3-
diketones via a rapid and general ‘one-pot’ synthetic methodology.22 (Scheme 1.4)  The 
1,3-diketone building blocks were synthesized directly from ketones and acid chlorides, 
and were then converted in situ into pyrazole products upon the addition of hydrazine.  
This method is fast, general, and chemoselective.  Moreover, it allows for the synthesis of 
some previously inaccessible pyrazoles and several synthetically demanding pyrazole-
containing fused ring systems.  No biological assay result is reported in their paper.   
 
Scheme 1.4.  ‘One-pot’ synthesis of highly substituted pyrazole library from 1,3-
diketones.   
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1.2.2 Other Five-membered Heterocycle-based Dipeptide Mimetics 
 Holmes et al reported the combinatorial synthesis strategies of 4-thiazolidinones 
and 4-metathiazanones derived from amino acids in both solution and solid-phase.23 
(Scheme 1.5)  In solution, 4-thiazolidinones could be obtained from the ‘one-pot’, three-
component condensation of amino acid esters, an aromatic aldehyde, and an α-mercapto 
carboxylic acid in moderate to high yields.  The solid-phase approach to the five and six-
membered heterocycles started from acylation of standard peptide synthesis resins with 
an Fmoc-protected amino acid, which was followed by Fmoc-removal and condensation 
with aldehydes and an α- or β-mercapto carboxylic acid.  Cleavage from the support 
 11 
using trifluoroacetic acid gave high yields and high purities of the liberated 4-
thiazolidinones and lower yields of 4-metathiazanones.  They did not report the 
biological properties of these compounds.   
 
 
Scheme 1.5.  Combinatorial organic synthesis of 4-thiazolidinones and derived from 
amino acids.   
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 Batey and coworker prepared of a series of N-terminal 2-iminohydantoin-based 
peptide heterocycle conjugates via a diverted Edman degradation protocol.24 (Scheme 
1.6)  This modified procedure provides an effective route to introduce a heterocycle at the 
N-terminus of an α-amino acid amide or peptide.  The iminohydantoins are generated 
from the reaction of a peptide with an isothiocyanate, followed by dehydrothiolative 
trapping of the intermediate thiourea, and intramolecular cyclization of the weakly 
nucleophilic adjacent amide nitrogen.  A solution-phase parallel synthesis of the 
peptidomimetics and a solid-phase synthesis of dipeptide- and tripeptide-derived 
iminohydantoins were developed.  They did not report the biological activities of these 
molecules.   
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Scheme 1.6.  Synthesis of N-terminal 2-iminohydantoins from di-/tripeptides and phenyl 
isothiocyanate.   
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 Grieco et al reported the design and synthesis of small libraries of 
peptidomimetics based on a thiazolidine moiety.25 (Scheme 1.7)  In this work, two series 
of conformationally constrained building blocks starting from amino acids were prepared 
via a short and general strategy.  Computer methods were used to evaluate the intrinsic 
tendency of the dipeptide mimetic scaffold to induce β-turn formation; the results 
indicate that the diastereomers with the (R) configuration at the C-2 position have high 
propensity to adopt the type II β-turn conformation.   
 
 
Scheme 1.7.  Synthesis of thiazolidine-based dipeptide mimetics from amino acid 
derivatives.   
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 Last year, Aubé’s group reported the one-step synthesis of a 60-member library of 
various disubstituted oxazolines and di- and trisubstituted dihydrooxazines.26 (Scheme 
1.8)  The reactions of 1,2- and 1,3-hydroxyalkyl azides and aldehydes in the presence of 
Lewis acid generate oxazolines and dihydrooxazines in one step, respectively.  Parallel 
synthesis was adapted using a polymer-bound phosphine to scavenge excess 
hydroxyalkyl azide.  The activities of the library members were being evaluated against 
various biological screens.   
 
 
Scheme 1.8.  Combinatorial synthesis of oxazoline and dihydrooxazine libraries from 
amino acid derivatives.   
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 This year, Reiser et al reported an efficient synthesis of γ-lactams by a tandem 
reductive amination/lactamization sequence.27 (Scheme 1.9)   This three-component 
method allows for the synthesis of highly substituted γ-lactams from readily available 
maleimides, aldehydes, and amines.  The reported synthetic strategy provides a 
straightforward route to the lactam products, and the parallel synthesis of a γ-lactam 
library further demonstrates its general utility.  The biological activities of these 
molecules have not been reported yet.   
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Scheme 1.9.  Synthesis of γ-lactams by a tandem reductive amination/lactamization 
sequence.   
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1.3 Six-membered Heterocyclic Dipeptide Mimetics  
Diketopiperazines (DKPs) are useful templates for constructing dipeptide 
mimetics.  Aubé’s group reported the synthesis of a small library of 2,5-diketopiperazines 
as potential inhibitors of calpain.28 (Figure 1.7)  These constrained dipeptide analogs 
were designed based on previously reported calpain inhibitors, e.g. phevalin; they were 
synthesized starting from corresponding amino acid building blocks.  A concise total 
synthesis of the structurally related natural product phevalin was also reported.  However, 
despite the dipeptidyl aldehyde analog Boc-Val-Phe-H was a potent calpain inhibitor as 
expected, none of the library members, including previously reported phevalin, showed 
any significant inhibition against recombinant human calpain I in their assay system.   
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Figure 1.7.  Dipeptide mimetics of calpain based on 2,5-diketopiperazines. 
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Figure 1.7. continued. 
 
 
 Goodfellow et al prepared a rationally designed library of variously substituted 
piperazines for the discovery of bradykinin antagonists and other G-protein-coupled 
receptor ligands on the basis of previous successful structures.29 (Scheme 1.10) The 
synthetic strategy uses diverse nonnatural amino acids, on-resin-submonomer synthesis to 
provide diverse N-substituted structures, and the adaptation of simultaneous ring closure 
and resin cleavage drives the formation of highly hindered amide bonds.  Thus a 
rationally directed library of ~ 2500 N,N'-disubstituted piperazines and piperazinediones 
was prepared and screened for ligand affinity on bradykinin, neurokinin, and opioid 
receptors.  A number of lead structures, including a bradykinin antagonist lead CP-2458 
(not shown), with good receptor selectivity and antagonist activity in human-cell assays 
were identified.   
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Scheme 1.10.  Combinatorial synthesis of piperazinediones and reduction to piperazines.   
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1.4 Larger (>6) Heterocyclic Ring Systems as Dipeptide Mimetics 
 Burkholder and coworkers reported the synthesis of a series of 6-amino-5-oxo-7-
phenyl-1,4-oxazepines as conformationally constrained gauche (-) Phe-X dipeptide 
mimetics, starting from β-phenylserine by a versatile route.30 (Figure 1.8)  To elucidate 
the solution conformation of the protected mimetics, NMR studies were conducted and 
showed that the 7-membered ring was in a chair conformation with the phthalimide 
moiety and the phenyl ring pseudo-equatorial, consistent with the gauche (-) 
conformation (dihedral angle X1= -60°).  These peptidomimetics may be useful probes 
for the investigation of conformational preferences of enzyme substrates and receptor 
ligands.  MDL 100,192, as a gauche (-) Phe-Leu constrained mimetic, was reported to be 
a poor inhibitor of atriopeptidase (neutral endopeptidase 24.11, NEP) and angiotensin 
converting enzyme (ACE).  The Ki for MDL 100,192 for NEP was 330 nM and the Ki for 
ACE was 50 µM.   
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Figure 1.8.  1,4-Oxazepines as conformationally constrained gauche (-) Phe-X dipeptide 
mimetics. 
 
 
Guichard et al reported the the design and synthesis of a structurally diverse small 
pilot library of 1,3,5-triazepan-2,6-diones as conformationally constrained dipeptide 
mimetics for identification of malaria liver stage inhibitors.31 (Scheme1.11)  The densely 
functionalized ring skeleton was readily accessible in only four steps from a variety of 
simple linear dipeptide precursors.  A general polymer-assisted parallel solution-phase 
synthesis approach compatible with library production was developed.  Conformational 
analyses by NMR spectroscopy and X-ray diffraction showed that the ring exhibits a 
characteristic folded conformation.  Preliminary biological screening of a portion of the 
library revealed two molecules active against the malaria liver stages, which do not show 
any toxicity on mouse hepatocytes, and also suggested strong potential functionality of 
this dipeptide-derived scaffold in biological pathways.   
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Scheme 1.11.  Synthesis of 1,3,5-triazepan-2,6-dione library as dipeptide mimetics.   
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In an early report by Olson et al, the design and synthesis of several protein β-turn 
mimetics based on a nine-membered-ring lactam framework was described.32  (Figure 
1.9)  The synthesis of model di- and tetrapeptide mimetics started from 1,5-
cyclooctadiene derivatives.  In the model dipeptide mimetic, the amide linkage is trans 
based on NMR and X-ray analyses, and functional groups at positions adjacent to the 
lactam amide bond correspond closely to the side-chain positions of residues i + 1 and i + 
2 of classical type II’ β-turns.  There is no biological data reported in this publication.   
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i+1
i+2
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H
H
N
O
CH3
H
design of lactam mimetics model dipeptide mimetic  
Figure 1.9.  Nine-membered-ring lactam-based dipeptide mimetic as β-turn analog.   
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1.5 Other Heterocylic Dipeptide Mimetics 
 There are some examples of heterocyclic dipeptide mimetics that are not covered 
in previous sections mainly because of lack of space.  These are also rationally designed 
molecules.  Some are secondary structure mimics, and some exhibit interesting activities 
in various biological systems.  Several examples are shown in Figure 1.10. 
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Figure 1.10.  Various heterocyclic dipeptide mimetics. a. dipeptide mimetics mimicking 
particular dipeptide sequences;33-37 b. dipeptide mimetics mimicking secondary 
structures;38,39 c. conformationlly restricted dipeptide mimetics.40-42 
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Figure 1.10.  continued. 
 
 
1.6 Monovalent Heterocyclic Dipeptide Mimetics Designed in Our Group 
The design of our previously reported triazole-based β-turn mimics (Figure 1.11a) 
was based on two major considerations.43  First, studies of protein complexes 
crystallographically have shown that main-chain carbonyl groups are much less (~ 11 %) 
involved in protein-protein interface regions than side-chains (~ 80 %).  Thus we 
believed it is far more important to represent amino acid side-chains in the mimics, than 
main-chain amides.  This is consistent with designs by some other groups, e.g. 
Hirschmann and Smith.  Second, syntheses of the mimics should also incorporate the 
side-chains that occur most frequently at hot-spots, i.e. those of Trp, Arg, Tyr, Lys, Glu, 
Ser, Asn, Leu; syntheses of β-turn mimics that do not allow this are unsatisfactory for 
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medicinal chemistry.  Actually, it is quite hard to devise syntheses of mimics that do 
satisfy this criterion because of the diversity of amino acid side-chain functionalities 
involved.   
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Figure 1.11.  a. The key distance of Cβ-separations of the i + 1 to i + 2 residues of a type 
1 β-turn and of the triazole-based turn mimics featured here; b. an overlay of the mimics 
onto a type 1 β-turn.   
 
 
Conformational and structural issues are also factors in our design considerations 
for these turn mimics.  As shown in Figure 1.11a, the bond vectors 1-2, 2-3, 3-4, 4-5, and 
5-6 populate relatively well-defined regions of space, whereas rotation about the 1-2 and 
5-6 bonds in β-turns are relatively free.  We also reasoned that good mimics should be 
able to access conformations with C1 – C6 separations that are close to those of β-turns. 
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Type-1 β-turn is known as the most common type among several different types of β-turn 
conformations.  However, most β-turns probably are somewhat flexible in solution, thus 
good mimics should reflect that characteristic without being so flexible that the entropic 
cost of binding at a protein interface is prohibitively high.  Although the conformation 
shown in Figure 1.11b is not the low energy conformation, which indicates the turn 
mimic does not always reside in it, this conformational state is readily accessible at room 
temperature since the enthalpic barrier to rotation about C2-N3 dihedral is low (not 
shown).  Computer-aided calculations showed that the lowest energy conformer that was 
identified has a C2-N3 dihedral angle of 50° which is 140° away from the targeted turn 
conformation.  However, the second lowest energy conformer was only 0.85 kcal•mol-1 
higher in energy and had a C2-N3 dihedral angle of –57°, which matched the target turn 
conformation much closer (deviation = 33°).  The calculations also showed that the 
molecule only need to surmount an enthalpic barrier of 0.99 kcal•mol-1 to reach the target 
turn conformation; which can be readily overcome at room temperature.  Overall, the turn 
conformation of our peptidomimetics is energetically accessible, and it represents a low 
energy conformation that is only slightly less stable than the minima.  The energy needed 
to reach this conformation is available at ambient temperatures, and the slight increase of 
energy over the lowest minimum may be easily compensated for via induced fit binding 
to a protein surface. 
The designated mimics in Figure 1.11a satisfy all the considerations outlined 
above.  The separations between Cβ atoms that correspond to the i + 1 and i + 2 amino 
acid side-chains (i.e. C1 and C6) in type-1 β-turns are close to that in the mimics in an 
energetically accessible conformation.  β-Turns have two bonds that are essentially freely 
rotating (1-2 and 5-6).  The core of triazole-based molecules has three rotatable (1-2, 2-3, 
and 5-6), and only one of these affects the C1-to-C6 distance (the 2-3 rotation).  
Consequently, the peptidomimetics can access appropriate conformations to mimic the 
C1-to-C6 spacing in β-turns simply via rotation around the 2-3 bond (Figures 1.11a and 
b).  In addition, the polar triazole part of the mimics introduces electrostatic polarity that 
can also resemble turn conformations (not shown).  Thus, we think the design is 
satisfactory by the match of the mimics to the target secondary structure.   
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Later, our group devised the synthesis of another series of similar β-turn 
peptidomimetics (not published).  These triazole-based molecules were also prepared via 
copper-mediated 1,3-dipolar cycloaddition reactions, but using only various natural 
amino acids derived alkynes and azido acids as building blocks.  Their biological 
activities are still under investigation.  We are currently working on the design and 
synthesis of other β-turn peptidomimetics based on different types of heterocycles.   
 
1.7 Conclusion 
To improve understanding of various protein-protein interactions, studies have 
been performed via mimicry of the crucial interacting sites.  Small peptides and 
peptidomimetics are typically used to mimic or disrupt the structural environment at hot-
spots. 
Hetercycles are frequently found in natural and synthetic bioactive compounds.  
Heterocycle-based dipeptide mimetics usually feature relatively constrained 
conformations and various functionalities.  Many reports describe using heterocyclic 
building blocks, such as azoles, azolines, and diketopiperazines, as successful amide 
bond surrogates for protein backbone modifications to improve their biological 
properties.  These molecules can also be used to resemble protein secondary structures.   
 In general, we think the incorporation of the amino acid side-chains that occur 
most frequently at hot-spots in the mimics is quite important, and good mimics should 
also be somewhat flexible to be able to access favorable conformations that are close to 
those of the parental peptides in binding protein targets.   
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CHAPTER II 
DIMERIZATION OF A MONOVALENT SMALL MOLECULE 
LIGAND CHANGES A TrkA RECEPTOR AGONIST INTO AN 
ANTAGONIST 
2.1 Introduction 
TrkA is a member of the receptor tyrosine kinase (RTK) family, and the high 
affinity receptor for Nerve Growth Factor (NGF).  RTKs in general, and TrkA 
specifically, are believed to act via receptor dimerization, where each receptor trans-
activates the juxtaposed intracellular tyrosine kinase domain of its neighbor.44  This 
hypothesis fits well with the fact that NGF is a dimeric ligand, so it seems logical that it 
can induce ligand-dependent TrkA receptor dimerization or stabilize the preformed 
receptor dimers.45  However, postulates based on the idea that RTK dimerization is the 
exclusive requirement for agonistic activities are inconsistent with the observation that 
monovalent ligands of RTK can be agonistic. 46-48  Actually in the specific case of TrkA, 
it has been shown that dimers exist on the cell surface before NGF is introduced.  This 
fact further suggests ligand binding may cause conformational changes for activation of 
the receptor intracellular domain.  Indeed, monovalent ligands of TrkA can be agonists of 
this receptor,49,50 indicating that pre-formed TrkA dimers can be activated by ligands that 
are non-dimeric.  Actually, monvalent and monomeric agonists have been reported for 
other RTKs,51-53 thus this phenomenon is not unique to TrkA.  This evidence supports the 
notion that conformational changes in TrkA receptor dimers may occur.  However, 
conformational changes in TrkA upon the binding of protein ligand, such as NGF, have 
not yet been demonstrated through structural analyses.54  
If the correlation between RTK dimerization and agonistic activity is still in 
question for protein ligands, it is even less certain for small molecule ligands.  Small 
molecule ligands and proteins normally have different kinetic and thermodynamic 
profiles for binding to RTKs.  Synthetic compounds can bind in allosteric sites, and 
 25 
especially bivalent small molecules could bind not only one, but also two receptor 
molecules at the same time.   
Our laboratory has been involved in the design and synthesis of small molecules 
to mimic surface exposed β-turn regions of NGF (and other neurotrophins).55-60  
Specifically, we have targeted mimics of the NGF turn regions that seem to be involved 
in those “hot-spot” interactions between NGF and TrkA.  Most of these small molecules 
are cyclic peptidomimetics with our so-called “ring fused C10 motif” as illustrated in 
Figure 2.1.  They were made via SPPS and SNAr macrocyclization reactions.  Residues at 
R1 and R2 positions were based on the i + 1 and i + 2 residues of the turn regions of NGF.   
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Figure 2.1.  Some β-turn nomenclature and some cyclic peptidomimics with ring-fused 
C10 motif. 
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Among libraries of these monovalent cyclic peptidomimetics, we have identified 
several lead compounds based on extensive biological assays, such as D3 and MPT18 
(Figure 2.2).58,61  Interestingly, peptidomimetic D3 was shown to have agonistic (or 
partial agonistic) properties for the NGF:TrkA interaction in biochemical (e.g. tyrosine 
phosphorylation), cellular (e.g. survival and neurite outgrowth),50,62 and in vivo assays 
(Robin’s maze test for gain of memory function in aged rats), which demonstrated that 
monovalent mimics on hot spot of NGF do not have to be antagonists.63,64  Compound D3 
has also been shown to bind the TrkA receptor in a non-competitive manner respect to 
NGF.   
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Figure 2.2.  Previously identified lead compounds D3 and MPT18. 
 
 
 Given the interesting biochemical and biological profile of peptidomimetic D3 
and the notion of changing a small molecule from a monovalent to bivalent form could 
generate more potent agonists for RTK ligands (actually more potent TrkA agonists have 
been generated by increasing ligand valency),49,62,65 it seemed reasonable to explore 
“bivalent analogs” in which two close analogs of D3 (which is A as shown in Figure 
2.3a) are combined in one molecule.66,67  However, what will be the ideal dimensions for 
the linker if they are to be combined?  It is almost impossible to surely answer this 
question because the precise binding site of D3 on TrkA is unknown, and also its bivalent 
analogs might bind differently in any case.  Furthermore, the only fragments of the Trk 
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receptor structure that have been crystallographically characterized are not the regions 
that contact the turns that D3 was designed to mimic.  Consequently, our strategy was to 
generate a set of bivalent molecules 1 using a novel combinatorial approach.  In this 
method, a close analog of D3 (which is A) would be attached to a short s, a medium m, 
and a long linker l.  They were then paired on a triazine scaffold via our previously 
published methodology, to give a small library of bivalent compounds representing all 
combinations of linkers of the different lengths, ie 1-ss, 1-sm, 1-sl, 1-mm, 1-ml, and 1-ll. 
(Figure 2.3b)   
 Two different “tags” were prepared in our lab and used on the triazine linker.  A 
triethylene glycol (TEG) based one had no particular function except to increase the 
water solubility of the unlabeled mimics.  However, fluorescein labeled compounds were 
critical because they facilitated screening via fluorescence activated cell sorting (FACS) 
using transfectant cells that overexpress TrkA; these experiments gave relative degrees of 
staining from which relative binding affinities could be inferred.  Then we examined the 
TEG-tagged compounds as competing ligands in the same assay.  Finally, the optimal 
binder was tested in: (i) competitive binding assays with radiolabeled NGF to obtain Kd 
values, and in: (ii) cell survival assays to test agonism or antagonistic effects for the 
NGF:TrkA interaction.  As a result, the data obtained was surprising in two respects.  
Firstly, the bivalent analog 1-ss, which featured the shortest linker combination, had the 
highest affinity to TrkA, when it might have been anticipated that those with longer, more 
flexible linkers would be better.  Second, unlike its parental monovalent peptidomimetic 
D3, 1-ss was shown to be an antagonist for the NGF: TrkA interaction in cellular assays. 
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Figure 2.3.  a. Generic scheme of the monovalent mimic A was attached to a short s, a 
medium m, and a long linker l bearing a nucleophile, then paired on a triazine scaffold to 
which either a FITC or a TEG tag was incorporated; b. structure of the bivalent 
compounds 1-ss, 1-sm, 1-mm, 1-sl, 1-ml, and 1-ll.   
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Figure 2.3. continued. 
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Figure 2.3. continued.   
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2.2 Solid Phase Synthesis of the Monovalent Cyclic Peptidomimetic A 
 Scheme 2.1 outlines the preparation of A, as a close analog of cyclic monovalent 
compound D3.  The synthesis represents a slight modification of the literature procedure 
from our group.68  FMOC-Hse-(Trt)-OH, FMOC-Lys(Boc)-OH and FMOC-Glu(OtBu)-
OH were sequentially coupled onto the deprotected Rink Amide MBHA resin under 
typical solid phase coupling conditions.  2-Fluoro-5-nitrobenzoic acid moiety was 
introduced following Glu and the side-chain protecting group (Trt) of the homoserine was 
removed by treatment with acid to afford the linear peptide precursor.  The 
macrocyclization step was carried out by treating the supported linear peptide with 
K2CO3 in DMF at room temperature for 1 day.  The nitro group of the cyclic compound 
was reduced to an amino group using SnCl2; this was used as a handle for further linker 
attachment.   
 
 
Scheme 2.1.  Solid phase synthesis of the protected monovalent peptidomimetic A.   
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Scheme 2.1.  continued.   
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2.3 Synthesis of the Labeled Bivalent Peptidimimetics 1 with s/m/l Linkers 
 The pre-formed supported arylamine was divided into three portions and each was 
coupled with the short, medium or long linker individually with PyBrOP activation.  
Every portion with linker moiety attached was then split into two portions.  One portion 
was subjected to FMOC deprotection and cleaved from the resin by treatment with a 
mixture of 90% TFA, 5% HSiiPr3, and 5% H2O.  The crude peptide was triturated using 
anhydrous ethyl ether, re-dissolved and then purified via RP-Preparative HPLC to give 
monovalent D3 derivative peptidomimetics.  Another portion of linker-attached resin was 
FMOC deprotected first and coupled with dichlorotriazinylaminofluorescein (DTAF) or 
triethylene glycol (TEG) tag.  After acid cleavage from the resin, the crude product was 
also purified by RP-preparative HPLC to yield the tagged peptidomimetics.   
 Assembly of the two monovalent molecules into one bivalent peptidomimetic was 
achieved by the method outlined in Scheme 2.2.  This dimerization method has been 
established previously by our group,43,69 however the work here is critically different 
insofar as the monovalent building blocks were essentially the same but the linker parts 
were varied as described above.  
Firstly, stock solutions of the non-tagged fragment (nucleophile) and tagged 
fragment (electrophile) were prepared in DMSO.  Then equal volumes of the two stock 
solutions of the non-tagged and the tagged peptidomimetic were mixed in the presence of 
solid K2CO3 as the base in 1 dr glass vials.  The reaction vessels were capped and stirred 
at room temperature for 1-3 days.  After HPLC analysis of the crude purity, the solution 
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in each vial was lyophilized to remove DMSO.  The solid materials were re-dissolved in 
1:1 mixture of H2O/CH3CN, and purified by RP-preparative HPLC to yield the final 
bivalent products.   
 
 
Scheme 2.2.  Overall scheme of preparation of the tagged bivalent peptidomimetics 1. 
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Scheme 2.2. continued.   
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 From three linkers (s, m and l) and two tags a total of six bivalent compounds 1a-
f (1-ss-F*, 1-sm-F*, 1-mm-F*, 1-sl-F*, 1-ml-F* and 1-ll-F*) with fluorescein tag and 
three compounds with TEG tag 1g-i (1-ss-TEG, 1-mm-TEG and 1-ll-TEG) were 
generated.  Purities and compositions of the bivalent molecules were established by 
HPLC/MS are summarized in Table 2.1.   
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Table 2.1.  Summary of the data of nine bivalent peptidimimetics 1a-i. 
 
Nu N
N N
HN
tag
Nu
linkerlinker
A A
labeled bivalent
peptidomimetics 1a-i  
 
bivalent 
comp’d 1 
compound 
code 
UV 
 purity 
(%)a 
retention 
time (min)a 
amount 
(mg)b 
[M+H]+ 
foundc 
      
a 1-ss-F* 100 10.567 3.1 1629.65 
b 1-sm-F* 100 11.050 2.0 1724.49 
c 1-mm-F* 100 11.267 3.9 1819.62 
d 1-sl-F* 98 12.683 4.0 1812.94 
e 1-ml-F* 100 12.917 4.8 1907.91 
f 1-ll-F* 100 14.133 3.0 1996.06 
g 1-ss-TEG 100 9.267 5.1 1469.68 
h 1-mm-TEG 100 10.133 2.5 1659.91 
i 1-ll-TEG 100 12.967 2.5 1836.27 
 
a Analytical HPLC analyses were carried out on 25 x 0.46 cm C-18 column using 
gradient conditions (10 – 90% B in 25 min) at 254 nm.  The eluents used were: solvent A 
(H2O with 0.1% TFA) and solvent B (MeCN with 0.1% TFA).  The flow rate used was 
1.0 mL/min. 
b Calculated after preparative HPLC separation and lyophilization.  
c Obatined from MALDI-MS. 
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2.4 Binding Assays 
 Binding assays were conducted by our collaborator, Dr. Uri Saragovi and his 
coworkers at McGill University in Canada.  Direct binding assay and competitive binding 
assys were carried out for FITC-labeled peptidomimetics 1a-f.  Full details of analyses 
materials and methods are given in Appendix A.   
2.4.1 Direct Binding Studies with Labeled Peptidomimetics 
 Direct FACScan-based binding assays were performed using FITC-labeled 
compounds and NIH-3T3 cells that were stably transfected to express the neurotrophin 
receptor TrkA, the neurotrophin receptor p75, or the control IGF-1R receptor to test for 
selectivity. 
 As shown in Figure 2.4, the use of longer length linkers based on the same 
triazine backbone caused a decrease in TrkA binding.  Peptidomimetic 1-ss-F* bound 
TrkA selectively and better than any other dimer.  Progressively longer peptidomimetics 
1-sm-F*, 1-mm-F*, 1-sl-F*, 1-ml-F*, and 1-ll-F* exhibited significantly lower TrkA 
binding than 1-ss-F*.  These studies were replicated using at least two independent 
syntheses of the compounds, with each synthesis being tested independently at least three 
times.   
 In additional specificity controls, NIH-3T3 cells that were transfected to express 
TrkC (NIH-TrkC) were also tested.  In all cases they did not bind the compounds above 
the level for non-transfected cells (data not shown). 
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Figure 2.4.  Direct binding FACScan assay with FITC-peptidomimetics.  Cells 
expressing the indicated receptor were bound with test ligand (20 µM) at 4°C.  After 
washing data was acquired and analyzed by FACScan/CellQuest with background 
subtracted.  Mean channel fluorescence ± sem, n = 3-6 independent experiments. 
 
 
2.4.2 NGF Binding Competitive Studies 
 Parental monovalent compound D3 has been shown to bind TrkA in a way that 
does not compete with binding of NGF, and actually potentiates NGF activity.  Wild type 
or TrkA-expressing NIH-3T3 cells was used to test the effect of 1-ss-F* on the binding of 
125I[NGF] to TrkA (Figure 2.5).  Unlabeled NGF was used as control competitor. 
 125I[NGF] dose-dependent binding data subjected to Scatchard plot analyses 
showed the expected number of receptors on the cell surface and high affinity binding to 
TrkA (Figure 2.5a).  A constant 500-fold excess of peptidomimetic 1-ss-F* inhibited the 
binding of 125I[NGF] by ~50% without changing the affinity of the residual 125I[NGF] 
bound to TrkA.  This result is suggestive of a competitive block.  In a positive control, 
100-fold excess cold NGF as competitor blocked nearly all the binding of 125I[NGF].  
The background cpms of these assays were determined by using the same concentration 
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range of 125I[NGF] binding to NIH-wild type cells (not expressing TrkA).  In all assays, 
background ranged from 5-15% of the total binding, and in each case these cpms were 
subtracted.   
 Similar binding assays were carried out using a constant 125I[NGF] concentration 
(1 nM, resulting in maximal 16,500 cpms bound) and a dose-range of inhibitors cold 
NGF or mimetic 1-ss-F*.  The competitors were observed to reduce 125I[NGF] binding in 
a dose-dependent manner.  The IC50 of cold NGF competing 125I-NGF is 2 nM.  The IC50 
of peptidomimetic 1-ss-F* is 1,800 nM (~900-fold higher than NGF competing itself) 
(Figure 2.5b).  From three different IC50 obtained for cold NGF versus peptidomimetic in 
independent assays, it was estimated that mimetic 1-ss-F* has a Kd ~ 135 ± 30 nM.   
 At last, anti-TrkA mAb 5C3 was used as a competitor because the parental 
mimetic D3 competed with mAb 5C3 for binding.  In this experiment MAb 5C3 
competed for binding of FITC-labeled 1-ss-F* in a dose dependent manner. The IC50 of 
mAb 5C3 upon mimetic 1-ss-F* is ~60 nM (Figure 2.5c).  Because the affinity of mAb 
5C3 is ~4 nM,70 we estimated that mimetic 1-ss-F* has a Kd ~ 240 nM.  
 Overall, both estimates of affinity for 1-ss-F* correlated well, and suggested 
higher affinity binding to TrkA than parental monovalent compound D3, which was 
anticipated from 1-ss-F* bivalency.   
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Figure 2.5.  Binding competition studies using NIH-TrkA cells. a. scatchard plot analysis 
of high affinity 125I[NGF] binding data; b. displacement of specific 125I[NGF] binding by 
unlabeled NGF or by mimetic 1-ss-F*; c. mAb 5C3 competes for binding of FITC-tagged 
mimetic 1-ss-F*. 
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c. 
 
 
Figure 2.5. continued. 
 
 
2.5 Receptor Dimerization Studies 
The reason for increased affinity of 1-ss, compared to parental monovalent A, is 
likely to be its bivalent binding.  Moreover, blocking of NGF binding was only observed 
by 1-ss but not by monovalent A, which may be due to the triazine linker bridge that fills 
the inter-receptor space where NGF fits.  Both of these observations would be consistent 
with 1-ss binding a TrkA-TrkA dimer.  Thus, the chemical cross-linking experiments are 
performed to address this question.  
NIH-TrkA cells were exposed to no ligand or to test ligands, followed by 
chemical cross-linking with disuccinimidyl suberate (DSS) to stabilize receptor dimers 
before resolution in denaturing SDS-PAGE and analyses by western blotting with highly 
specific anti-TrkA antibodies (Figure 2.6).  
Untreated cells have a prominent band at p140 (cell surface TrkA monomer) and 
a less intense p110 band previously reported to be intracellular TrkA with a lower degree 
of glycosylation.  There is also a less intense band at ~280 kDa detected in untreated 
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NIH-TrkA cells, which consistent with the existence of ligand independent pre-formed 
dimers in receptor over-expressing cells.45  Exposure of NIH-TrkA cells to NGF (10 nM), 
to 1-ss-F*, or to 1-ss-TEG increased formation of TrkA dimers at 280 kDa.  Without 
chemical cross-linking, there is no detection of bands at ~280 kDa because the receptor 
dimers are non-covalent (data not shown). 
These data indicate that 1-ss and NGF each is able to induce or to stabilize TrkA 
dimers at the cell surface, in such a way that covalent chemical cross-linking at the cell 
surface is more efficient.  These data support the notion that one bivalent 1-ss molecule 
may bind two TrkA receptors. 
 
 
 
 
Figure 2.6.  Induction of putative TrkA dimers.  After exposure to the indicated ligand 
(30 min at 4°C), NIH-TrkA cells were chemically cross-linked with DSS.  After washing, 
they were detergent solubilized and samples (20 mg protein/lane) were studied by 
western blotting with a highly specific anti-TrkA mAb 5C3.  
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2.6 Cellular Assays 
Biological assays were also conducted by Dr. Uri Saragovi and his coworkers at 
McGill University in Canada.  These assays were carried out especially for TEG-labeled 
peptidomimetics 1g-i.  Full details of analyses materials and methods are given in 
Appendix A. 
2.6.1 Cell Survival Assays 
 Using NIH-3T3 cells expressing either TrkA, TrkC or IGF-1R in quantitative 
MTT assays, the effect of peptidomimetics on bioactivity was evaluated in functional 
studies of receptor-mediated cell survival.  The cells undergo apoptosis when they are 
placed in serum-free media (SFM). In these conditions, cells can be protected by their 
appropriate growth factors (NIH-TrkA is protected by NGF, NIH-TrkC is protected by 
NT-3, NIH-IGF-1R is protected by IGF-1).  Growth factor protection of cells from 
apoptosis in SFM is dose-dependent; suboptimal doses of growth factor quantitatively 
and consistently give reduced survival (25-40% of maximal).   
In initial binding assays the FITC-containing peptidomimetic 1-ss-F* was used 
and these assays proved that 1-ss-F* was an antagonist of NGF (data not shown).  
However, it is not desirable to use a FITC-labeled compound in bioassays.  To verify the 
irrelevancy between the FITC moiety and the antagonistic function, we tested analogs 1-
ss-TEG, 1-mm-TEG, and 1-ll-TEG that contain a TEG instead of the FITC moiety in 
additional survival assays.  
Mimetic 1-ss-TEG showed antagonistic function of NGF bioactivity, measured as 
NGF-mediated protection of NIH-TrkA cells stressed to undergo apoptosis (Figure 2.7a).  
Antagonism was selective because 1-ss-TEG did not antagonize the protective functions 
of NT-3 upon NIH-TrkC cells (Figure 2.7b), or the function of IGF-1 upon NIH-IGF-1R 
(data not shown).  In further control assays, mimetics 1-mm-TEG and 1-ll-TEG had no 
significant effect on the survival-promoting effect of any growth factor, NGF (Figure 
2.7a), NT3 (Figure 2.7b), or IGF-1 (data not shown).  Although inactive, these bivalent 
mimetics are highly related to the active mimetic 1-ss-TEG and are therefore controls of 
great importance.   
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Antagonism of NGF action by 1-ss-TEG was found to be dose-dependent.  The 
survival promoted by 0.2 nM NGF (~40% of maximal survival) was reduced by 1-ss-
TEG.  The mimetic at 5 µM, 20 µM, and 50 µM respectively reduced the survival 
promoted by NGF from ~40% to ~25% (non-significant), and to a statistically significant 
~15%, and ~0% survival (Figure 2.7d). 
Interestingly, mimetic 1-ss-TEG also significantly accelerated the death of NIH-
TrkA cells in SFM (in the absence of NGF) (Figure 2.7c).  Over-expressed TrkA in these 
cells was known to have spontaneous ligand-independent trophic functions.  In the 
experiment high baseline ligand-independent activity was observed in cells over-
expressing TrkA and other RTKs.  
Antagonism of baseline TrkA activity by 1-ss-TEG was also TrkA selective, for 
the fact that inhibition of ligand-independent activity was not observed in NIH-TrkC cells 
(Figure 2.7c) or NIH-IGF-1R cells (data not shown).  Moreover, accelerated death of 
NIH-TrkA cells in SFM by 1-ss-TEG was dose dependent and significant at 
concentrations of 20 µM and 50 µM (Figure 2.7e). 
In control assays, mimetics 1-mm-TEG and 1-ll-TEG showed no significant 
effect on ligand-dependent activation (Figure 2.7a and b), or in baseline ligand-
independent activity (Figure 2.7c) of any receptor.  And there was no detectable toxicity 
in MTT assays when cells were cultured in serum containing media + 50 µM of the 
mimetics (data not shown).   
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Figure 2.7.  Mimetic 1-ss-TEG antagonizes NGF and TrkA in cell survival assays.  
Mimetics were tested at 20 µM for antagonism of a. 0.2 nM NGF for TrkA cells; b. 0.1 
nM NT-3 for TrkC cells; or c. accelerated cell death in SFM.  Antagonism of d. NGF; or 
e. TrkA baseline activity were dose-dependent. 
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Figure 2.7. continued. 
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Figure 2.7. continued. 
 
 
2.6.2 Antagonism of Biochemical Signals by 1-ss 
Over-expressed TrkA in these cells has spontaneous ligand-independent trophic 
functions; and high baseline ligand-independent activity has been reported in cells over-
expressing TrkA and also for other RTKs.  Indeed, the presence of TrkA-dimers was 
observed in these cells in the absence of ligand (e.g. see Figure 2.6).  
For this reason, we followed the observation that mimetic 1-ss-TEG significantly 
accelerated the death of NIH-TrkA cells in SFM in the absence of NGF.  We 
hypothesized that this may be due to antagonism of baseline receptor activity, which is 
partly protective of cell death.  We carried out biochemical analyses of receptor-tyrosine 
phosphorylation (pTyr) (Figure 2.8) by western blotting with anti-phosphotyrosine 
antibodies untreated or ligand treated cells. 
Untreated cells have some TrkA-pTyr, which decreases significantly after 
treatment with 1-ss-TEG (10 µM).  This was seen after cells were treated with ligand for 
2 hours (Figure 2.8 lane 1 versus 2) or 20 minutes (Figure 2.8 lane 5 versus 6). As 
expected, control treatment with NGF (10 nM) for 2 hours (Figure 2.8 lane 3) or 20 
minutes (Figure 2.8 lane 7) results in significant increases in TrkA-pTyr.  Interestingly, 1-
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ss was also able to reduce the level of TrkA-pTyr even in the presence of NGF (Figure 
2.8 lane 4).  To show equal receptor loading, the membranes were stripped and re-blotted 
with anti-TrkA mAb 5C3.  
All these data are consistent with the results of the bioassays, and indicate that 1-
ss has the ability to inhibit the baseline kinase activity of TrkA.  It is curious that 1-ss can 
do so while at the same time it can also increase the number of TrkA-TrkA dimers (e.g. 
see Figure 2.6), because dimeric receptors are thought to be in the active state.   
 
 
 
 
Figure 2.8.  Mimetic 1-ss-TEG antagonizes baseline (ligand-independent) and ligand-
dependent TrkA activity.  NIH-TrkA cells were cultured in SFM alone, and were then 
supplemented with the indicated ligand for 2 hours or for 20 min at 37°C in a cell 
incubator.  After detergent solubilization the phosphotyrosine levels of the samples were 
studied by western blotting with anti-pTyr mAb 4G10.  Total TrkA loading was verified 
on the same membranes with a highly specific anti-TrkA mAb 5C3.  
 
 
2.7 Docking/Modeling 
It is interesting to notice that the previous result of binding assays and biological 
assays of parental monovalent compound D3 showed that it bound to TrkA in a non-
competitive manner with binding of NGF and it potentiated NGF activity.50  However 
bivalent peptidomimetic 1-ss seems not to follow the same binding mode with NGF from 
the data shown in the previous section.  To better understand and explain the basis for 
NGF competition and receptor antagosim of 1-ss, molecular modeling was carried out to
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explore the interaction mode.  This modeling was conducted by Dr. Uri Saragovi and his 
coworkers at McGill University in Canada.  More details of docking/modeling methods 
are given out in Appendix A. 
Firstly, the 3D structures of 1-ss were built using SYBYL optimized by using 
Tripos force field71 and partial charges of 1-ss were calculated by the AM1-BCC 
method.72 The 200 lowest-energy conformers of 1-ss were selected. 
A model of the target TrkA-D5 was also prepared.  A rectangular box was 
constructed following the NGF-TrkA-D5 crystal complex (Figure 2.9a and 2.9b); 73,74 
this box defined the volume to be explored in docking 1-ss to TrkA-D5.  
These two molecules were then docked in an unbiased manner to explore possible 
binding sites.  The possible binding modes for the 200 lowest-energy conformers of 1-ss 
were posed on the TrkA-D5 rectangular box using a docking algorithm, WILMA; and 
resulted in 52 clusters of bound conformers.  The top-scoring poses of 1-ss had similar 
docking scores (–6 to –9 kcal/mol).  One of the top-scoring poses is shown in Figure 2.9c 
and 2.9d, in which 1-ss binds simultaneously to two monomers of TrkA-D5.  Each 
pharmacophore of the 1-ss homodimer binds to one monomer of the TrkA-D5 dimer, 
occupying mainly the membrane proximal part of TrkA-D5, which is solvent exposed.  
This is consistent with our hypothesis of non-covalent cross-linking of the receptor pair 
by 1-ss.  
A close-up of the binding mode of this pose is also shown in Figure 2.9d.  The 
lysine side-chain of one monomer of 1-ss forms a salt bridge (2.6 Ǻ) with the carboxylate 
group of E295 of TrkA-D5.  The glutamic acid side-chain of the same monomer also 
forms weak H-bonding interactions with the backbone amide of the Q350 (3.8 Ǻ) and 
indole nitrogen of W299 (2.8 Ǻ) of TrkA-D5.  The linker of 1-ss is mostly solvent 
exposed, but the amides connected to the triazine can form two weak H-bonds with N349 
(3.0 Ǻ) and Q350 (3.0 Ǻ) of the contralateral TrkA-D5 monomer.  Therefore, the linker 
may contribute, although minimally, towards receptor binding.  
 Besides, the binding affinity of this pose was estimated using a solvated 
interaction energy (SIE) approach75 and a value of -8.87 kcal/mol (0.29 µM) was 
obtained.  This value was compared with the experimental binding affinity (~0.2 µM) of 
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1-ss and found to be close, which further proved the consistency of the proposed binding 
mode with the experimental binding affinity and observed NGF binding inhibition.   
 
 
a. 
 
 
b. 
 
 
Figure 2.9.  Molecular modeling illustration of NGF:TrkA and 1-ss:TrkA interactions.  a. 
ribbon diagram representation of TrkA dimer (green) bound to NGF dimer (cyan and 
light blue).  The capped stick amino acids of the receptor indicate where monovalent D3 
binds, near the NGF hot spot; b. the red box representing the putative binding pocket of 
compound 1-ss, used for docking; c. the surface of TrkA-D5 (green) with 1-ss shown in 
capped stick representation; d. a close-up of the circled area in c as representation of 
TrkA-D5 (green) complexed with 1-ss.  The residues of TrkA-D5 forming hydrogen 
bonds with 1-ss (original atom color) were represented by capped stick models.  The 
hydrogen bonds between 1-ss and TrkA-D5 are shown by dashed lines.   
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c. 
 
 
d. 
 
Figure 2.9. continued.   
 
 
2.8 Discussion and Summary 
 An early lead, cyclic monovalent peptidomimetic D3 was found to bind NFG 
receptor, TrkA selectively and have intrinstic agonistic activity in the absence of NGF 
based on previous studies.  To improve the binding affinity, a library of nine new bivalent 
peptidomimetics that features two close monovalent moieties with D3 and linker 
combinations of various lengths (ss, sm, mm, sl, ml, ll) was prepared via Fmoc-SPPS, 
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SNAr macrocyclization reactions and a highly efficient dimerization method.  A 
fluorescein tag or TEG tag was attached to each dimer to facilitate the binding assay or 
biological assay.   
Direct binding assay and NGF competitive assay showed that 1-ss has higher 
affinity than other bivalent compounds with TrkA and a ~50-fold better affinity than the 
parental monovalent peptidomimetic D3 (~200 nM versus ~10 µM), and retains high 
selectivity towards TrkA.  While both molecules can block the binding of another ligand, 
anti-TrkA mAb 5C3 (the latter is more efficient), 1-ss can also block NGF binding.  In 
the subsequent biological assays, 1-ss was found to antagonize ligand-dependent 
activation of TrkA as a pure receptor antagonist while the parental monovalent 
peptidomimetic D3 is an agonist towards NGF.50   
 It is intriguing that the parental monovalent molecule D3 potentiates or facilitates 
NGF function (logically does not block NGF binding) and dimeric 1-ss with higher 
avidity and affinity to a different receptor hot spot blocks the binding and bioactivity of 
NGF.  The observation that 1-ss increases TrkA-TrkA dimers suggests that this bivalent 
mimetic may bind to two receptors; this is also consistent with the docking result that 1-
ss binds two TrkA receptors.  This model suggests that 1-ss can block NGF binding 
through the extended linker that bridges the homodimer and “fills” the inter-receptor 
space where NGF normally fits, which is probably why 1-ss is a competitive antagonist 
of NGF without binding to the same receptor hot spot.  Logically, blocking NGF binding 
also results in antagonism of NGF’s trophic activity as well.  Mimetic 1-ss reduces 
ligand-independent receptor activation in trophic survival assays, and reduces the 
baseline tyrosine phosphorylation of TrkA.   
The functional difference between 1-ss and D3 can be further interpreted by their 
different ability to allow or disallow putative receptor conformational changes that ought 
to take place before or after binding of an agonist to TrkA.  However, this is speculation, 
and further research is required to address whether dynamic conformational changes of 
the TrkA receptor may be important for bioactivity.   
To our knowledge, this is the first report of an agonist being converted to an 
antagonist through simple dimerization.  The experience can provide strategies to 
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discover inhibitors or activators of NGF receptors of new classes, and could possibly be 
expanded to other receptors. 
Overall, in this work we address whether and how dimerization of an agonistic 
monovalent ligand could generate an antagonist, whether simple binding to an agonistic 
hot spot of the receptor TrkA was sufficient for activation, or whether receptor 
conformational changes would be required to afford agonism.   
From the assay result and computer modeling, we propose that if receptor 
conformational changes must be induced when it binds an agonistic ligand, a relatively 
rigid bivalent ligand could “freeze” the receptor dimer by non-covalently cross-linking 
the receptor pair and prevent conformational changes.  Unfortunately, conformational 
changes in TrkA upon the binding of its protein ligand NGF have not yet been 
demonstrated through structural analyses, and this is still an issue in the current debate.54   
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CHAPTER III 
A COMBINATORIAL METHOD TO SOLUTION-PHASE 
SYNTHESIS OF BIOTIN-LABELED BIVALENT BETA-TURN 
MIMICS  
3.1 Introduction 
2,5-Diketopiperazines (DKPs), an important class of heterocyclic compounds, are 
the smallest cyclic peptides and have been known for over a century.76-78  They have 
attracted a lot of attention in organic and medicinal chemistry for their synthesis and 
biological activities.79-83  This unique heterocyclic system has been found in several 
natural products and many interesting biologically active synthetic molecules.84-88  Their 
wide spectrum of biological properties have gained significance in modern drug 
discovery.89   
Biologically, DKPs are related to some important bioactivities, such as inhibition 
of various enzymes, as well as plasminogen activator inhibitor-1,90-93 opioid receptor 
agonism and antagonism,94 and alternation of cardiovascular and blood-clotting 
functions.82  They also exhibit activities as antitumor, antiviral, antifungal, antibacterial, 
antihyperglycaemic agents, etc.79,80 These, including their resistance to proteolysis, make 
them very attractive for medicinal chemistry. 
Chemically, DKPs show well-defined and controlled substituent group 
stereochemistry in up to 4 combinations, which can provide structural diversity with 
particular orientation; this also makes them privileged structures for combinatorial 
chemistry in lead discovery.29,95  In addition, their conformational rigidity, and 
availability of hydrogen bonding donor and acceptor groups, is greatly favored in various 
interactions with biological targets.  Thus DKPs are frequently involved in mimicking of 
peptidic pharmacophoric groups,96,97 and their favorable characteristics are considered 
ideal for the rational development of new drugs.82,98   
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Synthetically, DKPs are a common scaffold that can be accessed easily from 
conventional procedures in good yields.79,80  Many DKPs can be synthesized efficiently 
from α-amino acid esters in solution, via intramolecular cyclization of corresponding 
dipeptides;28 this method does not require many reaction steps.  Dipeptides that are fixed 
on the solid support via a bond that is susceptible to nucleophilic attack (e.g. phenacyl 
ester bond),98 or even better, a safety-catch linker bond that is more stable and activated 
to allow for cleavage and cyclization,99 are commonly used building blocks in solid-
phase DKP synthesis.  Another way to obtain DKPs is via Ugi reaction, a multi-
component reaction also known as the Ugi 4-component coupling (4-CC).100-103  This 
approach is ideal for generation of highly substituted DKP libraries by parallel solution-
phase synthesis.104  Besides these conventional methodologies, microwave heating as an 
innovating strategy was used to synthesize symmetrical dimeric DKPs without 
epimerization at α-position of the amino acids in higher yields and shorter reaction 
times.105   
Most of the known DKPs generated from above procedures have a general 
structure as B (Figure 3.1a), the two substituents are attached to the α-carbons of the two 
amino acids; these side-chains usually carry the functionalities.28,106  However, during our 
attempts to overlay the optimized target structure onto a standard type I β-turn motif, we 
found that it did not fit very well with the backbone (Figure 3.1b).  This led to structural 
modification and development of a better design, which is shown as structure A (Figure 
3.1a).  In DKP A, the two side-chains from amino acids were retained, however at more 
favorable positions to offer a better overlay with standard β-turn in molecular modeling 
(Figure 3.1b).  Of course, this changes the synthetic route correspondingly. 
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Figure 3.1.  a. The key distance of Cb-separations of the i + 1 to i + 2 residues of a type I 
β-turn and of the monovalent turn mimics DKP A and B featured here; b. an overlay 
comparison of the two types of 2,5-DKP mimics onto a type I β-turn.   
 
 
 Dimerization of bioactive molecules is a strategy that is used to enhance the 
binding affinity by introducing more pharmacophores around the recognizing sites. 
Weakly binding molecules could also be jointed together to form bivalent molecules with 
higher binding affinity.  Actually a simple DKP, i.e. cyclo(Gly-Gly), itself has been used 
to interlink two other molecules.107  In this work, we followed a very efficient 
combinatorial methodology to generate a library of bivalent DKP-based peptidomimetics 
in solution.43,69  Two different length linkers (short and long) were used to increase the 
number of permutations, and more importantly, explore the optimal linker dimensions for 
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dimeric ligands docking with dimeric receptors.  A biotin derivatized ‘tag’ was attached 
to each bivalent molecule to facilitate further binding and biological assays.   
 
3.2 Preparation of Monovalent Diketopiperazine Peptidomimetics 
 In attempts to prepare the monovalent diketopiperazine building blocks, two 
routes were developed.  From four different DKPs and two linkers (short and long), a 
total of eight monomeric compounds were constructed.  The synthetic route (Scheme 3.1-
a) was chosen based on the amino acid sequence that was incorporated.   
For cyclo(Gly-Lys) and cyclo(Thr-Gly) (Scheme 3.1a), the synthesis began with 
Boc-protected N-methyl amino acid and N-terminal free amino acid tert-butyl ester.  
They were coupled under typical peptide coupling conditions.  The Boc group was then 
selectively removed108 in the presence of tert-butyl ester using TFA.  SN2 reaction 
between bromoacetyl bromide and the deprotected secondary amine intermediate109 
generated the linear bromide precursor.  Using a strong base, the NH from the backbone 
amide was deprotonated and nucleophilic attack at the carbon next to bromide109 
produced the cyclization product 2a-b as a 2,5-diketopiperazine ring.  After TFA removal 
of the tert-butyl ester108 we can obtain the corresponding carboxylic acid 3a-b, which is 
the handle for linker attachment. 
For cyclo(Glu-Lys) and cyclo(Ile-Lys) (Scheme 3.1b), the synthesis was slightly 
different.  It started from Cbz-protected N-methyl amino acid and N-terminal free amino 
acid methyl ester coupling as above.  Accordingly, the dipeptide was deprotected by 
hydrogenolysis and the free secondary amine intermediate reacted with bromoacetyl 
bromide.  The cyclization condition remained the same, however a gentle hydrolysis 
condition to remove the methyl ester in 2c-d was needed without causing racemization.  
After several tests, K. C. Nicolaou’s condition110 (trimethyltin hydroxide) was found to 
be ideal for this case to give the enantiomerically pure diketopiperazine carboxylic acids 
3c-d in good yields.   
With four DKP carboxylic acids 3a-d in hand, the next, as well as the last step for 
cyclo(Glu-Lys) and cyclo(Ile-Lys) monomers, was the linker coupling (Scheme 3.1c).  
Each carboxylic acid was efficiently coupled with a short or long linker to generate eight 
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monovalent compounds 4a-d and 5a-d in total.  For cyclo(Gly-Lys) 4a and 5a, and 
cyclo(Thr-Gly) 4b and 5b monomers, side-chain protections (Cbz, Bzl) were finally 
removed via convenient hydrogenolysis reactions to offer 6b and 7b.  For cyclo(Gly-
Lys), a Boc protection111 was installed back on the side-chain to give 6a and 7a for easier 
purification and handling.  The overall syntheses were successful with decent yields and 
all eight desired products were purified via flash column chromatography before being 
subjected to dimerization reactions.  Scheme 3.1 uses R1’ and R2’ to denote protected 
side-chains (and R1 and R2 to indicate deprotected ones).   
 
 
Scheme 3.1.  Two methods for preparing the monovalent mimics 4 and 5.  Route a. 
featuring cyclo(Gly-Lys) and cyclo(Thr-Gly) monomers; Route b. featuring cyclo(Glu-
Lys) and cyclo(Ile-Lys) monomers; c. linker attachment (for 4a-b and 5a-b, there is an 
additional hydrogenolysis step afterwards using H2 and Pd-C in MeOH to remove side-
chain protections to give 6b and 7b; and a Boc protection in CH2Cl2 to give 6a and 7a). 
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Scheme 3.1. continued.   
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 The data of eight monomeric diketopiperazine compounds prepared via methods a 
and b described above were summarized in Table 3.1. 
 
 
Table 3.1.  Monovalent peptidomimetics 4c-d, 5c-d, 6a-b and 7a-b prepared via method 
a and b. 
 
N
NBoc
NH
O
N
NBoc
5
short linker long linker
I II
 
 
compound  R1’ R2’ linker yield (%)a 
     
6a H NHBoc  I 48 
6b 
OH  
H I 61 
4c 
 
NHBoc  I 57 
4d CO2tBu  
NHBoc  I 48 
7a H NHBoc  II 49 
7b 
OH  
H II 50 
5c 
 
NHBoc  II 55 
5d CO2tBu  
NHBoc  II 40 
 
a From intermediate 3a-d after flash chromatography. 
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3.3 Application of the Solution-phase Procedure to Make a Library of Biotin-
labeled Bivalent Mimics 
 The protected monomeric DKPs 4c-d, 5c-d, 6a-b and 7a-b were subjected to 
global deprotection to give unmasked mimics then reacted with a dichlorotriazine 
derivative of biotin (i.e. DTAB) to give the electrophiles 8.  These were then reacted with 
second aliquots of the mimics 4c-d, 5c-d, 6a-b and 7a-b, in all permutations, to give the 
library of bivalent mimics 9.  Morpholine was also used in the couplings to generate 
specific mimics 9ai-hi that represent controls for testing which contain only one mimic, 
triazine with the biotin label, and the morpholine part which represents the linker.  
Bivalent compound 9ii featuring two morpholine moieties and the DTAB linker was also 
made as a complete control.   
 Our group has made some fluorescent or triethylene glycol derivatized tag labeled 
libraries in previous research.43  Different from the established methods, DMSO was used 
as the solvent instead of THF or acetonitrile in the first monomer addition and a lower 
concentration was necessary due to reduced solubility of the Biotin-containing linker 
DTAB.   
 
 
Scheme 3.2.  Solution phase method for the preparation of the biotin-labeled library of 
bivalent compounds 9.   
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Scheme 3.2. continued.   
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 Thus a library of 45 biotin-labeled bivalent mimics was prepared using the 
method outlined in Scheme 3.2.  Firstly, the monovalent compounds 4c-d, 5c-d, 6a-b and 
7a-b were deprotected with TFA in absence of scavenger.  The resulting unmasked 
intermediates dissolved in DMSO were reacted with equimolar amounts of DTAB and 
excess K2CO3 (4 equiv.) for 2-3 h to give the intermediates 8.  These intermediates in 
DMSO solution were split into small portions, and then coupled with another equivalent 
of the deprotected monomers 4c-d, 5c-d, 6a-b and 7a-b to give the desired bivalent 
compounds 9.  Alternatively, mophorline was used instead of the deprotected monomers 
as a capping group to generate a set of control compounds 9ai-ii.  
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In this process, the purities of intermediates 8 were monitored by analytical 
HPLC, and they were used to judge whether the first coupling was complete and whether 
the purity itself was high enough to carry on the next step without purification.  
Fortunately, the reactions all completed in a few hours and met our purity criteria.  After 
the second addition, the purities of bivalent compounds 9 were evaluated again by 
analytical HPLC (Figure 3.2a).  Ideally, they would be more than 85 % and could be used 
for biological studies directly after a simple work-up and desalting procedure.  However, 
we found that about 18 out of 45 bivalent compounds were satisfactory (≥ 85 %), 11 were 
not very pure (70-85 %), and another 1/3 of the molecules were less than 70 % pure, 
which definitely cannot be used directly for assays.   
The impurities might be caused by several reasons.  The major source of error 
was in weighing the compounds.  Very slight differences in masses can cause serious 
effects in these mg-scale reactions.  The oily monomers were much harder to weigh 
accurately in comparison with solid compounds.  Another possibility is from pipetting 
errors.  This has been found and proved in our previous work and could be corrected by 
simply repeating the syntheses for more times.  Unfortunately for this particular case, 
there were not enough monomers to re-prepare the bivalent compounds to increase the 
purity.  Other possible reasons for lower purities might include incomplete first addition 
and side-chain effects.  Since most of the monomers are not very UV active at our 
observation wavelength (254 nm), it was hard to tell whether there were unreacted 
monomers left in the first step and this could cause byproducts in the second step.  Amino 
acid side-chains that feature different functionalities might have a subtle influence on the 
monomer reactivity and reaction condition.  However this did not cause much trouble in 
previous similar experiments according to our experience.   
Finally we chose to purify all the bivalent compounds 9 (including the ones 
having a purity > 85 %) via RP-preparative HPLC.  This surely provided us compounds 
pure enough for both binding and cellular assays.  Most of the inorganic salt (K2CO3) was 
converted into KCl salt first by treating the lyophilized reaction residue with small 
amount of dilute HCl.  After removing the solvent, the product was separated from the 
salt by extracting them into methanol; these were then concentrated and re-dissolved in 
appropriate solution for HPLC purification.   
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HPLC and MALDI analyses were performed on all the bivalent compounds 9 
after purification.  UV detection was used to determine the purities shown in Figure 3.2b.  
Purity data before the purification is given in Figure 3.2a.  In summary, this dimerization 
methodology allows us to obtain a biotin-labeled bivalent compound 9 library from the 
monovalent compounds to combine with each other relatively cleanly in a one-
compound-per-well format.   
 
 
a. 
i(cap) 100              
a 100 75             
b 98 71 89            
c 100 72 68 80       UV  
d 100 47 80 58 89      purities (%)  
e 95 45 59 43 71 64     below 70  
f 100 88 87 70 79 56 100    70 – 85  
g 98 93 92 70 58 41 72 86   85  and up  
h 100 51 57 58 81 65 76 36 85      
 i a b c d e f g h      
 
b. 
i(cap) 100              
a 100 100             
b 100 98 100            
c 100 100 100 100       UV  
d 100 100 100 100 100      purities (%)  
e 100 100 100 100 100 100     below 85  
f 100 100 100 100 100 100 100    85 – 90  
g 100 100 100 100 100 100 100 100   90  and up  
h 100 100 100 100 97 100 100 100 100      
 i a b c d e f g h      
 
Figure 3.2.  Purities of the library of compounds 9 where the UV detection method was 
set at 254 nm.  a. crude purity; and b. after purification.  The term ‘cap’ is used for 
morpholine. 
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Twenty percent of the bivalent compounds 9 were characterized by one-
dimensional and two-dimensional NMR experiments. (See Appendix B)  All the 
compounds gave satisfactory molecular ions in MALDI-MS analyses.  The product yields 
were not determined due to the small scale of the synthesis.  
 
3.4 Biological Assays 
Binding assays were performed to assess the ability of peptidomimetics 9 to bind 
Trk and p75 receptors;112,69,58,113  these were conducted by our collaborator, Dr. Uri 
Saragovi and his coworkers at McGill University in Canada.   
The library of 45 bivalent compounds was tested for binding to transfected TrkC-
expressing, TrkA-expressing, or p75-expressing cells in a fluorescence activated cell 
sorting (FACScan) assay.  Live cells expressing the indicated receptors were incubated 
with ligands (50 µM) then with FITC-avidin, washed, and immediately studied by 
FACScan.  Data was acquired and analyzed via CellQuest software.  The NIH-IGF-1R 
cells which do not express any neurotrophin receptor served as a negative control.   
From the preliminary screening data, four bivalent compounds exhibited 
relatively high binding affinity and better selectivity against TrkC-expressing cells.  The 
structures of the four compounds are illustrated in Figure 3.3.  As shown in Figure 3.4, 
compounds 9gc, 9hg, 9ge and 9gg bind to TrkC but not significantly to TrkA.  Notably, 
the four “hits” all contain at least one cyclo(Ile-Lys)-long linker (i.e. 5c) monovalent 
fragment.  However, residues “IK”, “EK” and “GK” are found in NGF turn sequences 
from different sources but not in NT-3, while residue “TG” corresponds to one of the turn 
sequences in NT-3 but none of the cyclo(Thr-Gly) mimics showed high affinity in 
binding assay probably due to their relatively poor water solubility.   
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Figure 3.3.  Structures of compounds 9 that bind to TrkC from the preliminary FACScan 
assay. 
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Figure 3.3. continued. 
 
 
Figure 3.4.  FACscan assay data and the graph presentation of the four “hits”. 
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 In subsequent cell survival assays, three bivalent compounds 9hd, 9gi and 9gg 
were found to block the trophic activity of NT-3 in TrkC cells at 10 uM, and no 
significant effect was observed for these compounds in IGF-1R and TrkA cells. (Figure 
3.5 and 3.6)  The survival studies on these compounds will be repeated with different 
doses to confirm their selectivity for TrkC cells.  Among the three, compound 9gg is 
worthy of attention for its preferential binding to TrkC receptors shown in previous 
FACScan assays, while the other two mimics did not show the same trend.  More 
interestingly, 9gg is a homodimer of two cyclo(Ile-Lys)-long linker moieties.  Overall, 
there is no significant correlation found among these active compounds.   
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Figure 3.5.  Structures of compounds 9 that block the trophic activity of NT-3 in TrkC 
cells in cell survival assay (9gg is shown in Figure 3.3). 
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Figure 3.6.  Cell survival assay data and the graph presentation of the three “hits”. 
 
 
3.5 Summary 
The diketopiperazine (DKP) scaffold has proven to be a versatile template in 
combinatorial chemistry for its 4 ring atoms that are basis for the generation of molecular 
diversity.80  Their chiral, rigid and functionalized structure is favored for binding to 
various receptors with high affinity and gives a broad range of biological activities.79  
A library of eight monovalent DKP mimetics 4c-d, 5c-d, 6a-b and 7a-b is 
prepared from corresponding dipeptides via intramolecular SN2 cyclization reactions in 
solution.  These DKP compounds contain two amino acid side-chain functionalities that 
are both derived from natural amino acids.  Parallel solution phase synthesis allows quick 
and efficient generation of the desired peptidomimetics in good yields.  Each monomer 
was attached to a short or long linker before they were combined into dimers.   
The eight DKP mimics (along with morpholine as ‘capping’ group) were 
assembled into a library of 45 bivalent molecules 9 via an efficient combinatorial strategy 
previously reported by our group.  The two monovalent mimics were coupled to the 
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linker scaffold sequentially in solution.  A biotin ‘tag’ was attached to each bivalent 
molecule to facilitate further binding and biological assays.  The purities of bivalent 
compounds 9 were evaluated by analytical HPLC before and after purification.   
The fluorescence-activated cell sorting (FACScan) assay has performed on the 
biotin-labeled compounds for binding to transfected TrkC-expressing, TrkA-expressing 
or p75-expressing cells.  Four bivalent compounds 9gc, 9hg, 9ge and 9gg have exhibited 
relatively high binding affinity and better selectivity against TrkC-expressing cells at 50 
uM.  All of these molecules contain at least one cyclo(Ile-Lys)-long linker fragment.  In 
cell survival assay, three bivalent compounds 9hd, 9gi and 9gg blocked the trophic 
activity of NT-3 in TrkC cells at 10 uM, and no significant effect was observed for these 
compounds in IGF-1R and TrkA cells.  The survival on these compounds will be 
repeated with doses to confirm their selectivity for TrkC cells.  Interestingly, compound 
9gg, which also showed preferential binding to TrkC receptors, is a homobivalent 
peptidomimetic of two cyclo(Ile-Lys)-long linker moieties.   
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CHAPTER IV 
SOLUTION-PHASE SYNTHESIS OF OXADIAZOLE-BASED BETA-
TURN MIMETICS AND ATTEMPTS TOWARDS BIVALENT 
MOLECULES 
4.1 Introduction 
Screening of small molecule is the most viable way for the identification and 
optimization of potential bioactive compounds.  The main goal of our approach is to 
mimic the complex molecular interactions of natural proteins by designing small 
molecules that mimic protein secondary structures, especially β-turns.  This allows for 
the functionality identification of important 3D conformations from a molecular 
perspective and helps further the development of therapeutic agents.  Usually the unique 
conformational alignment of functional groups of proteins is relvent to their molecular 
recognition.  Therefore peptidomimetic probes can obtain rich, useful information from 
structure-activity relationship studies and conformational analyses of bioactive peptides 
and proteins.  An ideal solution is to combine selective and metabolically stable analogs, 
peptide backbone modifications and relatively constrained amino acids together into 
bioactive peptide sequences.   
5- and 6-membered heterocyclc moieties are common structure motifs in 
bioactive compounds, such as natural products and synthetic molecules, which play 
enormous impact on their bioactivity.114-120  These heterocycles rigidify otherwise 
flexible backbones, contribute to lipophilicity, and their presence frequently correlates 
with protein binding properties.  Thus the alternation and variation of these heterocycles 
are of major interest for the derivatization of these bioactive molecules.  Moreover, their 
small and rigid, conjugate and stable structures make them ideal scaffolds for mimicry of 
various protein motifs.   
For example, there are reports on the uses of hetercyclic rings in peptidomimetics 
to replace peptide fragments to convert peptides into chemically stable and orally 
available molecules (Figure 4.1).37  There are also many examples in the literature of 
 71 
using heterocycle derivatives as different types of protein recognition motif mimics 
(Figure 4.2).39,121 
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Figure 4.1.  Three heterocyclic ring systems as Xaa-Gly dipeptide mimetics. 
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Figure 4.2.  Examples of different azole type compounds as peptidomimetics. a. non-
peptidic tricyclic oxazole-pyrrole-piperazine scafold as α-helix mimetic; b. triazole ring-
based new β-turn mimic. 
 
 
Our group has been focusing on the design and synthesis of small molecules that 
mimic or disrupt protein-protein interactions and have gained some experience in 
designing β-turn mimics.43,58  In this work we design and synthesize a series of novel β-
turn mimics.  To mimic most possible protein motifs we use a heterocycle-based scaffold 
to obtain necessary backbone rigidity and incorporate the natural amino acid side-chains’ 
functionalities in somewhat restrained conformations.  These amino acids were chosen 
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from the most commonly found bioactive sequences in various protein-protein 
interactions.  Therefore these designated peptidomimetics bear peptidic and non-peptidic 
characteristics at the same time.  Most of these compounds comply with Lipinski’s ‘rule-
of five’ to be more ‘drug like’.122  
It is always important to start from an appropriate design to accquire good small 
molecule mimetics.  From the screening of many heterocyclic building blocks, we found 
that 1,3,4-oxadizole is a class of compounds that is thermally stable neutral and fully 
conjugated.123  Their chemistry has been known for more than 100 years.124,125  They 
have broad uses in many areas, for example in drug synthesis, scientilation materials, 
polymer and dyestuff industry.126,127   
Many oxadizole containing compounds have been reported to present various 
bioactivities.  In Figure 4.3, bactericidal and/or fungicidal activity was reported for 
oxadiazoles (a) and amino-oxadizoles (b).128  Analgesic activity, antiinflammatory and 
antiproteolytic properties, anticonvulsant and nervous system depressant activity, and 
local anaesthetic activity was shown by amino-oxadiazoles (c)-(f), respectively.129-131  
Diaryloxadiazoles (g) exhibit antiinflammatory, sedative and analgesic properties.132   
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Figure 4.3.  Examples of bioactive 1,3,4-oxadiazoles. 
 
 
Overall they are interesting synthetic targets and are ideal for our small molecule 
design as potencial turn analogs; this is further illustrated by the result of our molecular 
modeling study (Figure 4.4).  While reintaining the side-chain functionalities of natural 
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amino acids, our efforts to develop small molecule mimics 12 with less peptide character 
include using a 2,5-substituted 1,3,4-oxadizole as the backbone to bridge two amino acid 
side-chains corresponding to the ones found in the loop region of the neurotrophins.  The 
big advantage of this design is that the target compounds can be relatively easily made on 
large scale, and the natural amino acids that correspond to original protein sequences are 
highly accessible.  Conceptually the side-chains at R1 and R2 can mimic i + 1 and i + 2 
positions of a standard β-turn structure by adjusting two degrees of freedom.   
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b. 
overlay with type I β−turn  
 
Figure 4.4.  a. The key distance of Cb-separations of the i + 1 to i + 2 residues of a type I 
β-turn and of the monovalent turn mimics 12; b. an overlay of the 1,3,4-oxadiazole 
mimic onto a type I β-turn.   
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4.2 Preparation of 1,3,4-Oxadiazole Based Beta-Turn Mimetics 
 In this work, a library of twenty 1,3,4-Oxadiazole mimetics was prepared in 
solution.  At first a set of Boc-protected amino acid methyl esters was converted to acid 
hydrazides133 by reacting with hydrazine monohydrate in alcohol.  The Boc-protected 
hydrazides 9a-f were then coupled with different Cbz-protected amino acids134 to 
produce the diacid hydrazides with more functionality.  Using the diacid hydrazide as a 
cyclization precursor, the cyclodehydration19,135,136 proceeded cleanly with activated 
triphenylphosphine to offer the desired 5-member ring.  The Cbz protective group of 
seventeen synthesized 1,3,4-oxadiazole compounds 11a-q was removed under standard 
hydrogenolysis conditions.  Boc-Inp-OH as the short linker for this library was coupled to 
the cyclic core by forming an amide bond to give monovalent mimics 12a-q in good 
yields.   
 
 
Scheme 4.1.  General synthetic scheme of 1,3,4-oxadizole mimetics. a. synthesis of 
amino acid hydrazide fragments; b. synthesis of 1,3,4-oxadizole intermediates 11a-q; c. 
synthesis of monovalent oxadiazole mimics 12a-q. 
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Scheme 4.1. continued. 
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 The library of twenty monovalent peptidomimetics 12a-t is listed below (Table 
4.1).  All the compounds were functionalized with Boc-Inp-OH moiety as a short linker.  
Seventeen of them were prepared following the route shown in Scheme 4.1 while three 
(12r-t) were prepared from N,N-dimethyl substituted Serine methyl ester instead of Boc-
protected Serine methyl ester (Scheme 4.2).  Reductive alkylation provided N,N-dimethyl 
serine methyl ester 13,137,138 which was transformed to the corresponding acid hydrazides 
10g.  The remaining synthesis steps were carried through following the above general 
synthetic scheme to offer three more oxadiazole compounds 12r-t with a short linker 
through intermediates 11r-t.   
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Scheme 4.2.  Synthesis of N,N-dimethyl serine methyl ester 10g and intermediates 11r-t.   
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Table 4.1.  Summary of 1,3,4-oxadiazole library 12a-t.   
 
BocHN
R1'
N N
O
HN
R2'
O
Boc
N
12a-q
Me2N
R1'
N N
O
HN
R2'
O
Boc
N
12r-t
I II
 
 
comp’d 12 scaffold R1 R2 yield (%)a 
     
a I NHBoc  OtBu  70 
b I NHBoc  CO2
tBu  77 
c I NHBoc  CO2tBu  71 
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Table 4.1. continued. 
comp’d 12 scaffold R1 R2 yield (%)a 
     
d I NHBoc  
OtBu  
93 
e I 
 
OtBu  78 
f I H NHBoc  83 
g I OtBu  CO2tBu  84 
h I OtBu  
OtBu  
80 
i I OtBu  CO2
tBu  82 
j I OtBu  
NHBoc  77 
k I 
OtBu  
CO2
tBu  74 
l I 
OtBu  
NHBoc  78 
m I 
OtBu  
CO2
tBu  89 
n I 
OtBu  
OtBu  85 
o I H OtBu  74 
p I NHBoc   
92 
q I 
OtBu  
NHBoc  70 
r II OtBu  CO2tBu  82 
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Table 4.1. continued. 
comp’d 12 scaffold R1 R2 yield (%)a 
     
s II OtBu  CO2
tBu  89 
t II OtBu  
OtBu  
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a Calculated on the basis of intermediate 11a-t.   
 
 
4.3 Preparation of Bivalent Compounds 
 The preparation of the bivalent library of compounds 15 is similar to that 
discussed in Chapter III.43  As shown in Scheme 4.3, all the acid labile protecting groups 
of the monovalent compounds in Table 4.1 were removed by 50 % TFA and treated with 
DTAF (5-(4,6-dichloro-s-triazin-2-ylamino)fluorescein hydrochloride) and K2CO3 in 
THF for 4-6 h at 25 oC.  The resulting intermediate 14 was concentrated and redissolved 
in DMSO and split into small portions.  An equimolar amount of another deprotected 
monomer was added to each portion followed with the addition of excess of K2CO3.  The 
resulting mixture was placed on a shaker and reacted for 72 h to afford bivalent 
compounds 15.   
 
 
 
 
 
 
 
 
 
 79 
Scheme 4.3.  Preparation of bivalent mimetics 15.   
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 Purities of the crude materials of each step were evaluated by analytical HPLC, 
monitored at 254 nm by a UV detector.  Usually the crude purity after first monomer 
attachment is more than 95 % in order to achieve a purity more than 85 % for the final 
bivalent compounds.  However, for this library, the purities of intermediates 14 generated 
after the first addition are not good enough to carry forward with the dimer synthesis.  
Most of the compounds did not give satisfactory purities even after the first reaction step 
with DTAF.  There were always some impurities in the crude product 14 from analytical 
HPLC traces.  The same reactions were repeated several times and with different 
substrates and we still could not obtain satisfactory results.  It seems that this method may 
not be ideal for these oxadizole compounds.  
By analyzing the structure of the monomers 12a-q and reaction conditions, I think 
there are several possible reasons that may cause the reactions to be not very clean. (i) 
deprotection of the monomer is not complete, (ii) deprotection generates some impurities, 
(iii) functional groups on amino acid side-chains interfere with the SNAr reaction, (iv) the 
free amino group next to R1 interferes with the SNAr reaction. 
Among these possibilities, I first ruled out the incomplete deprotection by 
checking NMR and HPLC after deprotection.  Then I started to examine the last one 
through structure modification.  The free amino group next to R1 was replaced with fully 
substituted N,N-dimethyl group.  As was previously explained (section 4.2), this was 
achieved by using a slightly different starting material.  A total of three 1,3,4-oxadizole 
compounds 12r-t were prepared starting from N,N-dimethyl serine methyl ester 10g.  The 
three compounds were tested under the same reaction conditions and compared with 
unsubstituted serine compounds 12a-q.  After the reaction was complete (no more DTAF 
peak detected), I found that some major impurity peaks disappeared such as those used to 
be found from the HPLC chromatograms of 12i (SE mimic) and 12g (SD mimic), while 
some did not change much (i.e. 12h, a SY mimic).  It seems that the free amino group 
does affect the SNAr reaction.  Because when this amino group gets too reactive it tends 
to compete with the NH from the short linker, which theoretically is most reactive group 
in the whole molecule.  It will react as a nucleophile with DTAF and lead to a complex 
byproduct 16 as shown in Figure 4.5a as an example, which has been verified by LCMS 
 81 
analysis.  This also explains why the same impurity does not appear anymore when the 
specific amino group is blocked.  It should be noted that this result depends on the amino 
acid side-chains in the system, as some of them did not have this problem (e.g. SY mimic 
12h).  
However this did not fully solve the problem to obtain a clean reaction.  From 
analytical HPLC there are still some detectable impurity peaks, although very small, and 
these are very hard to identify.  I assume they are from the residues of acid cleavage 
(reason (ii) as mentioned above), however it is not easy to prove and this has not been 
done yet.  The deprotected compounds are not UV active under 254 nm and are 
extremely polar so that they are not ideal for HPLC analysis.   
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Figure 4.5.  a. Reaction of monomer 12i with DTAF (1:1) and the HPLC trace (UV at 
254 nm) of its crude purity; b. reaction of monomer 12s with DTAF (1:1) and the HPLC 
trace (UV at 254 nm) of its crude purity. 
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Figure 4.5. continued. 
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4.4 Biological Assays 
Since the twenty 1,3,4-oxadiazole compounds 12a-t were not made into a library 
of labeled bivalent compounds, they could not be tested in binding assays.  However, we 
were still able to test them in cell survival assay for their biological functionalities.  Our 
collaborator, Dr. Uri Saragovi and his coworkers at McGill University in Canada are still 
working on testing these compounds. 
Forty 1,3,4-oxadiazole compounds including twenty 12a-t in fully protected form 
and twenty 17a-t in fully deprotected form (not shown) were sent to NIH screening 
centers for extensive biological assays.  Several compounds were found to be active in 
different assays (these results and more details of the bioassays can be obtained from 
http://pubchem.ncbi.nlm.nih.gov).  
4.4.1 Screen for Chemicals that Inhibit the RAM Network 
This is a selection-based screening of compound libraries to discover highly 
specific small molecule inhibitors of the budding yeast RAM network.  The yeast strain 
used in the screen was engineered to contain an "analog-sensitive" mutant allele of the 
RAM network protein kinase Cbk1, which is susceptible to inhibition by 1-napthyl PP1 
(1-NA-PP1).  This permitted pre-inhibition of URA3 expression, a step that was 
necessary to ensure that cells did not begin growth under screening conditions with lethal 
levels of this gene product, and also allowed the use of 1-NA-PP1 as a positive control 
drug.  Percent inhibition of the RAM network signaling was calculated using the optical 
density in control wells with untreated cells as full RAM network activity (no growth; 0% 
inhibition) and wells treated with 10 µM 1-NA-PP1 as complete inhibition of the RAM 
network (full growth; 100% inhibition).  Library compounds were screened at 50 µM.   
Compounds in this primary screen were scored on a scale of 0-40 based on the 
lowest activity from the two runs where 0 corresponds to no inhibitory activity and a 
score of 40 corresponds to 100% inhibition.  An activity score of 4 or higher corresponds 
to compounds with an active outcome.   
In this screening assay for chemicals that inhibit the RAM network conducted at 
southern research molecular libraries screening center, two compounds 12i (SE mimic) 
and 12c (KD mimic) showed some activity and scored 12 and 11, respectively.   
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4.4.2 Primary Cell-based High Throughput Screening Assay for Inhibitors of 
Wee1 Degradation 
Previous studies suggest that nuclear tyrosine kinase Wee1 may act as a tumor 
suppressor.  The identification of probes that selectively increase levels of Wee1 may 
provide a potent route for cell cycle-based cancer therapy.  Compounds that inhibit Wee1 
degradation will provide information about the role of Wee1 in mitotic entry and cell 
cycle progression.  The hypothesis is based on studies that show that Wee1 stabilization 
inhibits mitotic entry.  Moreover, the liabilities of several reported intriguing compounds 
necessitate the discovery of high affinity, selective probes for Wee1 stabilization.  The 
assay uses HeLa cells transfected with a kinase negative mutant of Wee1 (Wee1K328M) 
fused to a luciferase reporter gene.  As designed, compounds that increase Wee1K328M-
luciferase stability and/or prevent its degradation will lead to increased well 
luminescence compared to untreated wells.  Specifically, compounds that increase 
luminescence are considered Wee1 degradation inhibitors.   
The reported activity score has been normalized to 100% of the highest observed 
activation.  The inactive compounds of this assay have activity score range of 0 to 6 and 
active compounds range of activity score is 6 to 100.   
From the data provided by the Scripps research institute molecular screening 
center, the activity ranking score of compound 12a (KS mimic) and 12s (S’E mimic) 
were 8 and 7, which are slightly higher than 6 to be in the active range.   
4.4.3 µHTS Identification of Diaphorase Inhibitors and Chemical Oxidizers: 
Counter Screen for Diaphorase-based Primary Assays 
 The purpose of this assay is to identify inhibitors of diaphorase, which is an 
enzyme that reversibly catalyzes the reaction of converting NAD(P)+ to NAD(P)H and 
transfers its electrons to a variety of Redox dyes.  It is expected that strong inhibitors of 
diaphorase would appear as inhibitors in the PMI assay.  Thus, diaphorase is a counter-
screen for the PMI and other diaphorase-based assays allowing identification of the 
artifacts of the coupled assay detection system.  In addition, compounds that have strong 
oxidative properties are also expected to suppress the resorufin formation and appear as 
inhibitors of diaphorase based reactions.  Thus, the assay could be utilized for library 
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characterization in respect to redox-active compounds.  Compounds with greater than 
50% inhibition at 20 µM concentration are defined as actives of the primary screening, 
and the primary screening actives proceed to the dose-response confirmation stage.  
However, no dose-response data has been published on PubChem so far.   
First tier (0-40 range) of the scoring system is reserved for primary screening 
data.  The score is correlated with % displacement in the assay demonstrated by a 
compound at 20 µM concentration.   
Compound 12j (SK mimic) scored 34 in this assay based on the result from San 
Diego center for chemical genomics.   
4.4.4 µHTS of Mcl-1/Bid interaction inhibitors 
 Currently there is still a lack of small-molecule inhibitors of Mcl-1.  Reports 
indicate that the most potent inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-xL and 
Bcl-w described to date, fail to bind to Mcl-1.  This is evidence that Mcl-1 has critical 
structural differences compared with other anti-apoptotic proteins and strongly suggests 
that specific targeting of Mcl-1 should be possible.  Bid is a broad acting Bcl-2 homology 
domain 3 (BH-3) only protein that binds Mcl-1 as well as other pro-survival proteins, 
including Bcl-2 and Bcl-xL.  To screen for small molecular inhibitors that disrupt the 
interaction of Mcl-1 protein and its binding partners, a homogeneous time-resolved 
fluorescence resonance energy transfer (TR-FRET) assay was developed.  In this assay, 
interaction of Mcl-1 protein with Bid peptide brings two conjugated fluorophores into 
proximity, leading to an energy transfer from europium to Dy647 and the generation of 
FRET signals.   
This assay is used for the screening of the NIH/DPI library for Mcl-1/Bid 
interaction inhibitors.  Compounds that cause > 50% inhibition are defined as positives.  
The percent inhibitions are rounded to 0 decimal places.  Percent inhibitions > 100 are 
rounded to 100, and those < 0 are rounded to 0.   
Compound 17j (derivative of 11j as a GK mimic) scored 90 in this assay 
conducted at Emory university molecular libraries screening center.  It is also the only 
unmasked 1,3,4-oxadizole compound that was found active in these bioassays so far.   
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4.5 Summary 
 Syntheses of rationally designed peptidomimics normally involve peptide bond 
surrogates or scaffolds wherein the critical side-chains are retained in a constrained 
conformation to maintain the desired biological properties.  Our efforts toward the 
synthesis of small molecule β-turn mimetics used a 1,3,4-oxadizole based scaffold and 
two amino acid side-chains to mimic the distance and orientation at i+1 and i+2 position. 
The natural amino acid side-chains can be sequentially incorporated via amide coupling 
and stabilized via ring cyclization reactions. 
This method produced a library of twenty β-turn mimics 12a-t.  These 
compounds contain a variety of amino acid side-chains, ca. glycine, isoleucine, lysine, 
serine, glutamic acid, aspartic acid, theronine, and tyrosine.  A short linker was attached 
to the monomers via an amide bond.  After removal of all the protecting groups, the 
monovalent compounds were introduced onto a fluorescent-labeled triazine scaffold 
sequentially.  Unfortunately for some reason the reaction did not proceed cleanly.  
Studies have been carried out and some problems could be partially solved.  More efforts 
are still needed to obtain a bivalent compound library.   
The biological activities of these monomers are still under investigation.  So far, 
based on the results from NIH screening centers, there are six compounds that showed 
certain activities in 4 bioassays of different types.   
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CHAPTER V 
SYNTHESIS OF CYCLIC PEPTIDOMIMETICS OF PROTEIN A 
AND SMALL MOLECULE MIMETICS OF PROTEIN G FOR 
PURIFICATION OF IMMUNOGLOBLIN G VIA AFFINITY 
CHROMATOGRAPHY 
5.1 Introduction 
An antibody is defined as “an immunoglobulin capable of specific combination 
with the antigen that caused its production in a susceptible animal.”  Antibodies, which 
are produced in response to the invasion of foreign molecules in the body, exist as one or 
more copies of a Y-shaped unit, composed of four polypeptide chains.  Each Y-shaped 
unit contains two identical copies of a large heavy chain, and two identical copies of a 
small light chain, named as such by their relative molecular weights.  Antibodies can be 
divided into five classes: IgG, IgM, IgA, IgD and IgE, based on the number of Y units 
and the type of heavy chain.  It is also the heavy chain that determines the subclass of 
each antibody, and each class of antibody has different abilities to find and help remove 
antigen in the body.   
The most commonly used antibody in immunochemical procedures is of the IgG 
class because they are the major immunoglobulin (Ig) released in serum.  For instance, it 
constitutes about 75 % of all Ig’s found in serum.  The classical Y shape of IgG is 
composed of the two variable, antigen specific F(ab) arms, which are critical for actual 
antigen binding, and the constant Fc tail that binds immune cell Fc receptors and also 
serves as a useful “handle” for manipulating the antibody during most immunochemical 
procedures (Figure 5.1).  The number of F(ab) regions on the antibody corresponds with 
its subclass and determines the valency of the antibody.  Direct-conjugated antibodies are 
labeled with an enzyme or fluorophore in the Fc region.  The Fc region anchors the 
antibody to the plate in Enzyme-Linked ImmunoSorbent Assay (ELISA) procedures and 
is also seen by secondary antibodies in immunoprecipitation, immunoblots and 
immunohistochemistry.  These three regions can be cleaved into two F(ab) and one Fc 
fragments by the proteolytic enzyme Papain, or into just two parts: one F(ab)2 and one Fc 
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at the hinge region by the proteolytic enzyme Pepsin.  Fragmenting IgG antibodies is 
sometimes useful because F(ab) fragments will not precipitate the antigen; and they will 
not be bound by immune cells in live studies because of the lack of an Fc region.  Often, 
because of their smaller size and lack of crosslinking (due to loss of the Fc region), Fab 
fragments are radiolabelled for use in functional studies.  Interestingly, the Fc fragments 
are often used as blocking agents in histochemical staining.  
 
 
 
Figure 5.1.  Schematic view of Y-shaped IgG. 
 
 
IgG has widespread and varied applications, including ones in diagnostics,139,140 
as bioaffinity ligands in purification of high-value pharmaceuticals (eg cytokines and 
blood-clotting factors)141 and as probes in diverse biochemical experiments.140,142-145  
Perhaps the most exciting potential applications of IgG are in the area of 
therapeutics.146,147  Animal IgG can be “humanized” so that it is not rejected by the 
human immune system.148  Consequently, time- and cost-effective techniques for large-
scale isolation and purification of IgG are extremely important. 
IgG is obtained from human plasma, ascites fluid, fetal calf serum culture 
supernatants of engineered cells (eg hybridoma and bacterial cells) and other sources, 
then it must be purified for most applications.  However, the purity of IgGs is critical for 
therapeutic applications.  Usually this is achieved via a chromatographic technique, and 
there are several options for this.  Size-exclusion and ion-exchange149 150methods have 
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both been used, but affinity chromatography is the most widely applied.141,151,152  
Monoclonal antibodies (mAbs) designed to bind a specific antigen may be purified using 
supports based on that substance.153  A drawback of this approach is that the binding 
constants for the antigen tend to be so high that harsh elution conditions are required and 
denaturation of the IgGs can occur.  Moreover, for widespread large scale purification of 
mAbs, methods that work irrespective of the mAb epitope are most important.  Such 
generalized methods for affinity chromatographic purification of antibodies rely on their 
interactions with ligands that bind non-variable regions on the antibody surface.152,154  
Usually these ligands are naturally occurring proteins that have this characteristic, like 
protein A from Staphylococcus aureus and protein G from Streptococcus.155,156   
Affinity columns based on protein-A are the most widely used for several reasons.  
First, protein A is well-characterized and may be obtained from recombinant 
bacteria.155,157  Second, protein A interacts with the Fc fragment of IgG with a high 
affinity constant (~10-7 M).158  Third, protein A is stable over a wide pH range (2-11), it 
can refold after treatment with denaturating solutions like urea and guanidinium salts,159 
(it can even be “cleaned’ using 0.5 M NaOH) hence the affinity supports can sometimes 
be recycled.160  Finally, protein A is easily coupled to supports.  Besides protein A, 
protein G is also a well-known natural binder of IgG, which has a broader binding range 
and higher affinity of IgG.161  It binds all human IgG subclasses, and also mouse, rat and 
goat IgG.162  The Fc fragment of IgG appears mainly responsible for the interaction with 
protein G, although a low degree interaction was also found for Fab fragments.163  Protein 
G binds human IgG with a slightly higher dissociation constant (~10-8 M) than protein A 
(~10-7 M) does.158 
Despite the research on affinity purification of IgGs, several important 
applications of this material are still restricted by the costs of purification.  For the most 
common method, affinity chromatography using immobilized protein A or G, this relates 
to the cost of the native protein ligand.  Moreover, leakage of protein A or G from the 
supports further complicates the process if very high states of purity are required.164,165  
For these reasons, inexpensive, synthetic ligands with appropriate affinities for the non-
variable regions of IgG are interesting as potential ligands for affinity supports.   
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Prior work in this areas includes multimeric peptides,153,166-169 triazine 
derivatives,170-175 and some other molecules.176  Some of these synthetic ligands showed 
good affinity with IgG and could be used to purify the target antibody with decent 
capacity and yield in high purity in a test system.169,177,178  For example, a synthetic 
multibranched peptide ligand TG 19318 as a protein A mimetic had an apparent affinity 
constant with rabbit IgG of 3×105 M-1;179 another important synthetic small molecule 
ligand 22/8, which is a triazine derivative designed and made by Lowe’s group, 
mimicked protein A and was reported to have a Ka ∼105 M-1 with IgG (Figure 5.2).171  
However, none of these compounds have found widespread commercial application.  
This may be due to various issues such as selectivity, capacity, and inappropriate binding 
constants.   
 
 
N
N
N
HN NH
HN
OH
OH
NH2
ligand 22/8        
Figure 5.2.  Structure of 22/8 and docking of 22/8 on IgG/protein A binding pocket. 
 
 
Mabsorbent® A2P is a synthetic protein A mimetic that was commercialized by 
ProMetic Biosciences (UK).180  It is composed of a di-substituted phenolic derivative of 
tri-chlorotriazine and is commercially available coupled to a 6% cross-linked agarose 
base matrix.  The ligand was discovered from screening of ProMetic’s combinatorial 
ligand libraries in binding IgG and was thought to mimic the structure of two key amino 
acid side-chains of protein A - Phe132 and Tyr133 that are found to play an important 
role in formation of the binary complex between protein A and the Fc fragment of IgG.  It 
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binds all subclasses of IgG including IgG3, and could be used for the purification of 
polyclonal derived antibody therapeutics.181   
 
5.2 Design and Synthesis of Cyclic Peptidomimetics of Protein A 
5.2.1 Rationale 
Crystallographic data for the complex between the key helix-loop-helix region of 
protein A (the “B-domain”) and the human IgG Fc fragment (protein databank 
numbers:1l6x and 1FC2; Figure 5.3a) is thought to illustrate the key hot-spots for the 
interaction.157  It features contact of residues in the two helices of protein A/fragment B 
(residues Gln128-Leu136, Glu144-Asp155) with β-turns of the IgG Fc region.  This 
structural model is also supported by data from NMR182,183 and mutational studies.184  
Consequently, it has been proposed185 that the following protein A residues are important 
for binding the Fc region of IgG: Phe124, Phe132, Tyr133, Leu136, Ile150, Lys154, 
Gln128, Asn130, Asn147, and Arg146.  Of these, Phe132 and Tyr133 may be pivotal; 
they form a hydrophobic pocket that encapsulates the Ile253 of IgG (Figure 5.3c).  
Moreover, this dipeptide structure motif has been found in four highly conserved regions 
of protein A, each of which is capable of binding the Fc fragment IgG from various 
species.177  
 
 
a. 
IgG-Fc
Helix 1
Helix 2
 
Figure 5.3.  a. Fragment B of protein A complexed with IgG;157 b. an expanded view of 
the same interaction from a different perspective; and, c the protein A helix-loop-helix 
region with the residues that make contact with protein A highlighted. 
 92 
 
b. 
 
 
c. 
 
Figure 5.3. continued. 
 
 
This research was performed to design peptidomimetics of the protein A helix-
loop-helix region that would adopt similar conformations in solution, and which also 
retain the residues identified as hot-spots for binding to IgG.  Consequently, 
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peptidomimetics 19a-i were conceived (Figure 5.4).  Tyrosine and phenylalanine motif 
have proved crucial in the binding studies; these residues were retained in each synthetic 
ligand.  A Glutamine tail was used to help maintaining the desired conformation of the 
cyclic peptidomimetic.  To examine the design, low energy conformers of compound 19a 
were generated by quenched molecular dynamics (QMD) simulations186,187 and compared 
with the complex of protein A and IgG (Figure 5.5a and b), also compound 19c was 
docked with protein A fragment to prove their similarity (Figure 5.5c).   
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AA5 = Dbu, Orn
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Figure 5.4.  Cyclic peptidomimetics 19a-i of protein A.   
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a. 
Phe
Tyr
Gln
6.11 Å
3.59 Å
 
 
b. 
 
 
Figure 5.5.  a. Low energy conformer of compound 19a from quenched molecular 
dynamics (QMD) simulations; b. protein A fragment in complex with IgG; c. the best 
docking conformation of compound 19c on protein A backbone. 
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c. 
 
 
Figure 5.5. continued. 
 
 
The backbone of each peptidomimetic 19 was constructed from a six-amino acid 
sequence in a cyclic format.  Some amino acid residues were chosen for no particular 
reason except to construct the cyclic peptide scaffold.  However, every compound 
features a combination of the two key amino acid residues for binding between protein A 
and IgG, Phe132-Tyr133.  The combination can also be in reversed order, Tyr-Phe, or a 
close analog Phe-Phe.  Glutamine was also involved in every compound for its potential 
function of maintaining a desired conformation.   
5.2.2 Syntheses of Cyclic Peptidomimetics 19 of Protein A 
The synthesis of cyclic peptidomimetic 19a is outlined in Scheme 5.1 and used as 
an example.  All the linear peptides were prepared via solid phase peptide synthesis 
(SPPS).  Six Fmoc protected amino acids were coupled sequentially onto Wang resin 
following standard Fmoc peptide synthesis strategy.  The linear hexapeptides 18a-i were 
cleaved from the resin using TFA and the purity was evaluated by analytical HPLC, 
monitored by UV and SEDEX detector.  All the linear peptides were found to have a 
satisfactory crude purity and were used in the next cyclization step directly. 
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A clean and efficient way of to perform the intramolecular cyclization of the 
linear peptide 18a-i was not very easy to find because the long peptide chain made the 
intramolecular cyclization more difficult, and also the reaction solution needed to be 
dilute to avoid the formation of dimers, which required longer reaction times.  Several 
conditions188-190 were tested but gave unsatisfactory results because of epimerization 
formation of many byproducts, or slow and incomplete reaction.  The best result was 
obtained when BOP reagent191 was used along with HOBt, and DIEA as base in DMF at 
a concentration about 0.7 mM.  After two days, the reaction was complete with a 100 % 
conversion from analytical HPLC.  The cyclic compounds were purified via RP-
preparative HPLC and the pure cyclic peptides were then subjected to 20 % piperidine in 
DMF to remove the Fmoc protection on glutamine to provide the final products 19a-i, 
which were also purified via RP-preparative HPLC.   
 
 
Scheme 5.1.  Synthesis of cyclic hexapeptide 19a.   
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(i) 20 % piperidine/DMF
(ii) FmocGln-OH
HOBt, HBTU, DIEA  
 
NH2
O
O NH
FmocHN
H
N
O
NHO
BocHN
N
H
O
H
N
O
tBuO
O
O
(i) 95 % TFA, 2.5 % TIS 
2.5 % H2O
(ii) BOP, HOBt, DIEA, DMF
(iii) 20 % piperidine/DMF
NH2
O
O NH
H2N
H
N
O
NHO
HN
N
H
O
H
N
O
HO
O
19aPS-18a  
 97 
A series of nine cyclic peptidomimetics of protein A 19a-i was prepared; they 
were characterized by 1D and 2D NMR spectroscopes and ESI or MALDI-MS (Table 
5.1).   
 
 
Table 5.1.  Summary of cyclic peptidomimetics 19a-i.   
 
a determined after HPLC purification. 
b Mass of 19a-c and h was obtained from ESI ionization method, the rest was from 
MALDI. 
 
 
These compounds were sent to Amersham in Sweden for biological tests.  
However, no good binding data with IgG was obtained from these molecules. 
 
comp’d 
19 amino acid sequences 
UV 
puritya 
(%) 
SEDEX 
puritya 
(%) 
desired 
MS 
(M+H)+ 
actual 
MSb 
(M+H)+ 
      
a Gln-Dbu-Ala-Phe-Tyr-β-Ala 100 100 681.33 681.33 
b Gln-Dbu-Ala-Phe-Tyr-Ala 100 100 681.33 681.32 
c Gln-Orn-Ala-Phe-Tyr-Gly 100 100 681.33 681.35 
d Gln-Dbu-Ala-Tyr-Phe-β-Ala 100 100 681.33 681.27 
e Gln-Dbu-Ala-Tyr-Phe-Ala 100 100 681.33 681.21 
f Gln-Orn-Ala-Tyr-Phe-Gly 100 100 681.33 681.26 
g Gln-Dbu-Ala-Phe-Phe-β-Ala 100 100 665.33 665.30 
h Gln-Dbu-Ala-Phe-Phe-Ala 100 100 665.33 665.33 
i Gln-Orn-Ala-Phe-Phe-Gly 100 100 665.33 665.32 
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5.3 Design and Synthesis of Small Molecule Mimetics of Protein G 
5.3.1 Rationale 
The focus of this research was to find small ligands based on hot-spots in protein 
G that are known as key sites for interaction with IgG.  The essential features of the 
protein G:IgG interaction are as follows. 
Protein G has several structural segments, but the one called “domain III” is 
thought to contain the key hot spots for binding IgG.192-194  This domain interacts with 
both the Fab and Fc regions of IgG.  Crystal structures of the protein G domain III 
complexed with the Fab (PDB: 1IGC)193 and with the Fc fragments (PDB: 1FCC)195 of 
IgG are known.  Figure 5.6 shows details of the protein G domain III:Fab interaction.  
This features a sheet region and a helical region on the protein G fragment in close 
contact with the CH1 domain of Fab.  The first of these interactions is an antiparallel 
alignment of the second β-strand of the protein G domain III with the seventh β-strand of 
CH1 domain of Fab (Figure 5.6b).  The residues involved in this contact region are 
Lys15A to Thr22A from protein G, and Ser209H to Lys216H from the IgG Fab fragment.  
This β/β-sheet interaction site incorporates the charged residues, Lys18A, Glu20A on 
protein G interaction with Lys212H and Asp214H on IgG, which lie along the outer 
surface of the β-strand, exposed to the solvent environment.  The other key interaction is 
between Tyr38A to Gly43A in the C-terminal α-helix of protein G domain III, and 
Pro125H to Tyr129H on the first β-strand of the IgG CH1 region (Figure 5.6c).  We 
hypothesized that these two interactions form a hydrophilic perimeter around a 
hydrophobic core formed among Pro125H, Thr211H and Val213H.  This is a typical type 
of hot-spot in protein-protein interactions that has been compared with an “O-ring”.196  
We chose to target this region of the IgG Fab fragment for our peptidomimetic design.  
(Some target molecules with similar structures have been docked in the region of IgG that 
binds the protein G domain III using computer program AFFINITY to show the potential 
binding modes; these are not shown.)  
Dendric molecules like compound DAB-Am-4 are attractive frameworks for 
syntheses of tetravalent and higher oligomers of biologically active ligands.  This is 
important because many protein-protein interactions feature multivalent ligands 
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interacting with receptors to initiate or perturb their association.46,197-201  Within this area 
of interest there are many situations in which it would be advantageous to attach ligands 
to all the sites except one on a dendric system; for example, if three out of the four 
primary amine groups in DAB-Am-4 were coupled to biomolecules then the remaining 
unfunctionalized one could support a fluorescent or similar label, or be used to attach it to 
an affinity support.  Further, in combinatorial chemistry, size exclusion methods may 
facilitate more facile isolation of dendric molecules than similar monofunctionalized 
ones.202,203  For this particular case, it was anticipated that one unit on a dendrimer might 
rest comfortably in the hydophobic pocket while the others could form additional 
contacts with the protein surface.  The site on the dendric molecule that did not contain a 
peptiomimetic “warhead” would be used to anchor the whole dendric molecule to a solid 
support.   
 
 
a. 
CH1 domain
protein G:domain III
VH  domain
VL domain
CL domain
IgG:Fab fragment
 
 
Figure 5.6.  ViewerPro plot of interaction details between domain III of protein G and 
the CH1 domain of Fab.  Hydrogen bonds between these two domains are marked using 
dashed lines. a. the overall interaction; b. the contact between the Fab and protein G β-
sheets; and c. is the interaction between a β-strand of Fab (on the left) and the α-helix of 
domain III (on the right).   
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b. 
CH1 domain domain III
 
 
c. 
CH1 domain domain III
 
 
Figure 5.6. continued.   
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5.3.2 Synthesis of Small Molecule Mimetics 22 and 23 of Protein G 
 A set of 14 small molecule ligands 22a-k and 23a-c (Figure 5.7) was prepared in 
solution phase.  The concept was that after biology test, the active monomers will be 
selected from the library and used as monomeric ligands on DAB-Am-4 polyamine to 
make the trivalent molecules 24a-d with a free handle for further biological assays 
applying the prior methodology developed in our group (not published).  
 
 
N
X
O
HN
SAr
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O
O
O
X = N, CH
 
Figure 5.7.  Heterocyclic small molecules 22 and 23 as protein G mimetics. 
 
 
The target molecules consisted of three components, aryl sulfonyl chloride, 
pyrrole or imidazole carboxylic acid and a cis-amino ester.  The syntheses stared from the 
only conserved fragment, the amino ester, which was coupled with the heterocyclic 
carboxylic acid to form the amide 20 and 21.  Then different aryl sulfonyl chlorides were 
reacted with the coupling adducts under basic condition to afford each target compound 
22 and 23(Scheme 5.2).    
The coupling conditions for the pyrrole compounds and imidazole compounds 
were slightly different based on their properties.  We used DIC/DMAP for the pyrrole 
coupling and the desired product 20 was recrystallized from ethanol.  Coupling condition 
using EDC/HOBt/NMM was found to work better for the imidazole acid and the crude 
product 21 in high purity was used in the next step directly.  Different bases were used 
for deprotonation because of the difference in pKa of the pyrrole NH and imidazole NH.  
A stronger base (i.e. NaOH)204 was used for pyrrole and Et3N205 worked well for 
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imidazole in the nucleophilic substitution reaction with aryl sulfonyl chloride to yield 22 
and 23, respectively.  All the final products were purified via flash chromatography.   
 
 
Scheme 5.2. Synthetic scheme of pyrrole and imidazole derivatives. 
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 °C
              step B = NaOH, dicholoroethane, 0 °C to 25  °C
X = N,   step A = EDCI, HOBt, NMM, DMF, 25 °C
             step B = Et3N, THF, 25 
 °C  
 
 
We made a total of eleven pyrrole derivatized compounds 22a-k and three 
imidazole derivatives 23a-c following the above scheme.  Their structures and the yields 
were summarized in Table 5.2. 
 
 
Table 5.2. Summary of pyrrole and imidazole derivatized ligands 22 and 23.  
 
comp’d 22 and 23 Ar X yielda (%) 
    
22a F  
CH 43 
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Table 5.2. continued. 
comp’d 22 and 23 Ar X yielda (%) 
    
22b 
F  
CH 69 
22c 
F  
CH 45 
22d 
O
 
CH 44 
22e 
N
 
CH 71 
22f O  
CH 90 
22g 
O
 
CH 45 
22h 
O
O
 
CH 73 
22i 
O
O  
CH 84 
22j NC  
CH 44 
22k 
CN  
CH 33 
23a 
O
 
N 67 
23b NC  
N 65 
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Table 5.2. continued. 
comp’d 22 and 23 Ar X yielda (%) 
    
23c O  
N 80 
 
a Yields of pyrrole derivatives 22a-k are calculated based on the second step B; the yields 
of imidazole derivatives 23a-c are calculated based on two steps A and B. 
 
 
5.3.3 SAR Screening of Small Molecular Protein G Mimetics 22 and 23 
 All 14 compounds 22a-k and 23a-c were sent to Sweden along with other protein 
G mimetics made by another group member for SAR screening.   
All ligands were dissolved in 100% DMSO to a concentration of 50 mM.  The 
stock solutions were then further diluted to the concentration of 250 uM.  The dilution 
was done in such a way that the concentration of DMSO in the samples was carefully 
matched to 5%.  Eleven of the compounds had a low solubility at this concentration, and 
one compound 22h was totally precipitated. 
 A CM5 sensor chip was used and a monoclonal Fab κ fragment was immobilized 
to a level of 4000 RU in flow cell 2 (Fc2).  Fc1 was left totally unmodified and used in 
the DMSO calibration during the evaluation.  PBS with 5% of DMSO was used as 
running buffer during the assay.   
The compounds were injected one by one and in order to reduce carry over effects 
between sample injections.  The experiment was carefully designed by including wash 
steps and buffer injections in addition to the sample injections.  The protein surface was 
also regenerated with an injection of 1 M ethanolamine, pH 8.5 after each sample 
injection.  Every sample was injected in duplicates over the two surfaces (Fc1 and Fc2).  
 The soluble compounds were first tested in duplicates and then the compounds 
that showed less solubility were tested.  Buffer injections were also made during the 
assay and warfarin was used as a negative control ligand.  Protein G, used as a positive 
control, was injected every 10th cycle in order to measure that the protein surface 
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maintained activity.  It was observed that the protein G responses showed only a slight 
decrease during the assay, which indicated that the protein surface remained active.  The 
signals from these sample injections were shown in Table 5.3. 
 
 
Table 5.3.  SAR signals from sample injections. 
 
comp’d 
22 and 
23 
M. W. 
normalised 
response: 
replicate 1 
normalised 
response: 
replicate 2 
D1: 
replicate 
1 
D2: 
replicate 
1 
D1: 
replicate 
2 
D2: 
replicate 
2 
        
22c 408.12 4.58 1.76 1.4 1.2 0.4 0.4 
22d 432.14 14.75 14.14 5.1 4.7 5 4.8 
22i 450.15 11.13 8.60 3.6 3.4 2.8 2.7 
22k 415.12 9.78 9.16 3.1 2.8 3.2 3.1 
22j 415.12 9.30 12.54 2.8 2.5 2.4 2.3 
23b 416.12 2.56 4.22 -0.5 -0.5 -0.3 -0.4 
23c 421.13 0.86 2.82 0.3 -0.1 0 0 
23a 433.13 2.59 3.89 1 0.9 0.8 0.4 
22a 408.12 4.63 4.03 0.6 0.3 1.7 1.6 
22b 408.12 -0.11 0.46 -0.3 -0.5 0.6 0.8 
22e 441.14 3.87 -1.24 0.5 0.3 0 -0.2 
22f 420.14 5.00 -0.62 -0.2 -0.5 0.1 0.4 
22g 420.14 2.00 -0.14 -0.3 -0.3 0.5 0.5 
 
 
 
Table 5.3 shows the reference subtracted (Fc2-1) and calibrated sample responses. 
The responses have also been normalized according to molecular weight, enabling the 
comparison of ligands of different sizes.  In general, the sample injections generated low 
SPR responses in the range 0-6.4 RU (calibrated, not normalized).  The compounds that 
generated the highest normalized signals, which indicating highest affinity towards a Fab 
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fragment were 22d, 22i, 22j and 22k (marked yellow in Table 5.3).  The response in Fc2-
1 after the sample injection was also registered in two dissociation points.  D1 is 
registered 10 seconds after end of sample injection and D2 at 20 seconds after 
termination of injection.  Ligands 22d, 22i, 22j and 22k (marked yellow) also showed 
high dissociation signals (not normalized), which indicate a slow dissociation.  
Unfortunately, the data was only collected from injections of a single concentration; 
therefore no affinity constants could be calculated.   
5.3.4 Synthesis of Multivalent Mimetics 25 from Active Monovalent Ligands 22 
To increase the binding affinity, we attached the 4 active ligands 22d, 22i, 22j and 
22k selected from SAR screening to a dendrimer core, DAB-Am-4 to generate 4 
corresponding multivalent mimetics 25a-d (Figure 5.8).  
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active 
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active ligand = 22d, 22i, 22j, 22k
25a-d  
Figure 5.8.  Structure representation of active ligand fuctionalized dendrimers 25a-d on a 
DAB-Am-4 core. 
 
 
The whole process is outlined in Scheme 5.3.  First, each monomer ester was 
hydrolyzed to a carboxylic acid.  To avoid the possible retro-reaction of forming the 
sulfonamide bond under basic condition, the esters were hydrolyzed under mild acidic 
conditions.  At 40 °C the hydrolization proceeded smoothly without racemization and 
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offered the desired carboxylic acid 24a-d in high yield after flash chromatography 
(Scheme 5.3a).  
To selectively use n – 1 functional groups out of a total of n at the periphery of a 
dendric entity, we used the methodology developed in our group as depicted in Scheme 
5.3b, which takes advantage of the relatively disperse arrangement of functional groups 
on supports for solid-phase syntheses.206   
TentaGel S PHB resin (which is functionalized with the Wang acid linker) was 
further derivatized with 4-nitrophenyl chlorocarbonate to give the electrophilic resin.207  
This was reacted with DAB-Am-4, coupled with the monomeric carboxylic acid ligand 
24a-d.  In any event, after considerable experimentation, we found that the efficiency of 
the synthesis with respect to formation of the desired product was highly dependent on 
the concentration of the DAB-Am-4 used in the ligand coupling reaction.  To satisfy both 
the coupling efficiency and ease of handling (eg washing), the optimal concentration we 
used was 1.5 M; if higher concentrations (> 2 M) were used then the reaction liquid phase 
became quite viscous and the coupling efficiency declined.  Finally, the trivalent 
compounds were cleaved from the resin using TFA (Scheme 5.3b).   
 
 
Scheme 5.3.  Synthesis of trivalent ligands 25a-d. a. hydrolysis of ester 22d, 22i, 22j and 
22k; b. attachement of monovalent ligand 24a-d to a DAB-Am-4 core. 
 
a. 
N
O
HN
SAr
O
O
O
EtO
10 % HCl
Ar S
O
O
N
O
HN
O
OH
1, 4-dioxane, 40 oC
22d, 22i, 22j, 22k 24a-d  
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Scheme 5.3. continued. 
b. 
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The final products 25a-d were purified via RP-preparative HPLC, and identified 
via MALDI-MS.  Table 5.4 outlines details of the purities of the material cleaved from 
the resin, and the yields of the desired products are based on the loading of the resin. 
 
 
Table 5.4. Summary of the active ligand-functionalized dendrimers 25a-d. 
 
trivalent 
compound 25 
Monovalent 
ligand 
functionality R 
Ar (in R) X (in R) yield (%) 
     
a i 
O
O  
CH 20 
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Table 5.4. continued. 
trivalent 
compound 25 
monovalent 
ligand 
functionality R 
Ar (in R) X (in R) yield (%) 
     
b k 
CN  
CH 18 
c j NC
 
CH 21 
d d 
O
 
CH 24 
 
 
Since the attempts to develop a methodology of coupling synthetic ligands to a 
higher homolog of DAB-Am-4 having more amine groups were unencouraging, we only 
made these four functionalized dendrimers.  Unfortunately, these compounds were never 
sent to other places for testing, so their activities and affinities still remain unrevealed. 
 
5.4 Summary 
IgG, as the most commonly used antibody in immunochemical procedures, has 
widespread applications in various area such as diagnostics,139,140 pharmaceutical 
purifications, and perhaps the most exacting one, therapeutics, 140,142-145,146,147 in which 
the purity of IgGs is particularly critical.  Therefore, development of time- and cost-
effective techniques for large-scale isolation and purification of IgG are of great 
importance. 
One of the most widely applied purification technique of IgG is affinity 
chromatography.141,151,152  Monoclonal antibodies (mAbs) designed to bind a specific 
antigen may be purified using supports based on that substance.153  Usually the affinity 
ligands used for this purpose are naturally occurring proteins that bind non-variable 
regions on the antibody surface,152,154 like Staphylococcus aureus protein A and 
Streptococcus protein G,155,156 which both have a high affinity constant (≥10-7M) with 
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IgG (protein A binds the Fc fragment and protein G binds the Fc and Fab fragment of 
IgG) 2,158.  However, due to the cost and other practical reasons, inexpensive, appropriate 
synthetic ligands of IgG are extremely interesting as potential ligands for affinity 
supports.  Prior work in this area did not provide many compounds of widespread 
commercial application. 
In a collaborative project with Amersham company, we prepared a series of 
mimetics of protein A and protein G from careful and reasonable design based on their 
interactions with IgG.  The targets were usually generated from molecular modeling 
studies of the protein-ligand interaction information obtained from their crystal complex.    
 A set of nine cyclic hexapeptides 19a-i was prepared from SPPS and solution 
phase intramolecular macrocyclization reaction.  All the peptidomimetics feature the 
dipeptide motif, “Phe132-Tyr133” (or Tyr-Phe, Phe-Phe), which was found pivotal in the 
protein A and IgG binding event.  However, no interesting binding result was obtained 
for these compounds. 
 For protein G, we prepared a total of 14 pyrrole or imidazole derivatized small 
molecule ligands 22a-k and 23a-c with aromatic functionalities through efficient and 
straightforward syntheses.  These synthetic ligands were tested in SAR screening with 
IgG Fab fragment and 4 of them (22d, 22i, 22j and 22k) showed relatively higher 
affinity.  Therefore we attached these selected ligands to a dendrimer core, DAB-Am-4 
and generated 4 trivalent mimetics 25a-d (with a free handle); we were hoping this would 
increase the binding affinity.  Unfortunately, these compounds were never tested.  
 Overall, we made some novel synthetic ligands as natural protein A and protein G 
mimetics for affinity chromatography of IgG purification.  They were tested in binding 
assays and several showed some kind of binding affinity with Fab fragment of IgG in 
SAR screening, which may be useful for further development in this area.   
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CHAPTER VI 
CONCLUSIONS 
Peptidomimetics are useful tools in studying protein-protein interaction events via 
mimicry of the crucial interaction sites.  They are typically used to mimic or disrupt the 
structural environment at hot-spots.  Heterocyclic building blocks can be useful as 
scaffolds for peptide backbone modifications.  They import rigidity and enable the 
functionalized side-chain substituents to adopt relatively constrained conformations.  
Heterocyclic dipeptide mimetics can be accessed from conventional procedures and show 
various functionalities.  They are used as protein secondary structure mimics and for 
structure modification.  In chapter I, strategies in design and synthesis of heterocyclic 
amide bond surrogates of dipeptide mimetics was discussed. 
 In general, we think the incorporation of the amino acid side-chains, particularly 
those that occur most frequently at hot-spots, in the mimics is quite important; and good 
mimics should also be somewhat flexible to be able to access favorable conformations 
that are close to those of the parental peptides in binding protein targets.   
Our laboratory has been involved in the design and synthesis of small molecules 
to mimic surface exposed β-turn regions of NGF (and other neurotrophins).  Specifically, 
we have targeted mimics of the NGF turn regions that seem to be involved in those “hot-
spot” interactions between NGF and TrkA.   
 Given the interesting biochemical and biological profile of previously reported 
peptidomimetic D3 and the notion that changing a small molecule from a monovalent to 
bivalent form could generate more potent agonists for RTK ligands, we prepared a set of 
bivalent molecules 1 using a novel combinatorial approach.  A close analog of D3 (i.e. A) 
was synthesized on solid support and attached to different length linkers.  They were then 
paired on a triazine scaffold via our previously published methodology, to give a small 
library of bivalent compounds representing three linker fragments in all permutations.   
 One homo-bivalent compound, 1-ss showed higher affinity than others with TrkA 
and a ~50-fold better affinity than the parental monovalent peptidomimetic (~200 nM 
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versus ~10 µM), and retains high selectivity towards TrkA in binding assays.  It can 
block the binding of another more efficient ligand, anti-TrkA mAb 5C3, and also block 
NGF binding.  In biological assays, 1-ss was found to antagonize ligand-dependent 
activation of TrkA as a pure receptor antagonist while the parental monovalent 
peptidomimetic is an agonist towards NGF, which is intriguing.  This is probably because 
the bivalent mimetic binds to two receptors, and prevents conformational changes of the 
receptor dimer, which need to be induced by an agonistic ligand.  Unfortunately, 
conformational changes in TrkA upon the binding of its protein ligand NGF have not yet 
been demonstrated through structural analyses, and this is still an issue in the current 
debate.   
 The approach to a set of monovalent diketopiperazine mimetics 4-7 was 
illustrated.  Intramolecular SN2 cyclization of corresponding dipeptides in solution 
yielded the desired mimetics efficiently.  These DKP compounds contain two side-chain 
functionalities that are both derived from natural amino acids, which were chosen based 
on the i + 1 and i + 2 residues of the turn regions of NGF.  Each monomer was attached 
to a short or long linker before dimerization.  A library of 45 biotin-labeled bivalent 
molecules 9 was obtained via the efficient combinatorial strategy described above with 
some modification.   
 In primary screening, four bivalent compounds exhibited relatively higher binding 
affinity and selectivity against TrkC-expressing cells at 50 uM in FACScan assay, and 
they all contain at least one cyclo(Ile-Lys)-long linker fragment.  In cell survival assay, 
three bivalent compounds blocked the trophic activity of NT-3 in TrkC cells at 10 uM, 
and no significant effect was observed for them in IGF-1R and TrkA cells.  These results 
need to be further confirmed by repeating with doses.  Interestingly, compound 9gg, 
which also showed preferential binding to TrkC receptors, is a homo-bivalent molecule 
of two cyclo(Ile-Lys)-long linker moieties.   
 Parallel solution phase synthesis allows quick and efficient generation of a set of 
1,3,4-oxadizole based dipeptide mimetics 12 in good yields on gram scale.  These 
heterocyclic compounds feature various natural amino acid side-chain functionalities.  In 
attempts to assemble the monovalent mimics into bivalent molecules 15 via the above 
dimerization method by simply manipulating the solvent systems, we found that some 
 113 
reactions did not proceed cleanly, which perhaps is due to some certain reactive groups in 
the molecule based on our test results.  The problems were partially solved but more 
studies need to be done.  The biological activities of the oxadiazole molecules 12 and 17 
are under investigation.  So far, NIH screening centers have reported six compounds 
showing certain activities in four bioassays of different types.   
In a collaborative project with Amersham company, two different peptidomimetic 
types that resemble protein A and protein G binding regions were generated and tested as 
binding factors in affinity columns for purification of IgG.  Cyclic hexapeptides 19 as 
protein A mimics feature the dipeptide motif, “Phe132-Tyr133”, which was found pivotal 
in the binding event.  However, no interesting binding result was obtained for these 
compounds.  Heterocycle-based small molecules 22 and 23 featuring a variety of 
aromatic functionalities were synthesized as protein G mimics.  Four compounds in this 
library showed some affinity towards a Fab fragment of IgG in SAR screening, thus they 
were attached to a dendrimer core to give four multivalent mimetics 25 to obtain higher 
binding affinity.  These compounds have not been tested yet. 
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APPENDIX A 
EXPERIMENTAL FOR CHAPTER II 
 General Methods.  All the amino acids used had the L-configuration and they 
were purchased from NovaBiochem, Advance BioTech or Chem-Impex.  All chemicals 
were obtained from commercial suppliers and used without further purification.  N-
Hydroxybenzotriazole (HOBt), N-methylmorpholine, N,N-diisopropylethylamine were 
purchased from Aldrich.  Ethyl-(N’,N’-dimethylamino)propylcarbodiimide (EDC) was 
obtained from Advanced ChemTech.  Reverse phase high performance liquid 
chromatography (RP-HPLC) was carried out on Vydac C-18 column with the dimension 
of 25 x 0.46 cm for analytical studies, and on XTerra C-18 column with the dimension of 
10 x 1.9 cm for preparative work.  All HPLC experiments were performed using gradient 
conditions.  The eluents used were: solvent A (H2O with 0.1% TFA) and solvent B 
(CH3CN with 0.1% TFA).  The flow rate used was 1.0 mL/min for analytical, and 10 
mL/min for preparative HPLC.   
 
 General Procedure for Preparation of 1a-i.  The Rink Amide resin MBHA (1.0 
g; 0.72 mmol) was treated with 20% piperidine in DMF (2 x 10 mL, 10 min), and 
washed.  The resin was treated with FMOC-Hse-(Trt)-OH (2 equiv), HBTU (1.95 equiv), 
HOBt (2 equiv), and DIEA (3 equiv) in DMF (6 mL) for 24 h.  After washing and FMOC 
deprotection, the resin was then treated with FMOC-Lys(Boc)-OH (2 equiv), HBTU 
(1.95 equiv), HOBt (2 equiv), and DIEA (3 equiv) in DMF (6 mL) for 24 h.  After 
washing and FMOC deprotection, the resin was then treated with FMOC-Glu(OtBu)-OH 
(2 equiv), HBTU (1.95 equiv), HOBt (2 equiv), and DIEA (3 equiv) in DMF (6 mL) for 
24 h.  The washing cycle and FMOC deprotection were repeated, and 2-fluoro-5-
nitrobenzoic acid moiety was introduced by treating the resin with 2-fluoro-5-
nitrobenzoic acid (2 equiv), HBTU (1.95 equiv), HOBt (2 equiv), and 2,6-lutidine (15 
equiv) in CH2Cl2/DMF (1:1, 6 mL) for 12 h.  The side chain protecting group (Trt) of the 
homoserine was removed by treatment with 1% TFA and 5% HSiiPr3 in CH2Cl2 (3×2 
min, or until color disappeared).  After the resin was washed, the macrocyclization step 
 127 
was carried out by treating the supported peptide with K2CO3 (10 equiv) in DMF at 25°C.  
After gentle shaking for 24 h, the peptide-resin was washed then dried in vacuo for 4 h.  
Resin containing side chain protected cyclic peptidomimetic D3 with the nitro group was 
swelled in CH2Cl2 in a fritted syringe for 30 min and treated with 2M SnCl2•2H2O in 
DMF for 12 h.  After the washing and drying under vacuum for 2 h, the resulting 
arylamine was treated with the short, medium or long linker (4 equiv), PyBrOP (4 equiv), 
and 2,6-lutidine (10 equiv) in DMF for 24 h.  The resin was then washed, dried, and split 
into two portions. One portion was subjected to FMOC deprotection by 20% piperidine in 
DMF (2 x 10 mL, 10 min).  After that the peptide was cleaved from the resin by 
treatment with a mixture of 90% TFA, 5% HSiiPr3, and 5% H2O for 3 h.  The cleavage 
solution was separated from the resin by filtration.  After most of the cleavage cocktail 
(about 90%) was evaporated in vacuo, the crude peptide was triturated using anhydrous 
ethyl ether, dissolved in H2O, and then lyophilized to give the crude product.  Preparative 
HPLC (Beckman System, 10-80% CH3CN in H2O + 0.1% TFA in 40 min) was carried 
out to give D3 derivative peptidomimetics.  Another portion of dry resin was swelled in 
CH2Cl2 for 30 min, washed with DMF, treated with 20% piperidine in DMF (2 x 10mL, 
10 min), and washed.  After the washing dichlorotriazinylaminofluorescein (DTAF, 2 
equiv), DIEA (3 equiv) in 3:1 mixture of CHCl3:DMSO were added and the mixture was 
shaken for 3 h.  The resin was washed and subjected to the above cleavage conditions.  
The crude product was purified by preparative HPLC to give dye-labeled 
peptidomimetics. 
Glass vials with caps (short form style, 1 Dr, VWR International products) were 
used as reaction vessels.  Stock solutions of all reagents in DMSO were prepared: 0.030 
M of first cleavage portion (non-tagged) and 0.033 M of second cleavage portion (dye-
tagged).  Solid K2CO3 (4 equiv) was first added to each vial, followed by equal volumes 
of the two stock solutions of the non-tagged and the dye-tagged peptidomimetic.  The 
reaction vessels were capped and stirred at 25 °C for 24 h.  After analysis of the crude 
purity on analytical HPLC, the solution in each vial was lyophilized to remove DMSO. 
The solid materials were re-dissolved in 1:1 mixture of H2O/CH3CN, and then purified by 
preparative HPLC to yield the final products 1a-i.   
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 Materials and Methods for Biological Assays.  Cell LinesNIH-TrkA cells are 
NIH3T3 fibroblasts transfected with human trkA cDNA. NIH-TrkC cells are NIH3T3 
fibroblasts transfected with human trkC cDNA. NIH-IGF-1R cells are NIH3T3 
fibroblasts transfected with human IGF-1R cDNA.  All cells are stably transfected 
subclones that express high levels of their receptor.  Cells are grown under drug selection 
(0.5 mg/ml G418) and are routinely screened for receptor expression by FACScan using 
monoclonal antibodies directed to the receptor extracellular domains.  
Antibodiesmouse anti-TrkA mAb 5C3, mouse anti-TrkC mAb 2B7, mouse 
anti-p75 mAb MC912, and mouse anti-IGF-1R mAb alphaIR3 were purified using 
protein G-Sepharose (Pharmacia, Baie d’Urfe, Quebec, Canada).  They have all been 
described. 
FACScan analysisCells (2 x 105) in 100 µl of FACScan binding buffer 
(phosphate-buffered saline, 0.5% BSA, and 0.1% NaN3) were immunostained as 
described.  Saturating mAbs, or control non-binding mouse IgGs were added to cells for 
20 min at 4 °C, excess primary antibody was washed off, and cells were immunostained 
with fluoresceinated goat anti-mouse IgG (FITC-G-α-M) secondary antibody.  As cellular 
controls NIH-3T3 cells not expressing NGF receptors were used (e.g. NIH-IGF-1R).  
Cells were acquired on a FACScan, and bell-shaped histograms were analyzed using 
LYSIS II and the CellQuest-pro program as described. 
FACScan analysis of peptidomimeticsPeptidomimetics labeled with FITC were 
used in FACScan binding studies, as described above.  The assay was slightly modified 
to extend the incubation of the “primary” reagent to 40 minutes, followed by two washes 
to remove unbound material.  There was no secondary reagent added, as the compounds 
are directly labeled. 
FACScan binding competition assaysBlocking to the binding of FITC-labeled 
peptidomimetics were studied by pre-incubation of the cells with increasing 
concentrations of TrkA ligands anti-TrkA mAb 5C3, for 30 min at 4°C.  Then, the FITC-
labeled peptidomimetic was added, without previous washing, and the study progressed 
as described above.   
Ligand Binding125I[NGF] (73.1 mCi/mg; NEN Life Science Products) binding 
assays and Scatchard plot analysis were done on cells as described.  NIH-TrkA cells 
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(1x106 per point) were added to serial dilutions of 125I[NGF] in BB at 4°C, in the 
presence or absence of competitor (cold NGF or peptidomimetic).  NIH-3T3 wild type 
cells not expressing NGF receptors were used to assess nonspecific background (<15% of 
total binding).  
Proliferation and Survival AssaysCells (5,000–10,000 cells/well) were added to 
96-well plates (Becton Dickinson, Lincoln Park, NJ) and cultured either in media 
containing 5% fetal bovine serum or in serum free media with 0.1% BSA (SFM).  
Ligands consisted of serial dilutions of neurotrophins or peptidomimetics were then 
added.  FITC-tagged and TEG-tagged mimetics were tested, but only the data for TEG-
tagged mimetics are shown.  A suboptimal dose of neurotrophins (0.1 – 0.2 nM, affording 
~25% of survival) was used to test the effect of combination of NGF with 
peptidomimetics.  The proliferative/survival profile of the cells was quantitated using the 
tetrazolium salt reagent (3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
Sigma) and optical density (OD) readings as described. Assays were done 4-7 times, each 
assay n 4–8. 
Receptor Dimerization AssaysReceptor cross-linking assays were carried out as 
reported elsewhere.  Here, NIH-TrkA cells (106 cells/ml each group) were washed and 
placed in suspension in phosphate-buffered saline (pH 7.5) at 4°C.  Then they were 
exposed to the indicated ligands (untreated control, NGF 10 nM, 1-ss-F* (20 µM), or 1-
ss-TEG (20 µM)) for 30 min at 4°C. Following washing, cells were chemically cross-
linked with 1 mM final disuccinimidyl suberate (DSS, Pierce) for 7 min.  To quench 
unreacted DSS a 5-molar excess of ammonium acetate was added and after 1 min the 
cells were washed two times with HBSS at 4°C.  Then each cell pellet was detergent 
solubilized (1% NP40 containing protease inhibitors), lysates were centrifuged (15,000 
G, 15 min 4°C) to remove nuclei and detergent-insoluble material.  Protein concentration 
for each of the clear lysates was determined using a detergent-compatible BioRad kit.  
Equal protein (20 µg/lane) of each sample were resolved by SDS-PAGE, and after 
Western transfer the membranes were analyzed by western blotting with anti-TrkA 
mAbs.  Equal loading was further verified Coomassie blue staining of the gels.  
Receptor Activation AssaysNIH-TrkA cells were cultured at 37°C in SFM for 
12 hours to reduce their baseline tyrosine phosphorylation. Then the cells were exposed 
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to the indicated ligand (NGF, 1-ss, untreated control) at 37°C for 20 minutes or for 2 
hours.  After washing in PBS, cells were detergent solubilized as above, and equal 
protein (20 µg/lane) of each of the clear lysates were resolved by SDS-PAGE, and after 
Western transfer the membranes were analyzed by western blotting with anti-pTyr mAb 
4G10 (Promega), as previously reported; and total TrkA loading was verified using anti-
TrkA mAb 5C3.   
 
 Methods for Docking/Modeling.  3-D structure of 1-ssThe three dimensional 
structures of 1-ss were built by using the BIOPOLYMER module of SYBYL.  The initial 
structure was optimized by using Tripos force field.  GAFF (Generalised amber force 
field) atom types were obtained using the antechamber module of AMBER.  This facility 
automatically generates parameters that are compatible with the AMBER force field.  
Partial charges of 1-ss were calculated by the AM1-BCC method.  
Model of TrkA-D5 target for dockingThe extracellular immunoglobulin-like 
domain (D5) of the TrkA receptor forms a high-affinity binding site for NGF.  It is 
necessary and sufficient for NGF binding.  The crystal structure of human TrkA-D5 in 
complex with human NGF with was retrieved from the Protein Data Bank (PDB code 
1www).  The bound NGF dimer and the crystallographic water molecules were removed 
from the pdb file.  The program Reduce was used to add hydrogen atoms to the target 
atoms and to optimize the orientation of the polar hydrogens.  Both N- and C- termini of 
the protein were modeled in the ionized state.  Structure manipulation and visualization 
were done using SYBYL 7.3 (Tripos, Inc., St. Louis, MO, USA).  
Docking of 1-ssTo explore possible binding sites for 1-ss, a rectangular box 
was constructed such that it almost completely enclosed the NGF dimer in the NGF-
TrkA-D5 crystal complex.  This box defined the volume to be explored in docking 1-ss to 
TrkA-D5.  A molecular docking program, WILMA, was used for docking.  This program 
is a rigid body docker that takes as input a collection of low-energy conformers of the 
ligand, 1-ss.  OMEGA (OpenEye Scientific, Inc.) generated 200 conformers within the 20 
kcal/mol cutoff.  Each of these conformers was exhaustively docked within the 
rectangular search box by WILMA.  The poses were ranked according to their 
electrostatic, hydrogen bonding, van der Waals and shape complementarity scores.   
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APPENDIX B 
EXPERIMENTAL FOR CHAPTER III 
 General Methods.  All the amino acids used had the L-configuration and they 
were purchased from NovaBiochem, Advance BioTech or Chem-Impex.  All chemicals 
were obtained from commercial suppliers and used without further purification.  N-
Hydroxybenzotriazole (HOBt), N-methylmorpholine, N,N-diisopropylethylamine were 
purchased from Aldrich.  Ethyl-(N’,N’-dimethylamino)propylcarbodiimide (EDC) was 
obtained from Advanced ChemTech.  Dichloromethane was obtained anhydrous by 
distillation over calcium hydride and THF was distilled over sodium metal and 
benzophenone.  Reverse phase high performance liquid chromatography (RP-HPLC) was 
carried out on Vydac C-18 column with the dimension of 25 x 0.46 cm for analytical 
studies, and on Axia C-18 column with the dimension of 10 x 2.12 cm for preparative 
work.  All HPLC experiments were performed using gradient conditions.  The eluents 
used were: solvent A (H2O with 0.1% TFA) and solvent B (CH3CN with 0.1% TFA).  
The flow rate used was 1.0 mL/min for analytical, and 10 mL/min for preparative HPLC.  
NMR spectra of compounds 2-7 were recorded on Inova instruments at 300 MHz and at 
500 MHz.  NMR chemical shifts were expressed in ppm relative to internal solvent 
peaks, and coupling constants were measured in Hz.   
 
 General Procedure for Preparation of 2a-b.  N-methyl Boc protected amino 
acid (1.0 equiv) and amino acid tert-butyl ester (1.0 equiv) was dissolved in dry CH2Cl2 
(0.15 M).  N-methylmorpholine (2.1 equiv) was added to the above solution followed 
with HOBt (1.1 equiv) and EDC (1.1 equiv).  The resulting solution was stirred at room 
temperature for 12h.  The reaction mixture was washed with H2O (30 ml), 1N HCl (30 
ml), saturated NaHCO3 (30 ml) and brine (30 ml).  The organic layer was separated and 
dried with Na2SO4 and concentrated to dryness to afford the crude product.  Without 
further purification this dipeptide (1 equiv) was dissolved in a mixture of dry CH2Cl2  (32 
equiv) and TFA (13 equiv) at 0 °C.  It was allowed to warm up to 25 °C after 1h and 
stirred for another 1h until the reaction is complete.  The reaction mixture was dried 
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under reduced pressure and the product was used directly for the next reaction.  To a 
solution of crude secondary amine in CH2Cl2 (0.12 M) was added an aqueous solution of 
0.5 M K2CO3 (2.1 equiv), and the mixture was cooled to 0 °C.  To the vigorously stirred 
mixture was added bromoacetyl bromide (1.1 equiv) in one portion.  After 2-4h (when no 
more starting material was present) the organic layer was separated and washed with H2O 
(30 ml), 1N HCl (30 ml), saturated NaHCO3 (30 ml) and brine (30 ml).  The organic 
phase was separated and dried with Na2SO4 and concentrated to dryness.  The product 
was used for the next reaction without further purification.  The bromide was dissolved in 
a mixture of CH2Cl2 (0.10 M) and 50 % aqueous NaOH (v:v=10:1).  The resulting 
mixture was stirred vigorously at 25 °C for 12 h until the starting material was consumed.  
The mixture was diluted with H2O, and the organic layer was separated, washed with 1N 
HCl (30 ml) and brine (30 ml), dried with Na2SO4, and concentrated under reduced 
pressure.  Flash chromatography of the residue provided pure 2a-b.   
 
N N
O
O
OtBu
O
NHCbz
2a  
Compound 2a was prepared from (0.58 g, 1.1 mmol) of Sar-Lys bromide derivative.  
Flash chromatography (2 % to 3 % MeOH/CH2Cl2) afforded 0.48 g (95 %) 2a as a white 
solid.   
1H NMR (500 MHz, CDCl3) δ 7.29-7.17 (m, 5H), 4.97 (s, 2H), 4.91-4.82 (m, 2H), 3.95 
(d, 1H, J = 17.1 Hz), 3.91-3.85 (m, 2H), 3.73 (d, 1H, J = 17.1 Hz), 3.12-3.00 (m, 2H), 
2.85 (s, 3H), 1.90-1.79 (m, 1H), 1.66-1.54 (m, 1H), 1.52-1.31 (m, 11H), 1.25-1.13 (m, 
2H) 
13C NMR (125 MHz, CDCl3) δ 169.1, 164.5, 163.8, 156.4, 136.5, 128.4, 128.0, 128.0, 
82.6, 66.5, 55.5, 51.7, 46.1, 40.5, 33.2, 29.1, 27.9, 27.2, 23.1 
MS (APCI, m/z) 447.9 (M+H)+ 
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Compound 2b was prepared from (0.46 g, 1.0 mmol) of Thr-Gly bromide derivative.  
Flash chromatography (30 % to 70 % EtOAc/Hexanes) afforded 0.29 g (78 %) 2b as a 
white solid.  
1H NMR (500 MHz, CDCl3) δ 7.31-7.19 (m, 5H), 4.55 (d, 1H, J = 11.5 Hz), 4.39 (d, 1H, 
J = 11.5 Hz), 4.13 (d, 1H, J = 16.4 Hz), 4.03-3.95 (m, 2H), 3.84 (d, 1H, J = 17.4 Hz), 3.79 
(d, 1H, J = 4.6 Hz), 3.60 (d, 1H, J = 16.4 Hz), 3.03 (s, 3H), 1.40 (s, 9H), 1.29 (d, 3H, J = 
6.3 Hz) 
13C NMR (125 MHz, CDCl3) δ 166.7, 166.3, 165.1, 137.5, 128.2, 127.6, 127.6, 82.2, 
76.5, 71.0, 68.2, 51.1, 47.7, 35.9, 27.7, 17.2 
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 General Procedure for Preparation of 2c-d.  N-methyl Boc protected amino 
acid (1.0 equiv) and amino acid methyl ester (1.0 equiv) was dissolved in dry CH2Cl2 
(0.15 M).  N-methylmorpholine (2.1 equiv) was added to the above solution followed 
with HOBt (1.1 equiv) and EDC (1.1 equiv).  The resulting solution was stirred at room 
temperature for 12h.  The resulting mixture was washed with H2O (30 ml), 1N HCl (30 
ml), saturated NaHCO3 (30 ml) and brine (30 ml).  The organic layer was separated and 
dried with Na2SO4 and concentrated to dryness to afford the crude product.  Without 
further purification, a solution of this dipeptide in dry methanol (0.10 M) was stirred 
vigorously with 10 % Pd-C (0.1 equiv) in a H2 atmosphere for 16 h at 25 °C until the 
reaction is complete.  Filtration and evaporation of the solvent in vacuo yielded the crude 
product and it was used directly for the next reaction.  To a solution of crude secondary 
amine in CH2Cl2 (0.12 M) was added an aqueous solution of 0.5 M K2CO3 (2.1 equiv), 
and the mixture was cooled to 0 °C.  To the vigorously stirred mixture was added 
bromoacetyl bromide (1.1 equiv) in one portion.  After 2-4h (when no more starting 
material was present) the organic layer was separated and washed with H2O (30 ml), 1N 
HCl (30 ml), saturated NaHCO3 (30 ml) and brine (30 ml).  The organic phase was 
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separated and dried with Na2SO4 and concentrated to dryness.  The product was used for 
the next reaction without further purification.  The bromide was dissolved in a mixture of 
CH2Cl2 (0.10 M) and 50 % aqueous NaOH (v:v=10:1).  The resulting mixture was stirred 
vigorously at 25 °C for 12 h until the starting material was consumed.  The mixture was 
diluted with H2O, and the organic layer was separated, washed with 1N HCl (30 ml) and 
brine (30 ml), dried with Na2SO4, and concentrated under reduced pressure.  Flash 
chromatography with MeOH/CH2Cl2 mixtures provided pure 2c. 
 
N N
O
O
OMe
O
NHBoc
2c  
Compound 2c was prepared from (1.40 g, 2.7 mmol) of Ile-Lys bromide derivative.  
Flash chromatography (2 % to 10 % MeOH/CH2Cl2) afforded 0.85 g (72 %) 2c as a white 
solid.  
1H NMR (300 MHz, CDCl3) δ 4.95-4.82 (m, 1H), 4.52 (br, 1H), 4.01-3.78 (m, 3H), 3.67 
(s, 3H), 3.14-3.00 (m, 2H), 2.96 (s, 3H), 2.09-1.79 (m, 2H), 1.77-1.14 (m, 13H), 1.00-
0.85 (m, 6H) 
13C NMR (75 MHz, CDCl3) δ 170.6, 165.6, 164.1, 155.9, 79.2, 66.8, 55.9, 52.6, 47.5, 
40.1, 38.7, 33.5, 29.4, 28.4, 27.7, 26.3, 23.6, 14.7, 11.9 
 137 
 
 
 
 138 
N N
O
O
OMe
O
NHBoc
ButO2C
2d  
Compound 2d (1.18 g, 81 %) was prepared from (1.45 g, 2.5 mmol) of Glu-Lys bromide 
derivative as a white solid.  
1H NMR (500 MHz, CDCl3) δ 4.87-4.75 (m, 1H), 4.69 (br, 1H), 3.97-3.87 (m, 3H), 3.66 
(s, 3H), 3.13-2.98 (m, 2H), 2.95 (s, 3H), 2.36-2.10 (m, 3H), 2.04-1.92 (m, 2H), 1.78-1.67 
(m, 1H), 1.54-1.32 (m, 20H), 1.31-1.22 (m, 2H) 
13C NMR (125 MHz, CDCl3) δ 171.3, 170.3, 166.2, 163.4, 155.9, 81.1, 79.0, 61.7, 55.9, 
52.5, 46.9, 40.0, 32.3, 30.3, 29.3, 28.3, 27.9, 27.6, 26.7, 23.3 
MS (ESI, m/z) 500.3 (M+H)+ 
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 General Procedure for Preparation of 3c-d.  The carboxylic ester (1 equiv) was 
dissolved in dry 1,2-dichloroethane (0.10 M) and after addition of trimethyltin hydroxide 
(3.0 equiv), the mixture was heated at 80 °C and stirred for 4-6 h under N2.  After 
completion of the reaction, the mixture was concentrated in vacuo, and the residue wad 
taken up in EtOAc (20 ml).  The organic layer was washed with 5 % HCl (3×30 ml) and 
brine (30 ml), and dried over Na2SO4, and concentrated to dryness.  Flash 
chromatography with MeOH/CH2Cl2 mixtures provided pure carboxylic acid 3c-d. 
 
N N
O
O
OH
O
NHBoc
3c  
Compound 3c was prepared from (0.53 g, 1.2 mmol) of Ile-Lys methyl ester 2c.  Flash 
chromatography (2 % to 10 % MeOH/CH2Cl2) afforded 0.34 g (66 %) 3c as a white solid.  
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1H NMR (300 MHz, CDCl3) δ 9.31 (br, 1H), 5.06-4.88 (m, 1H), 4.70 (br, 1H), 4.07-3.78 
(m, 3H), 3.14-2.86 (m, 5H), 2.08-1.78 (m, 2H), 1.74-1.13 (m, 13H), 1.01-0.76 (m, 6H) 
13C NMR (125 MHz, CDCl3) δ 173.3, 165.8, 165.3, 156.1, 79.1, 67.0, 55.7, 46.7, 40.0, 
38.5, 33.8, 29.2, 28.3, 27.6, 26.2, 23.6, 14.7, 11.8 
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3d  
Compound 3d was prepared from (0.82 g, 1.6 mmol) of Glu-Lys methyl ester 2d.  Flash 
chromatography (3 % to 5 % MeOH/CH2Cl2) afforded 0.50 g (64 %) 3d as a white solid.  
1H NMR (500 MHz, CDCl3) δ 10.54 (br, 1H), 4.95-4.78 (m, 2H), 4.01-3.79 (m, 3H), 
3.07-2.81 (m, 5H), 2.35-2.02 (m, 3H), 2.00-1.85 (m, 2H), 1.71-1.57 (m, 1H), 1.51-1.16 
(m, 22H) 
13C NMR (125 MHz, CDCl3) δ 172.0, 171.3, 166.1, 164.2, 155.9, 81.0, 78.9, 61.6, 55.4, 
46.2, 39.9, 32.3, 30.2, 29.0, 28.2, 27.8, 27.4, 26.3, 23.3 
MS (ESI, m/z) 484.3 (M-H)- 
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 General Procedure for Preparation of 4a-d and 5a-d.  The diketopiperazine 
carboxylic acid 3a-d (1 equiv) and short or long linker (1 equiv) were dissolved in dry 
CH2Cl2 (0.15 M).  N-methylmorpholine (2.1 equiv) was added to the above solution 
followed with HOBt (1.1 equiv) and EDC (1.1 equiv).  The resulting solution was stirred 
at room temperature for 12h.  The resulting mixture was washed with H2O (30 ml), 1N 
HCl (30 ml), saturated NaHCO3 (30 ml) and brine (30 ml).  The organic layer was 
separated and dried with Na2SO4 and concentrated to dryness to afford the crude product.  
Flash chromatography with MeOH/CH2Cl2 mixtures provided pure 4a-d. 
 
N N
O
O O
NHCbz
N NBoc
4a  
Compound 4a was prepared from (0.31 g, 0.7 mmol) of cyclo(Gly-Lys) tert-butyl ester 
2a and 1-Boc-piperazine.  3a (1 equiv) was first dissolve in a mixture of dry CH2Cl2  (32 
equiv), TFA (13 equiv) and triisopropyl silane (2.5 equiv).  The resulting mixture was 
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stirred at room temperature for 10 h.  The solvents were removed under reduced pressure. 
The crude product was used for the next reaction following the above general procedure 
for 4 and 5 without further purification.  Flash chromatography (2 % to 5 % 
MeOH/CH2Cl2) afforded 0.26 g (66 %) 4a as a white solid.   
1H NMR (500 MHz, CDCl3) δ 7.31-7.23 (m, 5H), 5.31 (t, 1H, J = 7.7 Hz), 5.10-4.96 (m, 
3H), 4.06 (d, 1H, J = 17.4 Hz), 3.95-3.85 (m, 3H), 3.64-3.54 (m, 1H), 3.54-3.46 (m, 1H), 
3.46-3.34 (m, 4H), 3.33-3.19 (m, 2H), 3.18-3.06 (m, 2H), 2.89 (s, 3H), 1.94-1.74 (m, 
1H), 1.74-1.62 (m, 1H), 1.55-1.35 (m, 11H), 1.27-1.14 (m, 2H) 
13C NMR (125 MHz, CDCl3) δ 167.9, 163.8, 163.6, 156.4, 154.3, 136.4, 128.4, 128.0, 
128.0, 80.3, 66.4, 51.5, 51.1, 45.4, 45.3, 41.9, 40.3, 33.1, 29.4, 28.2, 27.7, 22.6 
MS (APCI, m/z) 559.9 (M+H)+ 
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4b  
Compound 4b was prepared from (0.19 g, 0.5 mmol) of cyclo(Thr-Gly) tert-butyl ester 
2b and 1-Boc-piperazine following the same procedure with 4a.  Flash chromatography 
(2 % to 5 % MeOH/CH2Cl2) afforded 0.16 g (65 %) 4b as a colorless oil.  
1H NMR (500 MHz, CDCl3) δ 7.33-7.21 (m, 5H), 4.57 (d, 1H, J = 11.6 Hz), 4.41 (d, 1H, 
J = 11.6 Hz), 4.28 (d, 1H, J = 16.0 Hz), 4.22 (d, 1H, J = 16.5 Hz), 4.04-3.97 (m, 1H), 3.90 
(d, 1H, J = 16.0 Hz), 3.80 (d, 1H, J = 5.4 Hz), 3.65 (d, 1H, J = 16.5 Hz), 3.54-3.47 (m, 
2H), 3.46-3.41 (m, 2H), 3.40-3.32 (m, 4H), 3.05 (s, 3H), 1.43 (s, 9H), 1.31 (d, 3H, J = 6.4 
Hz) 
13C NMR (125 MHz, CDCl3) δ 166.5, 165.0, 164.9, 154.2, 137.6, 128.3, 127.6, 127.6, 
80.2, 76.6, 71.2, 68.3, 51.4, 47.1, 44.4, 41.5, 35.9, 28.1, 17.2 
MS (ESI, m/z) 489.3 (M+H)+ 
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Compound 4c was prepared from (0.26 g, 0.6 mmol) of cyclo(Ile-Lys) carboxylic acid 3c 
and 1-Boc-piperazine.  Flash chromatography (2 % to 3 % MeOH/CH2Cl2) afforded 0.30 
g (86 %) 4c as a white solid.  
1H NMR (500 MHz, CDCl3) δ 5.26 (t, 1H, J = 7.6 Hz), 4.60 (br, 1H), 4.11 (br, 1H), 3.83 
(d, 1H, J = 17.6 Hz), 3.74 (d, 1H, J = 4.3 Hz), 3.60-3.31 (m, 6H), 3.27-3.11 (m, 2H), 
3.04-2.97 (m, 2H), 2.88 (s, 3H), 1.88-1.78 (m, 2H), 1.59-1.47 (m, 2H), 1.47-1.39 (m, 
2H), 1.35 (s, 9H), 1.33 (s, 9H), 1.31-1.24 (m, 1H), 1.24-1.14 (m, 2H), 0.89 (t, 3H, J = 7.3 
Hz), 0.83 (d, 3H, J = 6.8 Hz) 
13C NMR (125 MHz, CDCl3) δ 167.8, 162.9, 164.0, 155.8, 154.2, 80.1, 78.9, 66.6, 51.1, 
45.6, 45.2, 41.9, 39.8, 38.6, 33.3, 29.5, 28.3, 28.2, 28.1, 26.2, 23.2, 14.5, 11.7 
MS (ESI, m/z) 582.4 (M+H)+ 
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Compound 4d was prepared from (0.22 g, 0.4 mmol) of cyclo(Glu-Lys) carboxylic acid 
3d and 1-Boc-piperazine.  Flash chromatography (2 % to 3 % MeOH/CH2Cl2) afforded 
0.22 g (75 %) 4b as a white solid.  
1H NMR (500 MHz, CDCl3) δ 5.22 (t, 1H, J = 7.6 Hz), 4.69 (br, 1H), 4.10(br, 1H), 3.88-
3.78(m, 2H), 3.60-3.09 (m, 8H), 3.05-2.96 (m, 2H), 2.89 (s, 3H), 2.30-2.17 (m, 2H), 
2.13-2.04 (m, 1H), 1.95-1.85 (m, 1H), 1.85-1.76 (m, 1H), 1.67-1.57 (m, 1H), 1.49-1.28 
(m, 29H), 1.23-1.12 (m, 2H) 
13C NMR (125 MHz, CDCl3) δ 171.1, 167.6, 165.6, 163.5, 155.8, 154.2, 81.0, 80.1, 
78.8, 61.6, 51.2, 45.2, 45.0, 41.9, 39.8, 32.2, 30.3, 29.5, 28.2, 28.1, 28.0, 27.9, 26.3, 23.0 
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MS (ESI, m/z) 676.4 (M+Na)+ 
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Compound 5a was prepared from (0.27 g, 0.6 mmol) of cyclo(Gly-Lys) tert-butyl ester 
2b and long linker following the same procedure with 4a.   
Flash chromatography (2 % to 5 % MeOH/CH2Cl2) afforded 0.27 g (61 %) 5a as a white 
solid.  
1H NMR (500 MHz, CDCl3) δ 7.33-7.21 (m, 5H), 6.28 (t, 1H, J = 5.4 Hz), 5.14-4.97 (m, 
3H), 4.82 (t, 1H, J = 7.6 Hz), 4.06 (d, 1H, J = 17.3 Hz), 3.93 (s, 2H), 3.89 (d, 1H, J = 17.3 
Hz), 3.52 (br, 2H), 3.42-3.30 (m, 8H), 3.20-3.02 (m, 4H), 2.89 (s, 3H), 2.25 (t, 2H, J = 
7.4 Hz), 1.93-1.81 (m, 1H), 1.69-1.59 (m, 1H), 1.59-1.44 (m, 4H), 1.44-1.35 (m, 11H), 
1.31-1.14 (m, 12H)  
13C NMR (125 MHz, CDCl3) δ 171.7, 168.8, 164.4, 163.4, 156.4, 154.4, 136.5, 128.4, 
128.0, 127.9, 80.1, 66.4, 55.5, 51.6, 45.6, 45.3, 41.2, 40.3, 39.4, 33.2, 33.0, 29.3, 29.3, 
29.2, 29.2, 29.2, 29.0, 28.2, 26.7, 26.7, 25.1, 22.8, 17.6 
MS (APCI, m/z) 743.2 (M+H)+ 
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Compound 5b was prepared from (0.15 g, 0.4 mmol) of cyclo(Thr-Gly) tert-butyl ester 
2b and long linker following the same procedure with 4a.   
Flash chromatography (2 % to 5 % MeOH/CH2Cl2) afforded 0.16 g (60 %) 4b as a 
colorless oil.  
1H NMR (500 MHz, CDCl3) δ 7.33-7.15 (m, 5H), 6.32 (t, 1H, J = 5.6 Hz), 4.57 (d, 1H, J 
= 11.6 Hz), 4.36 (d, 1H, J = 11.6 Hz), 4.10 (d, 1H, J = 16.6 Hz), 4.10-4.05 (m, 1H), 4.02 
(d, 1H, J = 15.9 Hz), 3.82 (d, 1H, J = 4.1 Hz), 3.75 (d, 1H, J = 15.9 Hz), 3.70 (d, 1H, J = 
16.6 Hz), 3.58-3.49 (m, 2H), 3.43-3.29 (m, 6H), 3.15-3.07 (m, 1H), 3.06-2.97 (m, 4H), 
2.27 (t, 2H, J = 7.6 Hz), 1.61-1.52 (m, 2H), 1.42 (s, 9H), 1.40-1.33 (m, 2H), 1.31 (d, 3H, 
J = 6.4 Hz), 1.29-1.14 (m, 12H) 
13C NMR (125 MHz, CDCl3) δ 171.6, 166.8, 166.7, 165.2, 154.4, 137.3, 128.4, 127.8, 
127.4, 80.0, 77.0, 70.9, 68.2, 51.6, 49.8, 45.2, 41.1, 39.4, 36.1, 33.1, 29.3, 29.2, 29.1, 
29.0, 28.2, 26.6, 25.1, 17.0  
MS (ESI, m/z) 672.4 (M+H)+ 
 152 
 
 
 
 
 153 
N N
O
O
NH
N
O
NBoc
O
NHBoc
5c  
Compound 5c was prepared from (0.26 g, 0.6 mmol) of cyclo(Ile-Lys) carboxylic acid 3c 
and long linker.  Flash chromatography (2 % to 3 % MeOH/CH2Cl2) afforded 0.38 g (83 
%) 5c as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.30 (t, 1H, J = 5.0 Hz), 4.75-4.69 (m, 2H), 4.07(d, 1H, J 
= 17.5 Hz), 3.83 (d, 1H, J = 17.5 Hz), 3.76(d, 1H, J = 4.1 Hz), 3.50-3.44 (m, 2H), 3.35-
3.25 (m, 6H), 3.15-2.94 (m, 4H), 2.86 (s, 3H), 2.21 (t, 2H, J = 7.5 Hz), 1.88-1.76 (m, 2H), 
1.57-1.38 (m, 6H), 1.35 (s, 9H), 1.31(s, 9H), 1.29-1.09 (m, 17H), 0.88(t, 3H, J = 7.2 Hz), 
0.80 (d, 3H, J = 6.8 Hz)  
13C NMR (125 MHz, CDCl3) δ 171.6, 168.8, 165.2, 163.7, 155.8, 154.3, 80.0, 78.8, 
66.4, 55.6, 46.0, 45.1, 41.0, 39.8, 39.2, 38.4, 33.1, 33.1, 29.3, 29.2, 29.1, 29.1, 28.9, 28.2, 
28.1, 26.9, 26.5, 26.1, 25.0, 23.1, 14.3, 11.7 
MS (ESI, m/z) 765.5 (M+H)+ 
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Compound 5d was prepared from (0.25 g, 0.5 mmol) of cyclo(Glu-Lys) carboxylic acid 
3d and long linker.  Flash chromatography (3 % MeOH/CH2Cl2) afforded 0.26 g (62 %) 
5d as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.22 (t, 1H, J = 5.6 Hz), 4.82-4.74 (m, 1H), 4.71(t, 1H, J 
= 7.8 Hz), 4.07 (d, 1H, J = 17.3 Hz), 3.87-3.79 (m, 2H), 3.50-3.44 (m, 2H), 3.35-3.25 (m, 
6H), 3.15-2.94 (m, 4H), 2.87 (s, 3H), 2.28-2.04 (m, 5H), 1.96-1.81 (m, 2H), 1.63-1.38 
(m, 5H), 1.35 (s, 9H), 1.33 (s, 9H), 1.31 (s, 9H), 1.24-1.09 (m, 16H)  
13C NMR (125 MHz, CDCl3) δ 171.6, 171.1, 168.6, 166.0, 163.2, 155.8, 154.3, 80.9, 
80.0, 78.7, 61.6, 55.6, 45.5, 45.2, 41.0, 39.8, 39.3, 38.4, 33.1, 32.1, 30.2, 29.3, 29.2, 29.1, 
29.1, 28.9, 28.2, 28.1, 27.8, 26.9, 26.5, 26.5, 25.0, 23.0  
MS (ESI, m/z) 837.6 (M+H)+ 
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 General Procedure for Preparation of 6a and 7a.  A solution of 
diketopiperazine (1 equiv) in dry methanol (0.10 M) was stirred vigorously with 10 % 
Pd-C (0.1 equiv) in a H2 atmosphere for 16 h at 25 °C until the reaction is complete.  
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Filtration and evaporation of the solvent in vacuo yielded the crude product and it was 
used directly for the next reaction.  To a solution of di-tert butyl dicarbonate (1.0 equiv) 
in dry CH2Cl2 (0.20 M) was added the crude secondary amine from previous step and 
Et3N (2.0 equiv).  The reaction mixture was stirred at 25 °C for 12 h.  The mixture was 
washed with H2O (30 ml), 1N HCl (30 ml), saturated NaHCO3 (30 ml) and brine (30 ml).  
The organic layer was separated and dried with Na2SO4 and concentrated to dryness to 
give the crude product.  Flash chromatography with MeOH/CH2Cl2 mixtures provided 
pure 6a and 7a. 
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Compound 6a was prepared from (0.17 g, 0.4 mmol) of cyclo(Gly-Lys) derivative 4a.  
Flash chromatography (2 % to 3 % MeOH/CH2Cl2) afforded 0.17 g (72 %) 6a as a white 
solid.  
1H NMR (500 MHz, CDCl3) δ 5.26 (t, 1H, J = 7.6 Hz), 4.69 (br, 1H), 4.03 (d, 1H, J = 
17.4 Hz), 3.96-3.81 (m, 3H), 3.58-3.30 (m, 6H), 3.27-3.18 (m, 2H), 3.03-2.93 (m, 2H), 
2.87 (s, 3H), 1.80-1.58 (m, 2H), 1.45-1.37 (m, 2H), 1.35 (s, 9H), 1.31 (s, 9H), 1.20-1.12 
(m, 2H) 
13C NMR (125 MHz, CDCl3) δ 168.1, 163.8, 163.7, 155.9, 154.4, 80.4, 79.1, 51.7, 51.3, 
45.6, 45.4, 42.0, 39.9, 33.2, 29.7, 28.4, 28.3, 27.8, 22.9 
MS (ESI, m/z) 548.3 (M+Na)+ 
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Compound 6b was prepared from (0.21 g, 0.4 mmol) of cyclo(Gly-Lys) derivative 5b.  
Flash chromatography (2 % to 10 % MeOH/CH2Cl2) afforded 0.20 g (81 %) 6b as a 
white solid.  
1H NMR (500 MHz, CDCl3) δ 6.22 (br, 1H), 4.81 (t, 1H, J = 7.7 Hz), 4.64 (br, 1H), 4.06 
(d, 1H, J = 17.7 Hz), 3.96 (s, 2H), 3.90 (d, 1H, J = 17.7 Hz), 3.52 (br, 2H), 3.38 (br, 4H), 
3.36-3.31 (m, 2H), 3.22-2.98 (m, 4H), 2.92 (s, 3H), 2.26 (t, 2H, J = 7.7 Hz), 1.94-1.82 
(m, 1H), 1.69-1.59 (m, 1H), 1.59-1.51 (m, 2H), 1.51-1.32 (m, 22H), 1.30-1.12 (m, 14H)  
13C NMR (125 MHz, CDCl3) δ 171.7, 168.8, 164.4, 163.4, 155.9, 154.4, 80.1, 79.1, 
78.9, 55.4, 51.6, 45.6, 45.2, 41.1, 39.3, 33.2, 33.0, 29.3, 29.2, 29.2, 29.2, 29.2, 29.0, 28.3, 
28.2, 28.2, 26.7, 26.6, 25.1, 22.8 
MS (ESI, m/z) 709.5 (M+H)+ 
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 General Procedure for Preparation of 6b and 7b.  A solution of Bzl protected 
diketopiperazine derivative (1 equiv) in dry methanol (0.10 M) was stirred vigorously 
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with 10 % Pd-C (0.1 equiv) in a H2 atmosphere for 12 h at 25 °C until the reaction is 
complete.  Filtration and evaporation of the solvent in vacuo yielded the crude product.  
The residue was purified by flash chromatography with MeOH/CH2Cl2 mixtures to 
provid pure 6b and 7b. 
 
N N
O
O O
OH
N NBoc
6b  
Compound 6b was prepared from (0.15 g, 0.3 mmol) of cyclo(Thr-Gly) derivative 4b.  
Flash chromatography (2 % to 5 % MeOH/CH2Cl2) afforded 0.11 g (94 %) 6b as a white 
solid. 
1H NMR (500 MHz, CDCl3) δ 4.93 (br, 1H), 4.85 (d, 1H, J = 16.1 Hz), 4.42-4.32 (m, 
2H), 3.77 (d, 1H, J = 1.7 Hz), 3.66 (d, 1H, J = 16.1 Hz), 3.62-3.32 (m, 8H), 3.06 (s, 3H), 
1.43 (s, 9H), 1.27 (d, 3H, J = 6.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 168.0, 165.4, 164.7, 154.2, 80.5, 71.2, 68.7, 52.0, 47.8, 
44.4, 42.0, 36.1, 28.2, 19.7 
MS (ESI, m/z) 399.2 (M+H)+ 
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Compound 7b was prepared from (0.18 g, 0.3 mmol) of Thr-Gly derivative 5b.  Flash 
chromatography (2 % to 10 % MeOH/CH2Cl2) afforded 0.13 g (83 %) 7b as a white 
solid.  
1H NMR (500 MHz, CDCl3) δ 6.76 (t, 1H, J = 5.6 Hz), 4.83 (d, 1H, J = 4.8 Hz), 4.67 (d, 
1H, J = 16.3 Hz), 4.40-4.33 (m, 2H), 3.77 (d, 1H, J = 1.9 Hz), 3.68 (d, 1H, J = 16.3 Hz), 
3.55-3.49 (m, 2H), 3.42-3.32 (m, 6H), 3.17 (q, 2H, J = 6.7 Hz), 3.04 (s, 3H), 2.31-2.15 
(m, 4H), 1.59-1.51 (m, 2H), 1.42 (s, 9H), 1.32-1.17 (m, 15H) 
13C NMR (125 MHz, CDCl3) δ 171.9, 167.4, 167.0, 164.9, 154.5, 80.3, 71.6, 68.6, 51.9, 
49.4, 45.3, 41.2, 39.7, 36.2, 33.2, 29.1, 29.1, 29.0, 29.0, 28.3, 26.6, 25.1, 20.1  
MS (ESI, m/z) 582.4 (M+H)+ 
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 General Procedure for Preparation of Biotin Labeled Monomers 9.  Boc-
protected monomeric compounds 4c-d, 5c-d, 6a-b and 7a-b (1.0 equiv) were treated with 
50% TFA in CH2Cl2, stirred in sealed glass vials for 10 h and solvent was removed. The 
resulting residue was dissolved in DMSO (0.033 M) and biotin tag derivative DTAB (1.0 
equiv) and K2CO3 (4.0 equiv) were added. The suspension was stirred for 2 h and the 
crude product 8 was used for the next step without further purification.  Analytical HPLC 
and MALDI MS were used to check the purities of these crude samples. 
 
(i) 1:1 TFA/CH2Cl2
(ii) DTAB, K2CO3
DMSO
N N
N
HN
biotin tag
Cl
N N
O
O O
R2'
R1'
s/l linker
N N
O
O O
R2
R1
s/l linker
4c-d, 5c-d, 6a-b and 7a-b
or morpholine 8  
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 Preparation of Biotin Labeled Dimers 9 and Monomers 9ai-ii.  Dimerization 
was carried out in 2 ml glass vials.  The monomeric compounds 4c-d, 5c-d, 6a-b and 7a-
b were treated with 50% TFA/CH2Cl2 for 10 h.  Stock solutions of deprotected mimics 
(0.03 M) or morpholine (0.33 M) in DMSO were prepared.  One stock solution of 
deprotected 74 (0.5 ml) or morpholine (0.5 ml) were added to a glass vial containing pre-
formed 76 (0.03 M, 0.5 ml) and followed with solid K2CO3 (4 equiv).  The reaction vial 
was sealed and the reaction mixture was stirred at 25 °C for 96 h then the DMSO was 
lyophilized.  Aqueous HCl solution (5%, ca 1-2 ml) was added to the above solid residue 
and sonicated for 2 min.  Most of the compounds were dissolved in the acidic aqueous 
solution and all K2CO3 was converted to KCl.  The aqueous solution was dried by 
carefully blowing N2.  The solid residue was redissolved in dry methanol and stirred for 2 
min.  Most KCl was precipitated from the solution and removed by filtration.  The MeOH 
solution was then concentrated to give crude bivalent compounds 9.  All crude products 
were purified by preprative HPLC and analyzed by analytical HPLC (10-90% B in 30 
min), and also by 1H NMR, gCOSY (21 out of 45 compounds) and MALDI-MS. 
 
N N
N
HN
biotin tag
Cl
N N
O
O O
R2
R1
s/l linker
K2CO3, DMSO
deprotected mimics or morpholine
8  
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biotin tag
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O
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H
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General structure of 9 
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O N
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N
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O
O
NH2
O
N
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a                                                             b  
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O N
i (cap)  
 
UV purity (%) of crude product 9 
i(cap) 100              
a 100 75             
b 98 71 89            
c 100 72 68 80       UV  
d 100 47 80 58 89      purities (%)  
e 95 45 59 43 71 64     below 70  
f 100 88 87 70 79 56 100    70 – 85  
g 98 93 92 70 58 41 72 86   85  and up  
h 100 51 57 58 81 65 76 36 85      
 i a b c d e f g h      
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UV purity (%) of compounds 9 after purification 
i(cap) 100              
a 100 100             
b 100 98 100            
c 100 100 100 100       UV  
d 100 100 100 100 100      purities (%)  
e 100 100 100 100 100 100     below 85  
f 100 100 100 100 100 100 100    85 – 90  
g 100 100 100 100 100 100 100 100   90  and up  
h 100 100 100 100 97 100 100 100 100      
 i a b c d e f g h      
 
 
Mass of bivalent compounds 9 
 MALDI-MS  MALDI-MS 
Comp’d 
9 
Calc'd 
(M+H)+ 
Found 
(M+H)+ 
Comp’d 
9 
Calc'd 
(M+H)+ 
Found 
(M+H)+ 
ii 465.2 465.0 fb 1236.8 1236.9 
ai 703.4 703.3 fc 1252.8 1252.9 
aa 941.5 941.5 fd 1153.7 1153.7 
bi 759.4 759.4 fe 1363.9 1364.1 
ba 997.6 997.6 ff 1420.0 1420.0 
bb 1053.6 1053.7 gi 958.6 958.7 
ci 775.4 775.3 ga 1196.7 1196.8 
ca 1013.5 1013.5 gb 1252.8 1252.8 
cb 1069.6 1069.5 gc 1268.7 1268.8 
cc 1085.6 1085.5 gd 1169.7 1169.8 
di 676.3 676.3 ge 1379.9 1380.0 
da 914.5 914.3 gf 1435.9 1436.0 
db 970.5 970.5 gg 1451.9 1452.0 
dc 986.5 986.4 hi 859.5 859.4 
dd 887.4 887.4 ha 1097.6 1097.7 
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ei 886.5 886.6 hb 1153.7 1153.8 
ea 1124.7 1124.7 hc 1169.7 1169.7 
eb 1180.7 1181.0 hd 1070.6 1070.7 
ec 1196.7 1196.8 he 1280.8 1280.8 
ed 1097.6 1097.7 hf 1336.9 1336.9 
ee 1307.8 1308.1 hg 1352.8 1352.9 
fi 942.6 942.7 hh 1253.7 1253.7 
fa 1180.7 1180.8    
 
 
 
Data for 9ii 
1H NMR (500 MHz, DMSO-d6) δ 7.30 (br, 1H), 6.46 (br, 1H), 6.40 (br, 1H), 4.31 (dd, 
1H, J = 5.2, 7.8 Hz), 4.12 (dd, 1H, J = 4.5, 7.8 Hz), 3.72 (br, 4H), 3.62 (br, 12H), 3.35-
3.22 (m, 2H), 3.12-3.06 (m, 1H), 2.81 (dd, 1H, J = 5.2, 12.6 Hz), 2.58 (d, 1H, J = 12.6 
Hz), 1.67-1.58 (m, 1H), 1.57-1.43 (m, 3H), 1.42-1.27 (m, 2H) 
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Data for 9ai 
1H NMR (500 MHz, DMSO-d6) δ 7.69 (br, 2H), 7.50 (br, 1H), 6.46 (br, 1H), 6.39 (br, 
1H), 5.30 (t, 1H, J = 7.4 Hz), 4.34-4.27 (m, 1H), 4.16-4.09 (m, 1H), 4.03 (br, 2H), 3.89-
3.75 (m, 3H), 3.72 (br, 2H), 3.68-3.38 (m, 13H), 3.29 (br, 2h), 3.13-3.05 (m, 1H), 2.85-
2.71 (m, 6H), 2.58 (d, 1H, J = 12.5 Hz), 1.75-1.43 (m, 8H), 1.43-1.28 (m, 2H), 1.28-1.15 
(m, 2H) 
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Data for 9di 
1H NMR (500 MHz, DMSO-d6) δ 7.46 (br, 1H), 6.47 (br, 2H), 4.38-4.28 (m, 2H), 4.21 
(d, 1H, J = 16.5 Hz), 4.18-4.10 (m, 2H), 4.08-4.02 (m, 1H), 3.87-3.59 (m, 12H), 3.51 (br, 
4H), 3.31 (br, 2h), 3.13-3.06 (m, 2H), 2.97 (s, 3H), 2.82 (dd, 1H, J = 5.0, 12.5 Hz), 2.58 
(d, 1H, J = 12.5 Hz), 1.68-1.58 (m, 1H), 1.58-1.43 (m, 3H), 1.43-1.26 (m, 2H), 1.17 (d, 
3H, J = 6.5 Hz) 
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 Data for 9gi 
1H NMR (500 MHz, DMSO-d6) δ 8.07 (t, 1H, J = 5.7 Hz), 7.70 (br, 2H), 7.33 (br, 1H), 
6.46 (br, 1H), 6.39 (br, 1H), 4.84-4.74 (m, 1H), 4.34-4.28 (m, 1H), 4.16-4.10 (m, 1H), 
4.04-3.94 (m, 3H), 3.79-3.56 (m, 12H), 3.49 (br, 4H), 3.27 (br, 2h), 3.13-3.06 (m, 1H), 
3.06-2.95 (m, 2H), 2.86 (s, 3H), 2.84-2.71 (m, 2H), 2.57 (d, 1H, J = 12.4 Hz), 2.39-2.23 
(m, 3H), 2.10-1.90 (m, 2H), 1.83-1.73 (m, 1H), 1.68-1.58 (m, 2H), 1.58-1.43 (m, 8H), 
1.43-1.30 (m, 4H), 1.30-1.12 (m, 16H) 
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Data for 9hi 
1H NMR (500 MHz, DMSO-d6) δ 7.93 (t, 1H, J = 5.5 Hz), 7.39 (br, 1H), 6.46 (br, 1H), 
6.39 (br, 1H), 4.34-4.28 (m, 1H), 4.17-4.10 (m, 2H), 4.09-4.03 (m, 1H), 3.97 (d, 1H, J = 
16.4 Hz), 3.88-3.81 (m, 2H), 3.79-3.56 (m, 13H), 3.50 (br, 4H), 3.30 (br, 2h), 3.12-3.07 
(m, 2H), 3.06-3.00 (m, 2H), 2.96 (s, 3H), 2.81 (dd, 1H, J = 5.2, 12.6 Hz), 2.58 (d, 1H, J = 
12.6 Hz), 2.32 (t, 2H, J = 7.4 Hz), 1.68-1.58 (m, 1H), 1.57-1.44 (m, 5H), 1.42-1.31 (m, 
4H), 1.30-1.20 (m, 12H), 1.17 (d, 3H, J = 6.6 Hz) 
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Data for 9cc 
1H NMR (500 MHz, DMSO-d6) δ 7.72 (br, 4H), 7.18 (br, 1H), 6.47 (br, 1H), 6.40 (br, 
1H), 5.27 (t, 2H, J = 7.2 Hz), 4.40-3.69 (m, 15H), 3.69-3.56 (m, 2H), 3.56-3.30 (m, 8H), 
3.24 (br, 2H), 3.13-3.06 (m, 1H), 2.90-2.70 (m, 10H), 2.58 (d, 1H, J = 12.5 Hz), 2.29 (t, 
4H, J = 7.7 Hz), 2.14-2.01 (m, 2H), 2.01-1.89 (m, 2H), 1.78-1.43 (m, 12H), 1.42-1.29 (m, 
2H), 1.29-1.15 (m, 4H) 
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Data for 9dd 
1H NMR (500 MHz, DMSO-d6) δ 7.43 (br, 1H), 6.47 (br, 2H), 4.40-4.28 (m, 3H), 4.21 
(d, 2H, J = 16.5 Hz), 4.18-4.10 (m, 3H), 4.09-4.01 (m, 2H), 3.88-3.60 (m, 14H), 3.51 (br, 
8H), 3.32 (br, 2H), 3.13-3.07 (m, 1H), 2.97 (s, 6H), 2.82 (dd, 1H, J = 5.0, 12.5 Hz), 2.58 
(d, 1H, J = 12.5 Hz), 1.69-1.59 (m, 1H), 1.59-1.44 (m, 3H), 1.44-1.28 (m, 2H), 1.17 (d, 
6H, J = 6.5 Hz) 
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Data for 9ff 
1H NMR (500 MHz, DMSO-d6) δ 8.05 (t, 2H, J = 5.6 Hz), 7.74 (br, 4H), 7.28 (br, 1H), 
6.46 (br, 1H), 6.39 (br, 1H), 4.84-4.77 (m, 2H), 4.31 (dd, 1H, J = 5.3, 7.8 Hz), 4.13 (dd, 
1H, J = 4.5, 7.8 Hz), 4.07-3.95 (m, 4H), 3.88 (d, 2H, J = 4.9 Hz), 3.78-3.57 (m, 8H), 3.48 
(br, 8H), 3.32-3.19 (m, 2H), 3.13-3.07 (m, 1H), 3.06-2.94 (m, 4H), 2.87 (s, 6H), 2.85-
2.70 (m, 5H), 2.57 (d, 1H, J = 12.5 Hz), 2.32 (t, 4H, J = 7.4 Hz), 1.93-1.84 (m, 2H), 1.81-
1.71 (m, 2H), 1.67-1.43 (m, 16H), 1.41-1.31 (m, 6H), 1.31-1.12 (m, 30H), 0.92 (t, 6H, J = 
7.4 Hz), 0.82 (d, 6H, J = 6.8 Hz) 
 
 181 
 
 
 182 
 
 
Data for 9gg 
1H NMR (500 MHz, DMSO-d6) δ 8.08 (t, 2H, J = 5.6 Hz), 7.73 (br, 4H), 7.40 (br, 1H), 
6.47 (br, 1H), 6.40 (br, 1H), 4.83-4.76 (m, 2H), 4.31 (dd, 1H, J = 5.0, 7.7 Hz), 4.13 (dd, 
1H, J = 4.5, 7.7 Hz), 4.06-3.94 (m, 6H), 3.80-3.57 (m, 8H), 3.49 (br, 8H), 3.34-3.21 (m, 
2H), 3.14-3.07 (m, 1H), 3.07-2.94 (m, 4H), 2.86 (s, 6H), 2.84-2.71 (m, 5H), 2.58 (d, 1H, 
J = 12.5 Hz), 2.39-2.20 (m, 8H), 2.10-2.00 (m, 2H), 2.00-1.89 (m, 2H), 1.83-1.72 (m, 
2H), 1.68-1.58 (m, 3H), 1.58-1.43 (m, 11H), 1.42-1.31 (m, 8H), 1.31-1.11 (m, 26H) 
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Data for 9hh 
1H NMR (500 MHz, DMSO-d6) δ 7.92 (t, 2H, J = 5.6 Hz), 7.49 (br, 1H), 6.55-6.32 (m, 
2H), 4.35-4.28 (m, 2H), 4.18-4.11 (m, 3H), 4.10-4.03 (m, 2H), 3.98 (d, 2H, J = 16.4 Hz), 
3.88-3.81 (m, 4H), 3.81-3.58 (m, 10H), 3.52 (br, 8H), 3.32 (br, 2H), 3.13-3.07 (m, 1H), 
3.07-3.01 (m, 2H), 2.96 (s, 6H), 2.82 (dd, 1H, J = 5.1, 12.4 Hz), 2.58 (d, 1H, J = 12.4 
Hz), 2.33 (t, 4H, J = 7.4 Hz), 1.69-1.59 (m, 1H), 1.59-1.44 (m, 7H), 1.42-1.32 (m, 6H), 
1.32-1.20 (m, 27H), 1.17 (d, 6H, J = 6.6 Hz) 
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Data for 9ab 
1H NMR (500 MHz, DMSO-d6) δ 7.71 (br, 4H), 7.24 (br, 1H), 6.47 (br, 1H), 6.40 (br, 
1H), 5.36-5.22 (m, 2H), 4.35-4.27 (m, 1H), 4.18-4.06 (m, 2H), 4.04 (br, 2H), 3.96-3.68 
(m, 8H), 3.68-3.31 (m, 12H), 3.31-3.15 (m, 2H), 3.14-3.05 (m, 1H), 2.86 (s, 3H), 2.85-
2.69 (m, 8H), 2.58 (d, 1H, J = 12.5 Hz), 1.97-1.85 (m, 1H), 1.79-1.43 (m, 12H), 1.43-
1.16 (m, 8H), 0.92 (t, 3H, J = 7.4 Hz), 0.84 (d, 3H, J = 6.9 Hz) 
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Data for 9ad 
1H NMR (500 MHz, DMSO-d6) δ 7.67 (br, 2H), 7.23 (br, 1H), 6.46 (br, 1H), 6.40 (br, 
1H), 5.30 (t, 1H, J = 7.7 Hz), 4.38-4.09 (m, 6H), 4.09-3.95 (m, 3H), 3.88-3.36 (m, 20H), 
3.32-3.20 (m, 2H), 3.13-3.06 (m, 1H), 2.97 (s, 3H), 2.86-2.70 (m, 6H), 2.58 (d, 1H, J = 
12.5 Hz), 1.75-1.59 (m, 3H), 1.59-1.43 (m, 5H), 1.43-1.28 (m, 2H), 1.28-1.19 (m, 2H), 
1.17 (d, 3H, J = 6.6 Hz) 
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Data for 9af 
1H NMR (500 MHz, DMSO-d6) δ 8.05 (t, 1H, J =5.6 Hz), 7.72 (br, 4H), 7.33 (br, 1H), 
6.46 (br, 1H), 6.40 (br, 1H), 5.30 (t, 1H, J = 7.6 Hz), 4.80 (dd, 1H, J =5.5, 10.2 Hz), 4.34-
4.28 (m, 1H), 4.17-4.10 (m, 1H), 4.09-3.96 (m, 4H), 3.92-3.38 (m, 20H), 3.34-3.20 (m, 
2H), 3.14-3.06 (m, 1H), 3.02-2.94 (m, 2H), 2.87 (s, 3H), 2.85-2.71 (m, 8H), 2.58 (d, 1H, 
J = 12.6 Hz), 2.32 (t, 2H, J = 7.2 Hz), 1.93-1.84 (m, 1H), 1.81-1.72 (m, 1H), 1.72-1.43 
(m, 14H), 1.42-1.31 (m, 4H), 1.31-1.12 (m, 16H), 0.92 (t, 3H, J = 7.4 Hz), 0.82 (d, 3H, J 
= 6.8 Hz) 
 
 
 189 
 
 
 
Data for 9bf 
1H NMR (500 MHz, DMSO-d6) δ 8.05 (t, 1H, J = 5.5 Hz), 7.72 (br, 4H), 7.25 (br, 1H), 
6.46 (br, 1H), 6.40 (br, 1H), 5.29 (t, 1H, J = 7.3 Hz), 4.80 (dd, 1H, J = 5.6, 10.3 Hz), 
4.34-4.28 (m, 1H), 4.17-4.08 (m, 3H), 4.07-3.96 (m, 2H), 3.96-3.91 (m, 1H), 3.91-3.79 
(m, 4H), 3.76-3.53 (m, 7H), 3.47 (br, 6H), 3.42-3.32 (m, 2H), 3.31-3.19 (m, 2H), 3.13-
3.06 (m, 1H), 3.06-2.95 (m, 2H), 2.90-2.85 (m, 6H), 2.85-2.71 (m, 5H), 2.58 (d, 1H, J = 
12.4 Hz), 2.32 (t, 2H, J = 7.2 Hz), 1.96-1.85 (m, 1H), 1.80-1.69 (m, 1H), 1.67-1.43 (m, 
14H), 1.42-1.31 (m, 4H), 1.30-1.13 (m, 18H), 0.96-0.89 (m, 6H), 0.87-0.79 (m, 6H) 
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Data for 9bh 
1H NMR (500 MHz, DMSO-d6) δ 7.93 (t, 1H, J = 5.5 Hz), 7.68 (br, 2H), 7.18 (br, 1H), 
6.46 (br, 1H), 6.39 (br, 1H), 5.29 (t, 1H, J = 7.3 Hz), 4.35-4.26 (m, 1H), 4.19-4.02 (m, 
4H), 4.02-3.91 (m, 3H), 3.91-3.78 (m, 4H), 3.78-3.59 (m, 7H), 3.59-3.43 (m, 8H), 3.43-
3.31 (m, 2H), 3.31-3.16 (m, 2H), 3.14-3.07 (m, 1H), 3.07-2.99 (m, 2H), 2.96 (s, 3H), 2.86 
(s, 3H), 2.84-2.69 (m, 3H), 2.58 (d, 1H, J = 12.5 Hz), 2.32 (t, 2H, J = 7.2 Hz), 1.96-1.87 
(m, 1H), 1.80-1.69 (m, 1H), 1.67-1.43 (m, 10H), 1.43-1.31 (m, 4H), 1.30-1.20 (m, 14H), 
1.17 (d, 3H, J = 6.5 Hz), 0.92 (t, 3H, J = 7.4 Hz), 0.84 (d, 3H, J = 6.8 Hz) 
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Data for 9ch 
1H NMR (500 MHz, DMSO-d6) δ 7.92 (t, 1H, J = 5.5 Hz), 7.65 (br, 2H), 7.11 (br, 1H), 
6.46 (br, 1H), 6.39 (br, 1H), 5.27 (t, 1H, J = 7.8 Hz), 4.36-4.27 (m, 1H), 4.18-4.09 (m, 
2H), 4.09-3.56 (m, 17H), 3.54-3.31 (m, 10H), 3.24 (br, 2H), 3.13-3.07 (m, 1H), 3.06-3.00 
(m, 2H), 2.96 (s, 3H), 2.88-2.72 (m, 6H), 2.57 (d, 1H, J = 12.5 Hz), 2.35-2.25 (m, 4H), 
2.13-2.02 (m, 1H), 2.01-1.89 (m, 1H), 1.76-1.43 (m, 9H), 1.41-1.31 (m, 3H), 1.30-1.20 
(m, 11H), 1.17 (d, 6H, J = 6.6 Hz) 
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Data for 9df 
1H NMR (500 MHz, DMSO-d6) δ 8.04 (t, 1H, J = 5.5 Hz), 7.68 (br, 2H), 7.19 (br, 1H), 
6.46 (br, 1H), 6.39 (br, 1H), 4.80 (dd, 1H, J = 5.7, 10.1 Hz), 4.38-4.27 (m, 2H), 4.25-4.10 
(m, 4H), 4.09-3.57 (m, 16H), 3.48 (br, 8H), 3.32-3.19 (m, 2H), 3.13-3.06 (m, 1H), 3.06-
2.93 (m, 5H), 2.87 (s, 3H), 2.85-2.71 (m, 3H), 2.58 (d, 1H, J = 12.5 Hz), 2.32 (t, 2H, J = 
7.2 Hz), 1.93-1.84 (m, 1H), 1.81-1.71 (m, 1H), 1.68-1.44 (m, 9H), 1.41-1.31 (m, 4H), 
1.31-1.11 (m, 17H), 0.92 (t, 3H, J = 7.4 Hz), 0.82 (d, 3H, J = 6.8 Hz) 
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Data for 9dh 
1H NMR (500 MHz, DMSO-d6) δ 7.92 (t, 1H, J = 5.5 Hz), 7.22 (br, 1H), 6.46 (br, 1H), 
6.40 (br, 1H), 4.39-4.27 (m, 3H), 4.25-3.94 (m, 7H), 4.02-3.91 (m, 3H), 3.88-3.58 (m, 
12H), 3.50 (br, 8H), 3.29 (br, 2H), 3.13-3.07 (m, 1H), 3.07-3.00 (m, 2H), 2.97 (s, 3H), 
2.96 (s, 3H), 2.82 (dd, 1H, J = 5.2, 12.5 Hz), 2.58 (d, 1H, J = 12.5 Hz), 2.33 (t, 2H, J = 
7.4 Hz), 1.68-1.58 (m, 1H), 1.57-1.44 (m, 4H), 1.42-1.31 (m, 4H), 1.30-1.20 (m, 12H), 
1.19-1.15 (m, 6H) 
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Data for 9ef 
1H NMR (500 MHz, DMSO-d6) δ 8.05 (br, 2H), 7.70 (br, 4H), 7.24 (br, 1H), 6.46 (br, 
1H), 6.39 (br, 1H), 4.86-4.76 (m, 2H), 4.34-4.28 (m, 1H), 4.16-3.93 (m, 5H), 3.91-3.82 
(m, 3H), 3.78-3.56 (m, 8H), 3.48 (br, 8H), 3.32-3.19 (m, 2H), 3.14-3.07 (m, 1H), 3.07-
2.95 (m, 4H), 2.87 (s, 3H), 2.85-2.70 (m, 8H), 2.57 (d, 1H, J = 12.5 Hz), 2.32 (t, 4H, J = 
7.2 Hz), 1.93-1.84 (m, 1H), 1.83-1.71 (m, 2H), 1.69-1.43 (m, 14H), 1.41-1.31 (m, 6H), 
1.31-1.09 (m, 30H), 0.92 (t, 3H, J = 7.4 Hz), 0.82 (d, 3H, J = 6.8 Hz) 
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Data for 9fh 
1H NMR (500 MHz, DMSO-d6) δ 8.04 (t, 1H, J = 5.6 Hz), 7.93 (t, 1H, J = 5.6 Hz), 7.69 
(br, 2H), 7.32 (br, 1H), 6.46 (br, 1H), 6.40 (br, 1H), 4.80 (dd, 1H, J = 5.5, 10.0 Hz), 4.34-
4.28 (m, 1H), 4.17-4.10 (m, 3H), 4.09-4.03 (m, 2H), 4.03-3.94 (m, 3H), 3.91-3.80 (m, 
4H), 3.80-3.58 (m, 7H), 3.49 (br, 8H), 3.35-3.21 (m, 2H), 3.13-3.07 (m, 1H), 3.07-2.97 
(m, 4H), 2.96 (s, 3H), 2.87 (s, 3H), 2.85-2.72 (m, 3H), 2.58 (d, 1H, J = 12.5 Hz), 2.32 (t, 
4H, J = 7.2 Hz), 1.93-1.84 (m, 1H), 1.81-1.72 (m, 1H), 1.68-1.43 (m, 11H), 1.42-1.31 (m, 
6H), 1.31-1.12 (m, 31H), 0.92 (t, 3H, J = 7.4 Hz), 0.82 (d, 3H, J = 6.8 Hz) 
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Data for 9gh 
1H NMR (500 MHz, DMSO-d6) δ 8.07 (t, 1H, J = 5.6 Hz), 7.93 (t, 1H, J = 5.6 Hz), 7.68 
(br, 2H), 7.18 (br, 1H), 6.46 (br, 1H), 6.39 (br, 1H), 4.79 (dd, 1H, J = 5.4, 10.1 Hz), 4.34-
4.28 (m, 1H), 4.17-4.10 (m, 2H), 4.09-4.03 (m, 2H), 4.03-3.92 (m, 4H), 3.87-3.81 (m, 
3H), 3.78-3.57 (m, 9H), 3.48 (br, 7H), 3.30-3.19 (m, 2H), 3.13-3.07 (m, 1H), 3.07-3.97 
(m, 4H), 2.96 (s, 3H), 2.86 (s, 3H), 2.84-2.72 (m, 3H), 2.57 (d, 1H, J = 12.5 Hz), 2.38-
2.22 (m, 6H), 2.10-2.00 (m, 1H), 1.99-1.89 (m, 1H), 1.83-1.73 (m, 1H), 1.68-1.58 (m, 
2H), 1.58-1.43 (m, 9H), 1.41-1.31 (m, 6H), 1.31-1.10 (m, 29H) 
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APPENDIX C 
EXPERIMENTAL FOR CHAPTER IV 
General Methods.  All chemicals were obtained from commercial suppliers and 
used without further purification. Dichloromethane was obtained anhydrous by 
distillation over calcium hydride and THF was distilled over sodium metal and 
benzophenone.  Analytical HPLC analyses were carried out on 25 x 0.46 cm C-18 
column using gradient conditions (5 – 95% B).  The eluents used were: solvent A (H2O 
with 0.1% TFA) and solvent B (CH3CN with 0.1% TFA).  The flow rate used was 1.0 
mL/min.  NMR spectra were recorded at 300 MHz and 500 MHz.  NMR chemical shifts 
were expressed in ppm relative to internal solvent peaks, and coupling constants were 
measured in Hz.   
 
N
OtBu
OMe
O
13  
 Preparation of Compound 13.  To a solution of 1.06 g (5.0 mmol) H-Ser(tBu)-
OMe in 16 mL CH3OH was added acetic acid to adjust the pH (~4.0).  To this solution 
was slowly added 4 mL (50.0 mmol) formaldehyde solution (concentration, 37 %), and 
then 471.3 mg (7.5 mmol) NaCNBH3 under stirring.  The reaction mixture was stirred 
under room temperature for 10 h.  The solvents were removed under reduced pressure.  
The residue was washed with sat. NaHCO3 and extracted with CH2Cl2.  The CH2Cl2 
solution was dried with Na2SO4 and concentrated to dryness.  Flash chromatography with 
EtOAc/hexanes mixtures (20 % to 30 %) afforded 761.3 mg (75 %) pure N, N-demethyl-
Ser(tBu)-OMe as a colorless liquid. 
1H NMR (300 MHz, CDCl3) δ 3.69 (s, 3H), 3.64 (dd, 1H, J = 7.4, 8.8 Hz), 3.55 (dd, 1H, 
J = 5.6, 8.8 Hz), 3.26 (dd, 1H, J = 5.6, 7.4 Hz), 2.33 (s, 6H), 1.14 (s, 9H) 
MS (APCI, m/z) 204.0 (M+H)+ 
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 General Procedure for Preparation of Compound 10a-f.  A solution of N-Boc 
protected L-amino acid methyl ester (1.0 equiv) in ethanol (0.4 M) was added hydrazine 
monohydrate (3 equiv) in one portion.  The reaction mixture was vigorously stirred at 25 
°C for 12 h.  The solvents were evaporated in vacuo and the crude amino acid hydrazide 
product was used in the next step without further purification. 
 
BocHN
NHNH2
O
10a  
Compound 10a was prepared from Boc-Gly-OMe (3.78 g, 20.0 mmol) as a white solid. 
1H NMR (300 MHz, CDCl3) δ 7.77 (br, 1H), 5.33 (br, 1H), 3.89 (br, 2H), 3.78 (d, 2H, J 
= 6.0 Hz), 1.42 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 170.3, 156.1, 80.5, 43.1, 28.3 
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BocHN
NHNH2
O
10b  
Compound 10b was prepared from Boc-Ile-OMe (3.68 g, 15.0 mmol) as a white solid.  
1H NMR (300 MHz, CDCl3) δ 7.70 (br, 1H), 5.15 (d, 1H, J = 8.6 Hz), 4.02-3.30 (m, 
3H), 1.82 (br, 1H), 1.60-1.27 (m, 10H), 1.18-1.01 (m, 1H), 1.00-0.75 (m, 6H) 
13C NMR (75 MHz, CDCl3) δ 172.4, 155.8, 80.1, 57.9, 37.0, 28.3, 24.8, 15.5, 11.2 
 
 206 
 
 
 
BocHN
NHNH2
O
NHBoc
10c  
Compound 10c was prepared from Boc-Lys(Boc)-OMe (5.41 g, 15.0 mmol) as a white 
solid. 
1H NMR (500 MHz, CDCl3) δ 7.94 (br, 1H), 5.31 (d, 1H, J = 7.5 Hz), 4.70 (br, 1H), 
4.13-3.61 (m, 3H), 3.13-2.96 (m, 2H), 1.83-1.71 (m, 1H), 1.67-1.55 (m, 1H), 1.51-1.24 
(m, 22H) 
13C NMR (125 MHz, CDCl3) δ 172.8, 156.2, 155.7, 80.1, 79.1, 53.0, 39.8, 31.9, 29.6, 
28.4, 28.3, 22.5 
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BocHN
NHNH2
O
OtBu
10d  
Compound 10d was prepared from Boc-Tyr(tBu)-OMe (5.27 g, 15 .0 mmol) as a white 
solid. 
1H NMR (500 MHz, CDCl3) δ 7.48 (br, 1H), 7.04 (d, 2H, J = 6.9 Hz), 6.88 (d, 2H, J = 
8.5 Hz), 5.16 (d, 1H, J = 7.5 Hz), 4.34-4.18 (m, 1H), 3.60 (br, 2H), 3.05-2.84 (m, 2H), 
1.36 (s, 9H), 1.29 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 172.0, 155.4, 154.3, 131.2, 129.6, 124.3, 80.2, 78.4, 
54.6, 37.8, 28.8, 28.2 
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BocHN
OtBu
NHNH2
O
10e  
Compound 10e was prepared from Boc-Ser(tBu)-OMe (4.13 g, 15.0 mmol) as a white 
solid. 
1H NMR (300 MHz, CDCl3) δ 7.74 (br, 1H), 5.35 (br, 1H), 4.15 (br, 1H), 3.88-3.49 (m, 
3H), 3.35 (dd, 1H, J = 7.0, 8.7 Hz), 1.41 (s, 9H), 1.13 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 171.5, 155.4, 80.2, 73.9, 61.5, 53.6, 28.3, 27.3 
MS (ESI, m/z) 276.2 (M+H)+ 
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BocHN
tBuO
NHNH2
O
10f  
Compound 10f was prepared from Boc-Thr(tBu)-OMe (2.89 g, 10.0 mmol) as a white 
solid. 
1H NMR (300 MHz, CDCl3) δ 7.91 (br, 1H), 5.54 (br, 1H), 4.20-3.99 (m, 2H), 3.86 (br, 
2H), 1.41 (s, 9H), 1.19 (s, 9H), 1.01 (d, 3H, J = 6.0 Hz) 
 
 
 
N
OtBu
NHNH2
O
10g  
Compound 10g was prepared from 13 (1.62 g, 8.0 mmol) N, N-dimethyl-Ser(tBu)-OMe 
as a white solid. 
 212 
1H NMR (500 MHz, CDCl3) δ 8.13 (br, 1H), 3.80 (br, 2H), 3.75 (dd, 1H, J = 4.3, 9.8 
Hz), 3.58 (dd, 1H, J = 6.1, 9.8 Hz), 3.03 (dd, 1H, J = 4.3, 6.1 Hz), 2.33 (s, 6H), 1.14 (s, 
9H) 
13C NMR (125 MHz, CDCl3) δ 172.3, 73.2, 68.5, 59.6, 42.8, 27.7 
MS (APCI, m/z) 204.0 (M+H)+ 
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 General Procedure for Preparation of 11a-q.  The Cbz protected amino acid 
(1.0 equiv) was dissolved in dry CH3CN (0.50 M).  HOBt (1.1 equiv) was added in one 
portion followed by EDC (1.1 equiv).  The mixture was stirred at room temperate for ~ 
1h (all of the acid was converted to the activated ester/amide mixture).  The resulting 
mixture was then slowly added to a solution of Boc protected amino acid hydrazide 10a-f 
(1.0 equiv) in dry CH3CN (0.50 M).  The reaction mixture was vigorously stirred at room 
temperature for 8 h.  The solvent was removed under reduced pressure and the residue 
was washed with H2O (30 ml), 1N HCl (30 ml), saturated NaHCO3 (30 ml) and brine (30 
ml).  The solid crude product was dried in vacuo and used in the next step directly.  To a 
stirred solution of this diacyl hydrazide intermediate in dry THF (0.10 M), PPh3 (2.0 
equiv), I2 (2.0 equiv) and Et3N (4.0 equiv) was added at 0 °C.  The cooling bath was 
removed after 30 min and stirring was continued at room temperature for 4-6 h.  Water 
(30 ml) was added and stirring was continued for 1 h.  The organic phase was separated 
and dried with Na2SO4 and concentrated in vacuo.  The residue was purified by flash 
chromatography with EtOAc/hexanes mixtures to provide pure compounds 11a-q. 
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NN
O
CbzHN NHBoc
OtBu
NHBoc
11a  
Compound 11a was prepared from 10c (4.75 g, 13.2 mmol) and Cbz-Ser(tBu)-OH (3.89 
g, 13.2 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 5.27 g 
(64 %) 11a as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.40-7.27 (m, 5H), 5.76 (d, 1H, J = 7.8 Hz), 5.19-5.07 
(m, 4H), 4.96 (br, 1H), 4.59 (br, 1H), 3.82-3.76 (m, 1H), 3.69 (dd, 1H, J = 3.9, 9.2 Hz), 
3.12-3.02 (m, 2H), 1.96-1.74 (m, 2H), 1.56-1.30 (m, 22H), 1.07 (s, 9H) 
13C NMR (75 MHz, CDCl3) δ 167.0, 165.6, 156.0, 155.8, 155.0, 136.0, 128.6, 128.3, 
128.2, 80.4, 79.2, 73.9, 67.3, 62.4, 48.7, 46.9, 40.0, 33.4, 29.4, 28.4, 28.3, 27.2, 22.3  
MS (ESI, m/z) 642.2 (M+Na)+ 
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NN
O
CbzHN NHBoc
NHBoc
O
tBuO
11b  
Compound 11b was prepared from 10c (3.48 g, 14.2 mmol) and Cbz-Glu(OtBu)-OH 
(5.40 g, 14.2 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 
4.52 g (48 %) 11b as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.40-7.29 (m, 5H), 5.65 (br, 1H), 5.27-5.05 (m, 4H), 4.97 
(br, 1H), 4.64 (br, 1H), 3.09 (br, 2H), 2.45-2.21 (m, 3H), 1.18-1.08 (m, 1H), 1.58-1.33 
(m, 31H) 
13C NMR (125 MHz, CDCl3) δ 171.7, 167.3, 166.2, 156.1, 155.7, 155.1, 135.9, 128.5, 
128.3, 128.1, 81.0, 80.4, 79.1, 67.3, 47.4, 47.0, 39.9, 33.4, 31.1, 29.4, 28.4, 28.3, 28.0, 
22.3   
MS (ESI, m/z) 684.3 (M+Na)+ 
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NN
O
CbzHN NHBoc
NHBoc
O
tBuO
11c  
Compound 11c was prepared from 10c (4.66 g, 12.9 mmol) and Cbz-Asp(OtBu)-
OH•DCHA (6.53 g, 12.9 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) 
afforded 3.32 g (40 %) 11c as a white solid.  
1H NMR (300 MHz, CDCl3) δ 7.39-7.26 (m, 5H), 6.02 (d, 1H, J = 7.8 Hz), 5.39-5.28 
(m, 1H), 5.21-5.06 (m, 3H), 4.95 (br, 1H), 4.61 (br, 1H), 3.12-2.84 (m, 4H), 1.95-1.73 
(m, 2H), 1.53-1.27 (m, 31H) 
13C NMR (75 MHz, CDCl3) δ 169.2, 167.3, 165.8, 156.0, 155.6, 155.0, 135.9, 128.5, 
128.3, 128.2, 82.1, 80.4, 79.1, 67.3, 47.0, 44.5, 40.0, 38.2, 33.4, 29.4, 28.4, 28.2, 27.9, 
22.3  
MS (ESI, m/z) 648.4 (M+H)+ 
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NN
O
CbzHN NHBoc
NHBoc
OtBu
11d  
Compound 11d was prepared from 10c (4.70 g, 13.0 mmol) and Cbz-Tyr(tBu)-OH (4.84 
g, 13.0 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 3.70 g 
(41 %) 11d as a white solid.  
1H NMR (300 MHz, CDCl3) δ 7.39-7.26 (m, 5H), 6.94 (d, 2H, J = 8.5 Hz), 6.84 (d, 2H, 
J = 8.5 Hz), 5.48 (d, 1H, J = 8.0 Hz), 5.36-5.21 (m, 1H), 5.20-5.00 (m, 3H), 4.97-4.84 (m, 
1H), 4.66 (br, 1H), 3.25-2.96 (m, 4H), 1.90-1.66 (m, 2H), 1.52-1.19 (m, 31H) 
13C NMR (75 MHz, CDCl3) δ 167.1, 166.1, 156.1, 155.4, 155.0, 154.6, 135.9, 132.1, 
129.7, 128.5, 128.3, 128.1, 124.3, 80.4, 79.1, 78.5, 67.2, 48.9, 47.0, 40.0, 39.0, 33.3, 29.4, 
28.8, 28.4, 28.3, 22.3  
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MS (MALDI, m/z) 718.1 (M+Na)+ 
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NN
O
CbzHN NHBoc
OtBu
11e  
Compound 11e was prepared from 10b (3.51 g, 14.3 mmol) and Cbz-Ser(tBu)-OH (4.22 
g, 14.3 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 5.42 g 
(75 %) 11e as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.40-7.27 (m, 5H), 5.74 (d, 1H, J = 8.8 Hz), 5.23-5.06 
(m, 4H), 4.96-4.88 (m, 1H), 3.83-3.75 (m, 1H), 3.68 (dd, 1H, J = 3.9, 9.1 Hz), 1.89 (br, 
1H), 1.48-1.35 (m, 10H), 1.21-1.10 (m, 1H), 1.06 (s, 9H), 0.93-0.80 (m, 6H) 
13C NMR (75 MHz, CDCl3) δ 175.3, 174.3, 163.6, 162.9, 141.9, 133.7, 133.4, 133.4, 
80.5, 73.5, 66.4, 61.2, 49.1, 45.8, 35.2, 23.4, 22.2, 19.7, 8.8, 4.8  
MS (ESI, m/z) 527.3 (M+Na)+ 
 
 221 
 
 
NN
O
CbzHN NHBoc
BocHN
11f  
Compound 11f was prepared from 10a (3.37 g, 17.8 mmol) and Cbz-Lys(Boc)-OH (6.78 
g, 17.8 mmol).  Flash chromatography (25 % to 50 % EtOAc/Hexanes) afforded 5.57 g 
(59%) 11f as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.34-7.18 (m, 5H), 6.04 (br, 1H), 5.54 (br, 1H), 5.10-4.94 
(m, 3H), 4.73 (br, 1H), 4.50-4.30 (br, 2H), 3.03 (br, 2H), 1.96-1.75 (m, 2H), 1.53-1.20 
(m, 22H) 
13C NMR (75 MHz, CDCl3) δ 167.1, 164.4, 156.1, 155.9, 155.4, 135.9, 128.4, 128.2, 
128.1, 80.4, 79.1, 67.1, 47.5, 39.8, 35.7, 32.8, 29.3, 28.3, 28.2, 22.3  
MS (ESI, m/z) 556.3 (M+Na)+ 
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NN
O
CbzHN NHBoc
OtBu
tBuO
O
11g  
Compound 11g was prepared from 10e (4.13 g, 15.0 mmol) and Cbz-Asp(OtBu)-
OH•DCHA (7.57 g, 15.0 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) 
afforded 3.80 g (45 %) 11g as a white solid.  
1H NMR (300 MHz, CDCl3) δ 7.36-7.25 (m, 5H), 6.01 (d, 1H, J = 9.2 Hz), 5.46 (d, 1H J 
= 8.7 Hz ), 5.38-5.28 (m, 1H), 5.16-4.98 (m, 3H), 3.78-3.67 (m, 1H), 3.62 (dd, 1H, J = 
4.0, 9.2 Hz), 3.03-2.81 (m, 2H), 1.47-1.29 (m, 18H), 1.04 (s, 9H) 
13C NMR (75 MHz, CDCl3) δ 169.1, 166.2, 165.6, 155.5, 155.0, 135.9, 128.2, 128.1, 
128.0, 82.0, 80.2, 73.7, 67.2, 62.2, 48.2, 44.4, 38.0, 28.2, 27.8, 27.1  
MS (ESI, m/z) 563.3 (M+H)+ 
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NN
O
CbzHN NHBoc
OtBu
OtBu
11h  
Compound 11h was prepared from 10e (2.34 g, 8.5 mmol) and Cbz-Tyr(tBu)-OH•DCHA 
(4.70 g, 8.5 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 4.20 
g (81%) 11h as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.35-7.26 (m, 5H), 6.95-6.88 (m, 2H), 6.86-6.81 (m, 2H), 
5.50-5.37 (m, 2H), 5.33-5.25 (m, 1H), 5.10-5.00 (m, 3H), 3.73 (br, 1H), 3.64 (dd, 1H, J = 
4.0, 9.2 Hz), 3.26-3.02 (m, 2H), 1.43 (s, 9H), 1.28 (s, 9H), 1.07 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 166.1, 165.8, 155.4, 155.1, 154.6, 136.0, 129.8, 129.5, 
128.5, 128.2, 128.0, 124.1, 80.4, 78.4, 73.8, 67.1, 62.3, 48.8, 48.2, 38.8, 28.8, 28.2, 27.2 
 225 
 
 
 
 
 226 
NN
O
CbzHN NHBoc
OtBu
O
tBuO
11i  
Compound 11i was prepared from 10e (3.99 g, 14.5 mmol) and Cbz-Glu(OtBu)-OH (4.89 
g, 14.5 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 7.02 g 
(48 %) 11i as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.36-7.26 (m, 5H), 5.45 (br, 2H), 5.15-5.02 (m, 4H), 
3.80-3.70 (br, 1H), 3.65 (dd, 1H, J = 3.8, 9.1 Hz), 2.41-2.17 (m, 3H), 2.16-2.05 (m, 1H), 
1.49-1.32 (m, 18H), 1.07 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 171.6, 166.2, 166.0, 155.6, 155.1, 135.9, 128.5, 128.2, 
128.1, 80.9, 80.4, 73.7, 67.2, 62.5, 48.3, 47.3, 31.1, 28.6, 28.2, 28.0, 27.2  
MS (ESI, m/z) 599.3 (M+Na)+ 
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NN
O
CbzHN NHBoc
OtBu
BocHN
11j  
Compound 11j was prepared from 10e (3.71 g, 13.5 mmol) and Cbz-Lys(Boc)-OH (4.55 
g, 13.5 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 5.0 g 
(60%) 11j as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.39-7.26 (m, 5H), 5.50 (br, 2H), 5.15-4.97 (m, 4H), 4.59 
(br, 1H), 3.74 (br, 1H), 3.65 (dd, 1H, J = 3.9, 9.1 Hz), 3.06 (br, 2H), 1.99-1.75 (m, 2H), 
1.54-1.28 (m, 22H), 1,06 (s, 9H) 
13C NMR (75 MHz, CDCl3) δ 166.5, 166.1, 156.0, 155.7, 155.2, 135.9, 128.5, 128.2, 
128.1, 80.4, 79.2, 73.8, 67.2, 62.5, 48.3, 47.5, 39.9, 33.2, 29.4, 28.4, 28.2, 27.2, 22.2   
MS (ESI, m/z) 642.4 (M+Na)+ 
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O
CbzHN NHBoc
OtBu
tBuO
O
11k  
Compound 11k was prepared from 10d (4.43 g, 12.6 mmol) and Cbz-Asp(OtBu)-
OH•DCHA (6.36 g, 12.6 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) 
afforded 3.40 g (42%) 11k as a white solid.  
1H NMR (300 MHz, CDCl3) δ 7.43-7.27 (m, 5H), 6.94 (d, 2H, J = 8.2 Hz), 6.86 (d, 2H, 
J = 8.2 Hz), 5. 94 (br, 1H), 5.38-4.98 (m, 5H), 3.22-2.82 (m, 4H), 1.46-1.20 (m, 18H) 
13C NMR (75 MHz, CDCl3) δ 169.3, 166.7, 165.8, 155.6, 154.7, 154.5, 135.9, 129.9, 
129.8, 128.6, 128.3, 128.2, 124.2, 82.2, 80.4, 78.4, 67.4, 48.3, 44.5, 39.1, 38.1, 28.8, 28.2, 
27.9 
MS (ESI, m/z) 639.3 (M+H)+ 
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O
CbzHN NHBoc
OtBu
BocHN
11l  
Compound 11l was prepared from 10d (4.78 g, 13.6 mmol) and Cbz-Lys(Boc)-OH (5.17 
g, 13.6 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 6.20 g 
(66 %) 11l as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.34-7.25 (m, 5H), 6.96 (d, 2H, J = 7.9 Hz), 6.84 (d, 2H, 
J = 7.9 Hz), 5. 71 (br, 1H), 5.36-4.93 (m, 5H), 4.73 (br, 1H), 3.20-2.94 (m, 4H), 1.98-1.72 
(m, 2H), 1.53-1.20 (m, 31H) 
13C NMR (75 MHz, CDCl3) δ 166.0, 156.1, 155.7, 154.8, 154.4, 135.9, 130.1, 129.7, 
128.5, 128.2, 128.1, 124.2, 80.3, 79.1, 78.5, 67.2, 48.4, 47.5, 39.8, 39.2, 33.0, 29.4, 28.7, 
28.4, 28.2, 22.2  
MS (ESI, m/z) 718.4 (M+Na)+ 
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NN
O
CbzHN NHBoc
OtBu
O
tBuO
11m  
Compound 11m was prepared from 10d (5.00 g, 14.2 mmol) and Cbz-Glu(OtBu)-OH 
(4.80 g, 14.2 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 
4.79 g (52 %) 11m as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.35-7.22 (m, 5H), 6.95 (d, 2H, J = 7.8 Hz), 6.84 (d, 2H, 
J = 7.8 Hz), 5. 85 (br, 1H), 5.32 (br, 1H), 5.20 (br, 1H), 5.14-4.93 (m, 3H), 3.22-2.93 (m, 
2H), 2.38-2.24 (m, 2H), 2.23-1.98 (m, 2H), 1.48-1.20 (m, 27H) 
13C NMR (75 MHz, CDCl3) δ 171.6, 166.6, 166.2, 155.6, 154.7, 154.3, 135.9, 130.1, 
129.6, 128.4, 128.1, 128.0, 124.1, 80.9, 80.2, 78.3, 67.1, 48.3, 47.2, 39.0, 31.0, 28.7, 28.3, 
28.1, 27.9  
MS (ESI, m/z) 675.3 (M+Na)+ 
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O
CbzHN NHBoc
OtBu
OtBu
11n  
Compound 11n was prepared from 10d (5.00 g, 14.2 mmol) and Cbz-Ser(tBu)-OH (4.20 
g, 14.2 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 3.75 g 
(43 %) 10d as a white solid.  
1H NMR (300 MHz, CDCl3) δ 7.40-7.26 (m, 5H), 6.95 (d, 2H, J = 8.3 Hz), 6.85 (d, 2H, 
J = 8.3 Hz), 5. 72 (d, 1H, J = 8.7 Hz), 5.28-4.98 (m, 5H), 3.78 (dd, 1H, J = 3.0, 9.2 Hz), 
3.67 (dd, 1H, J = 3.9, 9.2 Hz), 3.23-2.98 (m, 2H), 1.48-1.19 (m, 18H), 1.08 (s, 9H) 
13C NMR (75 MHz, CDCl3) δ 166.4, 165.6, 155.7, 154.7, 154.5, 136.0, 130.0, 129.8, 
128.5, 128.3, 128.2, 124.2, 80.4, 78.4, 73.9, 67.3, 62.3, 48.6, 48.3, 39.1, 28.8, 28.2, 27.2  
MS (ESI, m/z) 633.3 (M+Na)+ 
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 235 
N N
O
NHCbzBocHN
OtBu
11o  
Compound 11o was prepared from 10a (0.38 g, 2.0 mmol) and Cbz-Ser(tBu)-OH (0.59 g, 
2.0 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 0.36 g (40 
%) 11o as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.36-7.24 (m, 5H), 5.95 (br, 1H), 5.58 (d, 1H, J = 8.8 
Hz), 5.14-5.01 (m, 3H), 4.54 (d, 2H, J = 6.0 Hz), 3.77-3.70 (m, 1H), 3.64 (dd, 1H, J = 
4.0, 9.1 Hz), 1.42 (s, 9H), 1.06 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 166.2, 163.8, 156.0, 155.1, 135.9, 128.4, 128.1, 128.0, 
80.2, 73.7, 67.1, 62.1, 48.1, 36.0, 28.1, 27.0  
MS (ESI, m/z) 471.2 (M+Na)+ 
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O
NHCbzBocHN
BocHN
11p  
Compound 11p was prepared from 10c (2.26 g, 6.3 mmol) and Cbz-Ile-OH•DCHA (2.80 
g, 6.3 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 2.26 g (61 
%) 11p as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.39-7.26 (m, 5H), 5.60 (d, 1H, J = 8.5 Hz), 5.27 (d, 1H, 
J = 8.6 Hz), 5.14-5.03 (m, 2H), 5.02-4.84 (m, 2H), 4.63 (br, 1H), 3.13-3.00 (m, 2H), 
2.00-1.73 (m, 3H), 1.55-1.30 (m, 23H), 1.21-1.10 (m, 1H), 0.94-0.80 (m, 6H) 
13C NMR (125 MHz, CDCl3) δ 167.0, 166.1, 156.1, 155.8, 155.1, 135.9, 128.5, 128.2, 
128.1, 80.3, 79.1, 67.2, 52.2, 47.0, 39.9, 38.8, 33.2, 29.4, 28.4, 28.2, 24.9, 22.3, 15.1, 11.3  
MS (ESI, m/z) 590.4 (M+H)+ 
 237 
 
 
 
 
 238 
N N
O
NHCbzBocHN
NHBoc
tBuO
11q  
Compound 11q was prepared from 10f (2.59 g, 8.9 mmol) and Cbz-Lys(Boc)-OH (3.48 
g, 8.9 mmol).  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 3.42 g 
(60%) 11q as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.37-7.26 (m, 5H), 5.60-5.46 (m, 2H), 5.07 (s, 2H), 5.05-
4.97 (m, 1H), 4.87 (dd, 1H, J = 1.5, 9.6 Hz), 4.63 (br, 1H), 4.10-3.95 (m, 1H), 3.14-2.95 
(m, 2H), 1.98-1.77 (m, 2H), 1.53-1.30 (m, 22H), 1.21 (d, 3H, J = 6.1 Hz), 0.90 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 166.4, 166.3, 156.1, 155.7, 155.1, 135.9, 128.5, 128.2, 
128.1, 80.2, 79.1, 74.3, 68.0, 67.2, 53.2, 47.4, 39.8, 33.0, 29.4, 28.3, 28.2, 27.9, 22.3, 20.0  
MS (ESI, m/z) 634.4 (M+H)+ 
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OtBu
tBuO
O
11r  
Compound 11r was prepared from 10g (1.42 g, 7.0 mmol) and Cbz-Asp(OtBu)-
OH•DCHA (3.53 g, 7.0 mmol).  Flash chromatography (20 % to 50 % EtOAc/Hexanes) 
afforded 1.51 g (44 %) 11r as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.38-7.26 (m, 5H), 6.15 (d, 1H, J = 9.2 Hz), 5.36 (dt, 1H, 
J = 5.2, 9.2 Hz), 5.11 (s, 2H), 4.03-3.96 (m, 1H), 3.84-3.70 (m, 2H), 3.00 (dt, 1H, J = 4.7, 
16.6 Hz), 2.92 (dd, 1H, J = 5.4, 16.6 Hz), 2.25 (s, 6H), 1.38 (s, 9H), 1.11 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 169.0, 165.4, 164.8, 155.4, 135.9, 128.3, 128.1, 127.9, 
81.8, 73.3, 67.0, 61.0, 60.8, 44.4, 41.9, 38.1, 27.8, 27.1 
MS (ESI, m/z) 491.3 (M+H)+ 
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NN
O
CbzHN N
OtBu
O
tBuO
11s  
Compound 11s was prepared from 10g (1.02 g, 5.0 mmol) and Cbz-Glu(OtBu)-OH (1.69 
g, 7.0 mmol).  Flash chromatography (20 % to 50 % EtOAc/Hexanes) afforded 1.02 g (40 
%) 11s as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.33-7.17 (m, 5H), 5.86-5.75 (m, 1H), 5.12-4.97 (m, 3H), 
3.99-3.91 (m, 1H), 3.79-3.65 (m, 2H), 2.36-2.14 (m, 9H), 2.12-2.02 (m, 1H), 1.35 (s, 
9H), 1.07 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 171.5, 165.9, 164.9, 155.6, 135.9, 128.3, 128.0, 127.9, 
80.7, 73.3, 67.0, 61.1, 60.8, 47.2, 42.1, 31.0, 28.4, 27.8, 27.2 
MS (ESI, m/z) 505.3 (M+H)+ 
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O
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OtBu
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11t  
Compound 11t was prepared from 10g (2.66 g, 7.0 mmol) and Cbz-Tyr(tBu)-OH (2.60 g, 
7.0 mmol).  Flash chromatography (20 % to 50 % EtOAc/Hexanes) afforded 2.72 g (72 
%) 11t as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.30-7.14 (m, 5H), 6.98-6.90 (m, 2H), 6.80 (d, 2H, J = 
8.0 Hz), 6.22-6.13 (m, 1H), 5.33-5.23 (m, 1H), 5.06-4.94 (m, 2H), 3.99-3.90 (m, 1H), 
3.80-3.66 (m, 2H),  3.26-3.07 (m, 2H), 2.18 (s, 6H), 1.25 (s, 9H), 1.09 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 165.8, 164.3, 155.2, 154.1, 135.8, 129.6, 129.4, 128.0, 
127.7, 127.6, 123.7, 77.8, 73.0, 66.5, 60.7, 60.5, 48.6, 41.7, 38.4, 28.4, 26.9 
MS (ESI, m/z) 539.3 (M+H)+ 
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 General Procedure for Preparation of 12a-t.  A solution of Cbz protected 
oxadizole 11a-t in dry methanol (0.10 M) was stirred vigorously with 10 % Pd-C (0.1 
 244 
equiv) in a H2 atmosphere for 12 h at 25 °C until the reaction is complete.  Filtration and 
evaporation of the solvent in vacuo yielded the crude product and it was used directly in 
the next step.  The amine residue (1.0 equiv) and Boc-Inp-OH (1.0 equiv) was dissolved 
in dry CH2Cl2 (0.15 M).  N-methylmorpholine (2.1 equiv) was added to the above 
solution followed with HOBt (1.1 equiv) and EDC (1.1 equiv).  The resulting solution 
was stirred at room temperature for 12h.  The reaction mixture was washed with H2O (30 
ml), 1N HCl (30 ml), saturated NaHCO3 (30 ml) and brine (30 ml).  The organic layer 
was separated and dried with Na2SO4 and concentrated to dryness to afford the crude 
product.  Flash chromatography with EtOAc/hexanes mixtures provided pure compounds 
12a-t. 
 
NN
O
NH NHBoc
O
OtBu
NHBoc
BocN
12a  
Compound 12a was prepared from (4.83 g, 7.8 mmol) of 11a.  Flash chromatography (30 
% to 50 % EtOAc/Hexanes) afforded 3.78 g (70 %) 12a as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.59 (d, 1H, J = 8.2 Hz), 5.42-5.36 (m, 1H), 5.22 (d, 1H, 
J = 8.5 Hz), 4.98-4.89 (m, 1H), 4.65 (br, 1H), 4.10 (br, 2H), 3.78 (dd, 1H, J = 3.2, 9.4 
Hz), 3.15-2.94 (dd, 1H, J = 3.9, 9.4 Hz), 3.12-2.99 (m, 2H), 2.81-2.65 (br, 2H), 2.39-2.30 
(m, 1H), 1.94-1.75 (m, 4H), 1.70-1.57 (m, 2H), 1.51-1.31 (m, 31H), 1.06 (s, 9H)  
13C NMR (125 MHz, CDCl3) δ 174.2, 167.1, 165.4, 156.1, 155.0, 154.6, 80.3, 80.0, 
79.6, 79.1, 73.8, 62.1, 46.9, 46.5, 42.9, 39.9, 33.2, 29.4, 28.4, 28.4, 28.3, 28.2, 27.2, 22.3 
MS (ESI, m/z) 719.4 (M+Na)+ 
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O
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O
tBuO
12b  
Compound 12b was prepared from (4.43 g, 6.7 mmol) of 11b.  Flash chromatography (30 
% to 50 % EtOAc/Hexanes) afforded 3.83 g (77 %) 12b as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.77 (br, 1H), 5.32-5.23 (m, 2H), 4.98-4.89 (m, 1H), 4.70 
(br, 1H), 4.09 (br, 2H), 3.12-3.01 (m, 2H), 2.72 (br, 2H), 2.41-2.17 (m, 4H), 2.12-2.02 
(m, 1H), 1.96-1.74 (m, 4H), 1.69-1.55 (m, 2H), 1.52-1.32 (m, 40H) 
13C NMR (125 MHz, CDCl3) δ 174.4, 172.2, 167.3, 166.4, 156.1, 155.1, 154.6, 81.2, 
80.4, 79.6, 79.1, 47.1, 45.3, 42.9, 39.9, 33.2, 31.2, 29.4, 28.5, 28.4, 28.4, 28.3, 28.3, 28.0, 
22.3  
MS (MALDI, m/z) 761.1 (M+Na)+ 
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O
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O
NHBoc
BocN
O
tBuO
12c  
Compound 12c was prepared from (3.27 g, 5.0 mmol) of 11c.  Flash chromatography (30 
% to 50 % EtOAc/Hexanes) afforded 2.60 g (71 %) 12c as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.95 (br, 1H), 5.66-5.58 (m, 1H), 5.24-5.13 (m, 1H), 
5.03-4.93 (m, 1H), 4.73-4.63 (m, 1H), 4.25-4.05 (br, 2H), 3.16-3.06 (m, 2H), 3.06-2.97 
(m, 1H), 2.88 (ddd, 1H, J = 2.3, 5.2, 16.5 Hz), 2.78 (br, 2H), 2.35 (tt, 1H, J = 3.7, 11.5 
Hz), 2.00-1.79 (m, 4H), 1.73-1.62 (m, 2H), 1.57-1.36 (m, 40H) 
13C NMR (125 MHz, CDCl3) δ 174.0, 169.6, 167.4, 165.6, 156.1, 155.0, 154.6, 82.3, 
80.4, 79.6, 79.2, 47.0, 43.0, 42.2, 40.0, 37.6, 33.4, 33.2, 29.4, 28.4, 28.3, 28.3, 28.0, 22.3, 
22.2  
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MS (MALDI, m/z) 747.2 (M+Na)+ 
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NH NHBoc
O
NHBoc
OtBu
BocN
12d  
Compound 12d was prepared from (3.66 g, 5.3 mmol) of 11d.  Flash chromatography (30 
% to 50 % EtOAc/Hexanes) afforded 3.80 g (93 %) 12d as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.92 (d, 2H, J = 8.5 Hz), 6.85 (d, 2H, J = 8.5 Hz), 6.34 (d, 
1H, J = 8.2 Hz), 5.58-5.51 (m, 1H), 5.22 (d, 1H, J = 8.5 Hz), 4.96- 4.86 (m, 1H), 4.69 (br, 
1H), 4.05 (br, 2H), 3.21 (dd, 1H, J = 6.2, 14.0 Hz), 3.15-3.01 (m, 3H), 2.74-2.60 (br, 2H), 
2.21 (tt, 1H, J = 3.7, 11.5 Hz), 1.91-1.60 (m, 4H), 1.60-1.30 (m, 33H), 1.28 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 174.0, 171.2, 167.3, 166.2, 156.1, 155.1, 154.6, 129.8, 
129.7, 124.3, 80.4, 79.2, 78.6, 47.0, 45.5, 42.9, 39.9, 38.7, 33.1, 29.4, 28.8, 28.6, 28.4, 
28.4, 28.3, 28.1, 22.3 
MS (MALDI, m/z) 795.2 (M+Na)+ 
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O
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Compound 12e was prepared from (5.26 g, 10.4 mmol) of 11e.  Flash chromatography 
(30 % to 50 % EtOAc/Hexanes) afforded 4.80 g (78 %) 12e as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.53 (d, 1H, J = 8.6 Hz), 5.44 (dt, 1H, J = 3.5, 8.6 Hz), 
5.18 (d, 1H, J = 9.2 Hz), 4.98-4.90 (m, 1H), 4.14 (br, 2H), 3.81 (dd, 1H, J = 2.6, 9.2 Hz ), 
3.66 (dd, 1H, J = 3.7,  9.2 Hz), 2.78 (br, 2H),  2.37 (tt, 1H, J = 3.7, 11.5 Hz), 1.97-1.61 
(m, 5H), 1.51-1.38 (m, 19H), 1.24-1.13 (m, 1H), 1.10 (s, 9H), 0.95-0.87 (m, 6H) 
13C NMR (125 MHz, CDCl3) δ 174.1, 166.5, 165.2, 155.1, 154.6, 80.3, 79.6, 73.8, 62.3, 
51.6, 46.5, 43.0, 38.9, 28.5, 28.4, 28.3, 28.2, 27.2, 25.0, 15.1, 11.3 
MS (MALDI, m/z) 604.1 (M+Na)+ 
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O
BocHN
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Compound 12f was prepared from (5.41 g, 10.1 mmol) of 11f.  Flash chromatography (30 
% to 50 % EtOAc/Hexanes) afforded 5.10 g (83 %) 12f as a white solid.  
1H NMR (300MHz, CDCl3) δ 6.80 (d, 1H, J = 7.8 Hz), 5.44 (br, 1H), 5.35-5.21 (m, 1H), 
4.71 (br, 1H), 4.49 (d, 2H, J = 5.9 Hz ), 4.07 (br, 2H), 3.14-2.96 (m, 2H),  2.80-2.60 (m, 
2H), 2.40-2.24 (m, 1H), 2.01-1.56 (m, 6H), 1.54-1.25 (m, 31H) 
13C NMR (75MHz, CDCl3) δ 174.5, 167.2, 164.5, 156.2, 155.5, 154.6, 80.5, 79.6, 79.2, 
77.2, 45.2, 42.9, 39.8, 35.8, 33.0, 29.3, 28.5, 28.4, 28.4, 28.2, 22.2 
MS (ESI, m/z) 633.2 (M+Na)+ 
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Compound 12g was prepared from (3.62 g, 6.4 mmol) of 11g.  Flash chromatography (30 
% to 50 % EtOAc/Hexanes) afforded 3.50 g (84 %) 12g as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.91-6.82 (m, 1H), 5.58 (dt, 1H, J = 4.9, 8.8 Hz), 5.43 (d, 
1H, J = 8.8 Hz), 5.06 (br, 1H), 4.10 (br, 2H), 3.80-3.71 (m, 1H), 3.65 (dd, 1H, J = 4.1, 9.2 
Hz), 2.97 (dt, 1H, J = 4.5, 16.5 Hz), 2.82 (ddd, 1H, J = 2.6, 5.2, 16.5 Hz), 2.73 (br, 2H), 
2.33-2.25 (m, 1H), 1.87-1.76 (m, 2H), 1.68-1.57 (m, 2H), 1.42 (br, 18H), 1.39 (s, 9H), 
1.08 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 173.8, 169.6, 166.3, 165.5, 155.1, 154.6, 82.2, 80.4, 
79.6, 73.8, 62.3, 48.2, 43.0, 42.2, 37.6, 28.4, 28.4, 28.3, 28.2, 27.9, 27.2 
MS (MALDI, m/z) 661.9 (M+Na)+ 
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Compound 12h was prepared from (4.12 g, 6.7 mmol) of 11h.  Flash chromatography (30 
% to 50 % EtOAc/Hexanes) afforded 3.70 g (80 %) 12h as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.92-6.81 (m, 4H), 6.15 (d, 1H, J = 8.4 Hz), 5.59-5.53(m, 
1H), 5.43 (d, 1H, J = 8.4 Hz), 5.11-5.02 (m, 1H), 4.04 (br, 2H), 3.80-3.72 (m, 1H), 3.23 
(dd, 1H, J = 6.0, 14.1 Hz), 3.09 (dd, 1H, J = 6.5, 14.1 Hz), 2.67 (dd, 1H, J = 4.1, 9.3 Hz), 
2.19 (tt, 1H, J = 3.7, 11.5 Hz), 1.75-1.47 (m, 4H), 1.43 (s, 9H), 1.42 (s, 9H), 1.28 (s, 9H), 
1.10 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 173.8, 166.3, 165.9, 155.1, 154.6, 154.5, 129.8, 129.6, 
124.2, 80.5, 79.6, 78.5, 73.9, 62.4, 48.2, 46.4, 42.9, 38.5, 28.8, 28.6, 28.4, 28.3, 28.1, 27.2 
MS (MALDI, m/z) 710.0 (M+Na)+ 
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Compound 12i was prepared from (7.02 g, 12.2 mmol) of 11i.  Flash chromatography (30 
% to 50 % EtOAc/Hexanes) afforded 8.30 g (82 %) 12i as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.62 (d, 1H, J = 8.0 Hz), 5.46 (d, 1H, J = 8.5 Hz), 5.35-
5.26(m, 1H), 5.06 (br, 1H), 4.09 (br, 2H), 3.78-3.70 (br, 1H), 3.65 (dd, 1H, J = 4.0, 9.2 
Hz), 2.71 (br, 2H), 2.38-2.15 (m, 4H), 2.11-2.01 (m, 1H), 1.83-1.74 (m, 2H), 1.68-1.54 
(m, 2H), 1.49-1.31 (m, 27H), 1.07 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 174.5, 172.3, 166.5, 155.4, 154.9, 81.4, 80.7, 79.8, 74.1, 
62.8, 48.5, 45.4, 43.2, 31.4, 28.7, 28.7, 28.6, 28.5, 28.3, 27.5  
MS (MALDI, m/z) 676.1 (M+Na)+ 
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Compound 12j was prepared from (6.54 g, 10.6 mmol) of 11j.  Flash chromatography (30 
% to 50 % EtOAc/Hexanes) afforded 5.60 g (77 %) 12j as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.20 (d, 1H, J = 7.6 Hz), 5.59 (d, 1H, J = 8.5 Hz), 5.32-
5.19(m, 1H), 4.99 (br, 1H), 4.84 (br, 1H), 4.01 (br, 2H), 3.73-3.55 (m, 2H), 3.05-2.87 (m, 
2H), 2.62 (br, 2H), 2.33-2.21 (m, 1H), 1.90-1.50 (m, 6H), 1.49-1.23 (m, 31H), 1.01 (s, 
9H) 
13C NMR (125 MHz, CDCl3) δ 174.5, 166.9, 166.0, 156.0, 155.1, 154.4, 80.2, 79.3, 
78.8, 73.7, 62.3, 48.1, 44.9, 42.6, 39.8, 33.0, 29.1, 28.5, 28.3, 28.2, 28.1, 28.0, 27.1, 22.1  
MS (MALDI, m/z) 719.1 (M+Na)+ 
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Compound 12k was prepared from (3.35 g, 5.2 mmol) of 11k.  Flash chromatography (30 
% to 50 % EtOAc/Hexanes) afforded 2.80 g (74 %) 12k as a white solid.  
1H NMR (300MHz, CDCl3) δ 6.99-6.72 (m, 4H), 5.59-5.50 (m, 2H), 5.28-4.96(m, 2H), 
4.11 (br, 2H), 3.23-2.90 (m, 3H), 2.87-2.88 (m, 3H), 2.35-2.21 (m, 1H), 1.86-1.52 (m, 
4H), 1.48-1.32 (m, 27H), 1.29 (s, 9H) 
13C NMR (75MHz, CDCl3) δ 174.0, 169.8, 169.7, 166.9, 166.8, 165.7, 154.6, 129.9, 
129.8, 124.2, 82.3, 80.4, 79.6, 78.5, 48.4, 43.0, 42.2, 39.3, 37.6, 28.8, 28.4, 28.4, 28.3, 
28.2, 28.0  
MS (MALDI, m/z) 738.1 (M+Na)+ 
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Compound 12l was prepared from (5.96 g, 8.6 mmol) of 11l.  Flash chromatography (30 
% to 50 % EtOAc/Hexanes) afforded 5.20 g (78 %) 12l as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.97 (d, 2H, J = 8.3 Hz), 6.86 (d, 2H, J = 8.3 Hz), 6.54-
6.41(br, 1H), 5.30-5.13 (m, 3H), 4.73 (t, 1H, J = 5.7 Hz), 4.10 (br, 2H), 3.20-2.98 (m, 
4H), 2.71 (br, 2H), 2.34-2.24 (m, 1H), 1.92-1.69 (m, 4H), 1.51-1.20 (m, 40H) 
13C NMR (125 MHz, CDCl3) δ 174.4, 166.8, 156.2, 154.8, 154.6, 154.5, 130.1, 129.7, 
124.3, 80.4, 79.6, 79.1, 78.5, 48.4, 45.2, 42.9, 39.9, 39.2, 33.1, 29.3, 28.8, 28.6, 28.4, 
28.4, 28.3, 28.2, 22.2  
MS (MALDI, m/z) 795.2 (M+Na)+ 
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Compound 12m was prepared from (4.58 g, 7.0 mmol) of 11m.  Flash chromatography 
(30 % to 50 % EtOAc/Hexanes) afforded 4.60 g (89 %) 12m as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.99 (d, 2H, J = 8.3 Hz), 6.89 (d, 2H, J = 8.3 Hz), 6.52 (d, 
1H, J = 7.6 Hz), 5.32-5.18 (m, 2H), 5.11 (d, 1H, J = 8.4 Hz), 4.13 (br, 2H), 3.19 (dd, 1H, 
J = 6.5, 14.0 Hz), 3.13 (dd, 1H, J = 6.6, 14.0 Hz), 2.77 (br, 2H), 2.43-2.16 (m, 4H), 2.14-
2.04 (m, 1H), 1.90-1.56 (m, 4H), 1.50-1.34 (m, 27H), 1.32 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 174.3, 172.2, 166.7, 166.3, 154.7, 154.6, 154.6, 130.0, 
129.8, 124.3, 81.3, 80.4, 79.6, 78.5, 48.4, 45.3, 43.0, 39.2, 34.6, 31.2, 28.8, 28.5, 28.4, 
28.3, 28.2, 28.0  
 263 
MS (MALDI, m/z) 752.1 (M+Na)+ 
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Compound 12n was prepared from (3.63 g, 5.9 mmol) of 11n.  Flash chromatography (30 
% to 50 % EtOAc/Hexanes) afforded 3.50 g (85 %) 12n as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.96 (d, 2H, J = 8.4 Hz), 6.87 (d, 2H, J = 8.4 Hz), 6.35 (d, 
1H, J = 8.3 Hz), 5.38 (dt, 1H, J = 3.5, 8.4 Hz), 5.25-5.15 (m, 1H), 5.04 (d, 1H, J = 8.3 
Hz), 4.12 (br, 2H), 3.79 (dd, 1H, J = 2.7, 9.2 Hz), 3.63 (dd, 1H, J = 3.6, 9.2 Hz), 3.21-
3.04 (m, 2H), 2.76 (t, 2H, J = 12.2 Hz), 2.32 (tt, 1H, J = 3.7, 11.5 Hz), 1.86-1.76 (m, 2H), 
1.71-1.54 (m, 2H), 1.44 (s, 9H), 1.38 (s, 9H), 1.29 (s, 9H), 1.09 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 174.2, 166.6, 165.4, 154.7, 154.6, 154.5, 130.0, 129.8, 
124.2, 80.4, 79.6, 78.5, 73.9, 62.1, 48.3, 46.5, 43.0, 39.2, 28.8, 28.5, 28.4, 28.3, 28.2, 27.3  
MS (MALDI, m/z) 710.1 (M+Na)+ 
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Compound 12o was prepared from (0.36 g, 0.8 mmol) of 11o.  Flash chromatography (30 
% to 70 % EtOAc/Hexanes) afforded 0.31 g (74 %) 12o as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.61 (t, 1H, J = 5.4 Hz), 5.48 (d, 1H, J = 8.6 Hz), 5.07-
4.99 (m, 1H), 4.62 (d, 2H, J = 5.4 Hz), 3.76 (dd, 1H, J = 3.2, 9.3 Hz), 3.66 (dd, 1H, J = 
4.0,  9.3 Hz), 2.71 (br, 2H), 2.32 (tt, 1H, J = 3.7,  11.5 Hz), 1.84-1.74 (m, 2H), 1.69-1.57 
(m, 2H), 1.41 (s, 18 H), 1.07 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 174.6, 166.4, 163.8, 155.2, 154.6, 80.4, 79.6, 73.9, 62.2, 
48.2, 42.8, 34.4, 28.4, 28.2, 27.2   
MS (MALDI, m/z) 547.8 (M+Na)+ 
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Compound 12p was prepared from (1.18 g, 1.9 mmol) of 11p.  Flash chromatography (30 
% to 70 % EtOAc/Hexanes) afforded 1.16 g (92 %) 12p as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.65 (d, 1H, J = 7.2 Hz), 5.36 (d, 1H, J = 7.8 Hz), 5.30-
5.21 (m, 1H), 4.93 (br, 1H), 4.69 (br, 1H), 4.08 (br, 2H), 3.13-2.99 (m, 2H), 2.70 (br, 
2H), 2.32 (tt, 1H, J = 3.7,  11.5 Hz), 1.99-1.70 (m, 5H), 1.69-1.55 (m, 2H), 1.54-1.29 (m, 
32 H), 1.19-1.07 (m, 1H), 0.91-0.80 (m, 6H) 
13C NMR (125 MHz, CDCl3) δ 174.3, 167.2, 166.3, 156.1, 155.1, 154.6, 80.3, 79.6, 
79.1, 49.7, 47.0, 42.9, 39.9, 38.7, 33.1, 29.4, 28.7, 28.4, 28.3, 28.2, 28.1, 25.0, 22.3, 15.1, 
11.3  
MS (MALDI, m/z) 689.1 (M+Na)+ 
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Compound 12q was prepared from (1.70 g, 2.7 mmol) of 11q.  Flash chromatography (30 
% to 70 % EtOAc/Hexanes) afforded 1.35 g (70 %) 12q as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.47 (d, 1H, J = 8.5 Hz), 5.49 (d, 1H, J = 9.5 Hz), 5.33-
5.22 (m, 1H), 4.86 (dd, 1H, J = 1.7, 9.5 Hz), 4.70-4.60 (m, 1H), 4.22-3.96 (m, 3H), 3.13-
2.98 (m, 2H), 2.70 (br, 2H), 2.29 (tt, 1H, J = 3.7, 11.5 Hz), 1.98-1.86 (m, 2H), 1.85-1.71 
(m, 2H), 1.69-1.55 (m, 2 H), 1.54-1.21 (m, 31H), 1.22 (d, 3H, J = 6.2 Hz), 0.92 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 174.2, 166.6, 166.5, 156.1, 155.7, 154.6, 80.3, 79.6, 
79.1, 74.4, 68.1, 53.3, 45.1, 42.9, 39.9, 33.2, 29.3, 28.7, 28.5, 28.4, 28.4, 28.3, 28.0, 22.3, 
20.1  
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MS (MALDI, m/z) 733.1 (M+Na)+ 
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Compound 12r was prepared from (0.93 g, 2.6 mmol) of 11r.  Flash chromatography 
(5% MeOH/CH2Cl2) afforded 1.21 g (82 %) 12r as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.91 (d, 1H, J = 8.8 Hz), 5.55 (dt, 1H, J = 5.0, 8.8 Hz), 
4.16-3.92 (m, 3H), 3.80-3.66 (m, 2H), 2.96 (ddd, 1H, J = 1.5, 4.7, 16.6 Hz), 2.83 (dd, 1H, 
J = 5.1, 16.6 Hz), 2.71 (br, 2H), 2.28 (tt, 1H, J = 3.7, 11.5 Hz), 2.23 (s, 6H), 1.84-1.72 (m, 
2H), 1.66-1.54 (m, 2H), 1.45-1.28 (m, 18H), 1.09 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 173.9, 169.6, 165.4, 165.0, 154.5, 82.1, 79.5, 73.4, 61.2, 
61.0, 60.8, 42.9, 42.3, 42.3, 42.1, 37.7, 28.3, 27.9, 27.2 
MS (MALDI, m/z) 568.0 (M+H)+ 
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Compound 12s was prepared from (0.44 g, 1.2 mmol) of 11s.  Flash chromatography (5 
% to 10 % MeOH/CH2Cl2) afforded 0.62 g (89 %) 12s as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.74 (br, 1H), 5.32 (dt, 1H, J = 4.9, 8.2 Hz), 4.20-3.90 
(m, 3H), 3.82-3.67 (m, 2H), 2.70 (br, 2H), 2.37-2.15 (m, 10H), 2.13-2.01 (m, 1H), 1.78 
(br, 2H), 1.67-1.54 (m, 2H), 1.42-1.35 (m, 18H), 1.09 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 174.2, 172.0, 166.2, 165.1, 154.5, 81.1, 79.5, 73.4, 61.2, 
60.9, 45.3, 42.9, 42.2, 42.2, 31.1, 28.4, 28.3, 28.2, 28.0, 27.3 
MS (MALDI, m/z) 582.0 (M+H)+ 
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Compound 12t was prepared from (1.54 g, 3.8 mmol) of 11t.  Flash chromatography (2 
% to 3 % MeOH/CH2Cl2) afforded 1.65 g (71 %) 12t as a white solid.  
1H NMR (500 MHz, CDCl3) δ 6.96-6.75 (m, 4H), 6.36 (br, 1H), 5.65-5.51 (m, 1H), 
4.20-3.88 (m, 3H), 3.86-3.66 (m, 2H), 3.21 (dd, 1H, J = 5.8, 13.6 Hz), 3.08 (dd, 1H, J = 
5.7, 13.6 Hz), 2.66 (br, 2H), 2.30-2.16 (m, 7H), 1.75-1.61 (m, 2H), 1.60-1.46 (m, 2H), 
1.40 (s, 9H), 1.26 (s, 9H), 1.12 (s, 9H) 
13C NMR (125 MHz, CDCl3) δ 173.8, 166.0, 165.1, 154.6, 154.5, 129.8, 129.5, 124.1, 
79.5, 78.4, 73.5, 61.2, 61.0, 60.9, 46.5, 42.8, 42.2, 38.7, 38.6, 28.7, 28.3, 27.3 
MS (MALDI, m/z) 616.0 (M+H)+ 
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APPENDIX D 
EXPERIMENTAL FOR CHAPTER V 
 General Methods.  All chemicals were obtained from commercial suppliers and 
used without further purification. Dichloromethane was obtained anhydrous by 
distillation over calcium hydride and THF was distilled over sodium metal and 
benzophenone.  Analytical HPLC analyses were carried out on 25 x 0.46 cm C-18 
column using gradient conditions (5 – 95% B).  The eluents used were: solvent A (H2O 
with 0.1% TFA) and solvent B (CH3CN with 0.1% TFA).  The flow rate used was 1.0 
mL/min.  NMR spectra were recorded at 300 MHz and 500 MHz.  NMR chemical shifts 
were expressed in ppm relative to internal solvent peaks, and coupling constants were 
measured in Hz.   
 
HN
O
HN
O
O
 
 Preparation of 20.  To a solution of 1H-pyrrole-3-carboxylic acid (528.5 mg, 4.8 
mmol) in CH2Cl2 (25 mL) and DMF (10 mL) mixture, ethyl cis-2-amino-1-cyclopentane 
carboxylate hydrochloride (774.7 mg, 4.0 mmol) was added at 0 °C.  Then 4-
(dimethylamino)pyridine (977.4 mg, 8.0 mmol) and N, N′-diisopropylcarbodiimide (0.94 
mL, 6.0 mmol) was added to the above solution.  The reaction mixture was stirred at 25 
°C for 10 h.  The mixture was washed with saturated NaHCO3 (4 × 30 mL) and brine (30 
mL).  The organic layer was separated and dried over Na2SO4 and concentrated to 
dryness.  Recrystallization from ethanol yielded pure compound 20 (650 mg, 65 %) as a 
beige amorphous powder. 
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1H NMR (300 MHz, DMSO-d6) δ 11.06 (br, 1H), 7.42-7.27 (m, 2H), 6.74-6.67 (m, 1H), 
6.50-6.42 (m, 1H), 4.59-4.43 (m, 1H), 4.00-3.80 (m, 2H), 3.03-2.90 (m, 1H), 2.02-1.66 
(m, 5H), 1.60-1.42 (m, 1H), 0.99 (t, 3H, J = 7.0 Hz) 
13C NMR (75 MHz, DMSO-d6) δ 173.3, 163.7, 120.4, 119.5, 118.1, 107.4, 59.5, 52.0, 
47.0, 30.6, 26.9, 22.2, 13.9 
MS (ESI, m/z) 251.1 (M+H)+ 
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 General Procedure for Preparation of 22a-k.  Pyrrole 20 (1 equiv) was added 
to a well-agitated suspension of NaOH (3 equiv) in dichloroethane (0.10 M).  This 
mixture was then cooled to 0 °C and stirred for 20 min, following which a solution of 
sulfonyl chloride (1.2 equiv) in dichloroethane (0.24 M) was added dropwise over a 
period of 15 min.  Thirty minutes after the completion of addition, the reaction was 
allowed to come to room temperature and left stirring overnight.  After quenching the 
reaction by pouring onto 10 mL of H2O, the organic layer was separated, and the aqueous 
layer was extracted with CH2Cl2 (3 × 10 mL).  The combined organic extract was washed 
with H2O to neutrality and dried over Na2SO4.  Removal of the solvent in vacuo gave 
crude product.  Flash chromatography with EtOAc/hexanes mixture provided pure 22a-k. 
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Compound 22a was prepared from (25 mg, 0.1 mmol) of 20 and 4-fluorobenzenesulfonyl 
chloride.  Flash chromatography (15 % to 25 % EtOAc/Hexanes) afforded 17.7 mg (43 
%) 22a as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.92-7.87 (m, 2H), 7.62-7.58 (m, 1H), 7.21-7.14 (m, 2H), 
7.12-7.08 (m, 1H), 6.69 (d, 1H, J = 8.0 Hz), 6.50-6.46 (m, 1H), 4.60-4.53 (m, 1H), 4.13-
4.01 (m, 2H), 3.02-2.95 (m, 1H), 2.06-1.92 (m, 3H), 1.84-1.57 (m, 3H), 1.17 (t, 3H, J = 
7.0 Hz) 
13C NMR (125 MHz, CDCl3) δ 175.1, 167.0, 165.0, 130.2, 130.1, 122.2, 121.2, 117.1, 
116.9, 111.6, 60.7, 51.9, 46.1, 32.1, 28.6, 22.3, 14.1 
MS (ESI, m/z) 409.1 (M+H)+ 
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Compound 22b was prepared from (25 mg, 0.1 mmol) of 20 and 2-fluorobenzenesulfonyl 
chloride.  Flash chromatography (15 % to 25 % EtOAc/Hexanes) afforded 28.3 mg (69 
%) 22b as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.98-7.92 (m, 1H), 7.62 (br, 2H), 7.34-7.28 (m, 1H), 
7.22-7.13 (m, 2H), 6.68 (d, 1H, J = 8.0 Hz), 6.52-6.48 (m, 1H), 4.61-4.52 (m, 1H), 4.13-
4.02 (m, 2H), 3.04-2.96 (m, 1H), 2.06-1.92 (m, 3H), 1.85-1.56 (m, 3H), 1.17 (t, 3H, J = 
7.2 Hz) 
13C NMR (125 MHz, CDCl3) δ 175.0, 162.3, 160.0, 158.0, 137.0, 130.0, 124.0, 122.2, 
121.6, 117.8, 117.6, 111.2, 60.7, 51.9, 46.1, 32.1, 28.5, 22.3, 14.1 
MS (ESI, m/z) 409.1 (M+H) + 
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Compound 22c was prepared from (25 mg, 0.1 mmol) of 20 and 3-fluorobenzenesulfonyl 
chloride.  Flash chromatography (15 % to 25 % EtOAc/Hexanes) afforded 18.2 mg (45 
%) 22c as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.67 (dq, 1H, J = 8.0, 1.0 Hz), 7.62-7.59 (m, 1H), 7.56 
(dt, 1H, J = 8.0, 2.0 Hz), 7.50 (td, 1H, J = 8.0, 5.0 Hz), 7.34-7.29 (m, 1H), 7.13-7.10 (m, 
1H), 6.70 (d, 1H, J = 8.0 Hz), 6.52-6.49 (m, 1H), 4.60-4.52 (m, 1H), 4.13-4.02 (m, 2H), 
3.02-2.96 (m, 1H), 2.07-1.92 (m, 3H), 1.85-1.57 (m, 3H), 1.17 (t, 3H, J = 7.0 Hz) 
13C NMR (125 MHz, CDCl3) δ 175.1, 163.3, 162.2, 161.3, 140.0, 131.5, 125.0, 123.0, 
122.2, 121.3, 114.5, 111.8, 60.8, 51.9, 46.1, 32.1, 28.6, 22.3, 14.1 
MS (ESI, m/z) 409.1(M+H) + 
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Compound 22d was prepared from (25 mg, 0.1 mmol) of 20 and 4-acetylbenzenesulfonyl 
chloride.  Flash chromatography (15 % to 25 % EtOAc/Hexanes) afforded 18.9 mg (44 
%) 22d as a beige solid.  
1H NMR (500 MHz, CDCl3) δ 8.04 (d, 2H, J = 8.0 Hz), 7.95 (d, 2H, J = 8.0 Hz), 7.62 
(br, 1H), 7.12 (br, 1H), 6.71 (d, 1H, J = 8.0 Hz), 6.50 (br, 1H), 4.59-4.50 (m, 1H), 4.13-
4.01 (m, 2H), 3.02-2.94 (m, 1H), 2.60 (s, 3H), 2.06-1.91 (m, 3H), 1.84-1.57 (m, 3H), 1.17 
(t, 3H, J = 7.2 Hz) 
13C NMR (125 MHz, CDCl3) δ 175.1, 162.1, 141.8, 141.2, 129.3, 129.3, 127.4, 125.2, 
122.2, 121.3, 111.9, 60.7, 51.9, 46.1, 32.2, 28.6, 26.8, 22.3, 14.1 
MS (ESI, m/z) 455.1 (M+Na) + 
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Compound 22e was prepared from (25 mg, 0.1 mmol) of 20 and 8-
quinolinebenzenesulfonyl chloride.  Flash chromatography (20 % to 70 % 
EtOAc/Hexanes) afforded 31.1 mg (71 %) 22e as a beige solid.  
1H NMR (500 MHz, CDCl3) δ 9.10-9.02 (m, 1H), 8.41 (d, 1H, J = 8.0 Hz), 8.19 (d, 1H, 
J = 8.0 Hz), 8.09 (d, 1H, J = 8.0 Hz), 7.97-7.90 (m, 1H), 7.68-7.59 (m, 1H), 7.55-7.47 (m, 
1H), 7.47-7.39 (m, 1H), 6.63 (d, 1H, J = 8.0 Hz), 6.47-6.38 (m, 1H), 4.61-4.51 (m, 1H), 
4.13-3.98 (m, 2H), 3.03-2.94 (m, 1H), 2.06-1.92 (m, 3H), 1.90-1.54 (m, 3H), 1.13 (t, 3H, 
J = 7.6 Hz) 
13C NMR (125 MHz, CDCl3) δ 175.2, 163.0, 152.0, 143.8, 136.7, 135.7, 135.6, 132.2, 
129.2, 125.6, 123.9, 123.4, 123.2, 122.8, 110.2, 60.9, 52.1, 46.5, 32.4, 28.7, 22.5, 14.0 
MS (ESI, m/z) 464.1 (M+Na) + 
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Compound 22f was prepared from (25 mg, 0.1 mmol) of 20 and 4-
methoxybenzenesulfonyl chloride.  Flash chromatography (20 % to 30 % 
EtOAc/Hexanes) afforded 37.6 mg (90 %) 22f as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.80 (d, 2H, J = 9.0 Hz), 7.59 (br, 1H), 7.12-7.07 (m, 
1H), 6.93 (d, 2H, J = 9.0 Hz), 6.65 (d, 1H, J = 8.8 Hz), 6.48-6.43 (m, 1H), 4.60-4.51 (m, 
1H), 4.12-4.00 (m, 2H), 3.83 (s, 3H), 3.03-2.95 (m, 1H), 2.06-1.91 (m, 3H), 1.87-1.58 
(m, 3H), 1.15 (t, 3H, J = 6.7 Hz) 
13C NMR (125 MHz, CDCl3) δ 175.0, 164.2, 162.5, 129.5, 129.5, 124.3, 122.0, 121.0, 
114.7, 111.1, 60.8, 55.8, 51.9, 46.2, 32.1, 28.5, 22.3, 14.1 
MS (ESI, m/z) 421.1 (M+H) + 
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Compound 22g was prepared from (25 mg, 0.1 mmol) of 20 and 3-
methoxybenzenesulfonyl chloride.  Flash chromatography (20 % to 30 % 
EtOAc/Hexanes) afforded 19.0 mg (45 %) 22g as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.62-7.59 (m, 1H), 7.46-7.37 (m, 2H), 7.36-7.33 (m, 1H), 
7.14-7.08 (m, 2H), 6.66 (d, 1H, J = 8.6 Hz), 6.50-6.48 (m, 1H), 4.60-4.51 (m, 1H), 4.13-
4.01 (m, 2H), 3.82 (s, 3H), 3.03-2.96 (m, 1H), 2.06-1.92 (m, 3H), 1.87-1.57 (m, 3H), 1.16 
(t, 3H, J = 7.4 Hz) 
13C NMR (125 MHz, CDCl3) δ 175.1, 162.4, 160.1, 139.3, 130.7, 124.6, 122.2, 121.3, 
120.6, 119.2, 111.8, 111.4, 60.7, 55.8, 51.9, 46.1, 32.2, 28.6, 22.3, 14.1 
MS (ESI, m/z) 421.1 (M+H) + 
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Compound 22h was prepared from (25 mg, 0.1 mmol) of 20 and 3,4-
dimethoxybenzenesulfonyl chloride.  Flash chromatography (20 % to 35 % 
EtOAc/Hexanes) afforded 32.8 mg (73 %) 22h as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.62-7.58 (m, 1H), 7.50 (dd, 1H, J = 8.4, 2.2 Hz), 7.29-
7.26 (m, 1H), 7.12-7.08 (m, 1H), 6.89 (d, 1H, J = 9.5 Hz), 6.66 (d, 1H, J = 8.2 Hz), 6.47-
6.43 (m, 1H), 4.59-4.51 (m, 1H), 4.11-4.00 (m, 2H), 3.89 (s, 3H), 3.88 (s, 3H), 3.02-2.95 
(m, 1H), 2.06-1.90 (m, 3H), 1.86-1.55 (m, 3H), 1.17 (t, 3H, J = 7.5 Hz) 
13C NMR (125 MHz, CDCl3) δ 175.0, 162.4, 154.0, 149.4, 129.5, 124.3, 122.1, 121.7, 
121.1, 111.1, 110.9, 109.2, 60.7, 56.3, 56.3, 51.9, 46.1, 32.1, 28.5, 22.3, 14.1 
MS (ESI, m/z) 451.2 (M+H) + 
 293 
 
 
 
 
 
 294 
N
O
HN
S
O
O
O
O
O
O
22i  
Compound 22i was prepared from (25 mg, 0.1 mmol) of 20 and 2,5-
dimethoxybenzenesulfonyl chloride.  Flash chromatography (20 % to 35 % 
EtOAc/Hexanes) afforded 37.7 mg (84 %) 22i as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.64-7.61 (m, 1H), 7.48 (d, 1H, J = 3.3 Hz), 7.17-7.13 
(m, 1H), 7.10 (dd, 1H, J = 9.5, 3.3 Hz), 6.88 (d, 1H, J = 9.5 Hz), 6.65 (d, 1H, J = 8.3 Hz), 
6.46-6.42 (m, 1H), 4.61-4.53 (m, 1H), 4.12-4.02 (m, 2H), 3.80 (s, 3H), 3.79 (s, 3H), 3.02-
2.96 (m, 1H), 2.06-1.92 (m, 3H), 1.85-1.57 (m, 3H), 1.17 (t, 3H, J = 7.2 Hz) 
13C NMR (125 MHz, CDCl3) δ 175.0, 162.7, 153.1, 151.5, 126.2, 123.3, 122.9, 122.7, 
122.1, 114.3, 114.2, 109.9, 60.7, 56.6, 56.1, 51.9, 46.2, 32.2, 28.5, 22.3, 14.1 
MS (ESI, m/z) 451.2 (M+H) + 
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Compound 22j was prepared from (25 mg, 0.1 mmol) of 20 and 4-cyanobenzenesulfonyl 
chloride.  Flash chromatography (20 % to 30 % EtOAc/Hexanes) afforded 18.4 mg (44 
%) 22j as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.98 (d, 2H, J = 9.0 Hz), 7.80 (d, 2H, J = 9.0 Hz), 7.63-
7.59 (m, 1H), 7.14-7.09 (m, 1H), 6.76 (d, 1H, J = 8.0 Hz), 6.55-6.49 (m, 1H), 4.61-4.50 
(m, 1H), 4.16-4.02 (m, 2H), 3.04-2.95 (m, 1H), 2.09-1.55 (m, 6H), 1.18 (t, 3H, J = 7.3 
Hz) 
13C NMR (125 MHz, CDCl3) δ 175.2, 161.9, 142.2, 133.3, 127.7, 125.6, 122.2, 121.3, 
118.1, 116.6, 112.3, 60.8, 51.9, 46.1, 32.2, 28.7, 22.3, 14.1 
MS (ESI, m/z) 438.1 (M+Na) + 
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Compound 22k was prepared from (25 mg, 0.1 mmol) of 20 and 2-cyanobenzenesulfonyl 
chloride.  Flash chromatography (20 % to 50 % EtOAc/Hexanes) afforded 13.7 mg (33 
%) 22k as a white solid.  
1H NMR (300 MHz, CDCl3) δ 8.20-8.15 (m, 1H), 7.88-7.61 (m, 3H), 7.64-7.61 (m, 1H), 
7.33-7.38 (m, 1H), 6.71 (d, 1H, J = 8.4 Hz), 6.56-6.50 (m, 1H), 4.62-4.48 (m, 1H), 4.16-
4.02 (m, 2H), 3.04-2.94 (m, 1H), 2.09-1.54 (m, 6H), 1.19 (t, 3H, J = 7.3 Hz) 
 298 
13C NMR (125 MHz, CDCl3) δ 175.0, 162.1, 140.1, 136.0, 134.4, 133.5, 130.0, 125.5, 
122.3, 122.2, 115.0, 111.9, 110.9, 60.8, 51.9, 46.1, 32.1, 28.6, 22.3, 14.1 
MS (ESI, m/z) 438.1 (M+Na) + 
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 General Procedure for Preparation of 23a-c.  To a stirred mixture of 1H-
imidazole-4-carboxylic acid (33.6 mg, 0.3 mmol), ethyl cis-2-amino-1-cyclopentane 
carboxylate hydrochloride (38.7 mg, 0.2 mmol) and HOBt (27.0 mg, 0.2 mmol) in 1.5 
mL DMF were added EDC•HCl (38.2 mg, 0.2 mmol) and then N-methylmorpholine (33 
µL, 0.3 mmol) under N2 at 0 °C.  The reaction mixture was stirred at room temperature 
and left stirring overnight, and then evaporated.  The residue was dissolved in EtOAc and 
washed with water.  The organic layer was washed successively with saturated NH4Cl, 
saturated NaHCO3, water and brine, and dried over anhydrous Na2SO4.  Concentration of 
the organic layer afforded the crude amide 21 as a yellow oil.  This product was used for 
the next reaction without further purification.  To a solution of imidazole 21 (1 equiv) in 
anhydrous THF (0.10 M) was added Et3N (2.0 equiv) in one portion.  To this mixture was 
added dropwise over 10 min a solution of sulfonyl chloride in anhydrous THF (0.10 M), 
and the reaction mixture was left stirring overnight at room temperature.  The precipitate 
of Et3N•HCl was separated by filtration and the filtrate was evaporated in vacuo.  Flash 
chromatography with EtOAc/hexanes mixtures provided pure compounds 23a-c. 
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Compound 23a was prepared from (19.4 mg, 0.1 mmol) of ethyl cis-2-amino-1-
cyclopentane carboxylate hydrochloride and 1H-imidazole-4-carboxylic acid, and then 4-
acetylbenzenesulfonyl chloride.  Flash chromatography (20 % to 30 % EtOAc/Hexanes) 
afforded 29 mg (67 % in two steps) 23a as a white solid.  
 300 
1H NMR (500 MHz, CDCl3) δ 8.08 (d, 2H, J = 9.5 Hz), 8.03 (d, 2H, J = 9.5 Hz), 7.92 (s, 
1H), 7.83 (s, 1H), 7.62 (d, 1H, J = 9.0 Hz), 4.60-4.51 (m, 1H), 4.12-3.99 (m, 2H), 3.03-
2.95 (m, 1H), 2.62 (s, 3H), 2.08-1.56 (m, 6H), 1.13 (t, 3H, J = 6.6 Hz) 
13C NMR (125 MHz, CDCl3) δ 195.9, 174.2, 160.2, 141.9, 140.7, 139.5, 135.9, 129.6, 
127.9, 119.3, 60.6, 51.7, 46.5, 31.9, 28.0, 26.9, 22.2, 14.1 
MS (ESI, m/z) 434.1 (M+H) + 
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Compound 23b was prepared from (19.4 mg, 0.1 mmol) of ethyl cis-2-amino-1-
cyclopentane carboxylate hydrochloride and 1H-imidazole-4-carboxylic acid, and then 4-
cyanobenzenesulfonyl chloride.  Flash chromatography (20 % to 35 % EtOAc/Hexanes) 
afforded 27 mg (65 % in two steps) 23b as a colorless oil.  
1H NMR (500 MHz, CDCl3) δ 8.07 (d, 2H, J = 9.0 Hz), 8.03-7.80 (m, 4H), 7.67 (d, 1H, 
J = 8.0 Hz), 4.66-4.48 (m, 1H), 4.18-3.82 (m, 2H), 3.07-2.93 (m, 1H), 2.10-1.50 (m, 6H), 
1.13 (t, 3H, J = 6.9 Hz) 
 302 
13C NMR (75 MHz, CDCl3) δ 174.4, 156.9, 148.0, 135.9, 132.4, 128.3, 126.7, 120.5, 
118.0, 114.0, 60.9, 52.9, 47.4, 31.2, 27.8, 22.2, 14.0 
MS (ESI, m/z) 439.1 (M+Na) + 
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Compound 23c was prepared from (19.4 mg, 0.1 mmol) of ethyl cis-2-amino-1-
cyclopentane carboxylate hydrochloride and 1H-imidazole-4-carboxylic acid, and then 4-
methoxybenzenesulfonyl chloride.  Flash chromatography (20 % to 30 % 
EtOAc/Hexanes) afforded 33.7 mg (80 % in two steps) 23c as a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.90-7.83 (m, 3H), 7.78 (s, 1H), 7.59 (d, 1H, J = 9.0 Hz), 
6.97 (d, 2H, J = 8.6 Hz), 4.60-4.51 (m, 1H), 4.10-3.98 (m, 2H), 3.84 (s, 3H), 3.02-2.95 
(m, 1H), 2.06-1.55 (m, 6H), 1.12 (t, 3H, J = 6.6 Hz) 
13C NMR (75 MHz, CDCl3) δ 174.1, 164.9, 160.5, 138.9, 135.6, 130.0, 128.2, 119.3, 
115.1, 60.6, 55.9, 51.7, 46.5, 31.9, 28.0, 22.2, 14.0 
MS (ESI, m/z) 422.1 (M+H) + 
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